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CHAPTER I 
 
INTRODUCTION 
 
Inflammation 
 Inflammation is an immune response involving a series of complex events on a 
microscopic scale that includes responses such as vasodilation and increases in vascular 
permeability and blood flow.1 The release of pro-inflammatory mediators following 
exposure to toxic chemicals, microbial infection, or tissue injury launches a series of 
signaling cascades that destroy the invasive pathogen and repair tissue damage.2 Acute 
inflammation, characterized by pain, heat, redness, swelling, and loss of function, is a 
protective response that is an important aspect of the healing process.3 
 The inflammatory response, however, is also implicated in a variety of disease 
states. Because inflammation can occur as a result of exposure to toxins and tumor 
growth, deficiencies in the inflammatory response can compromise the host.1 In addition, 
when acute inflammation is unresolved and escalates to a state of chronic inflammation, 
it can lead to organ failure or one of many diseases including atherosclerosis, 
Alzheimer’s disease, rheumatoid arthritis (RA), and cancer, amongst others.4 
 
Inflammatory Diseases 
 There are several types of immunopathologic inflammatory processes. For 
example, allergic inflammation involves the stimulation of immunoglobulin E (IgE) 
production in response to certain antigens.5 Subsequent binding of IgE to receptors on 
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basophils and mast cells results in the secretion of cytoplasmic granules including 
histamine, as well as the production of pro-inflammatory mediators such as leukotrienes 
(LTs). This signaling results in altered blood flow, increased vascular permeability and 
bronchoconstriction, reactions that are commonly associated with allergic responses 
including seasonal allergies and asthma. 
 Inflammation is also mediated by cytotoxic antibodies including complement-
fixing antibodies, a component of the complement system that clears pathogens from the 
host as part of the innate immune system.6 Binding of IgG or IgM to an antigen, however, 
can lead to complement activation and deposition of complement fragments on the 
cellular surfaces of erythrocytes, platelets, or leukocytes, which activate the complement 
cascade leading to the generation of pro-inflammatory mediators. Many rheumatic 
diseases, such as lupus erythematosus, are associated with the development of antibodies 
to cells. 
 Similarly to cytotoxic antibody-induced inflammation, inflammatory signaling 
can be mediated by immune complexes.7 Following complement activation by IgG- or 
IgM-antigen complexes, several complement-derived peptides with pro-inflammatory 
activity are generated and deposited in various tissues. This can lead to the release of 
toxic metabolites and pro-inflammatory cytokines from phagocytes that cause damage to 
blood vessels, hemorrhagic necrosis and local tissue destruction, resulting in rheumatic 
diseases including RA. 
 Another type of immunopathologic inflammatory process is known as delayed-
type hypersensitivity. After exposure of an antigen to skin, allergic reactions occur within 
minutes and complement activation-mediated reactions occur within 24 hours, while 
3 
 
delayed-type hypersensitivity reactions peak at 48 to 72 hours.2 When antigens are 
recognized by receptors on T lymphocytes, the production of cytokines is stimulated, 
attracting and activating neutrophils, macrophages, and other lymphocytes, leading to 
inflammatory responses. While delayed-type hypersensitivity reactions appear to be 
important for the destruction of intracellular parasites, tumor cells, and viruses, they are 
also associated with diseases such as tuberculosis and polymyositis. 
 
Therapeutic Treatment of Inflammation 
 The therapeutic treatment of inflammation predates modern medicine. Ancient 
Egyptians, circa 1500 B.C., utilized the bark of willow trees to treat stiff and painful 
joints as noted in the Ebers papyrus, a medical text containing various therapeutic 
treatments for physical and mental diseases.8 One thousand years later, ancient Greek 
physicians continued to recommend various willow tree preparations to alleviate pain, 
fever, and inflammation.9 The first clinical trial of willow bark for the treatment of 
inflammation was performed by the reverend Edward Stone in 1763, in which he 
successfully treated fever in 50 patients using powdered willow bark suspended in water, 
tea, or beer.8 
 It was not until 1828 that the active anti-inflammatory component of willow bark, 
salicin (Figure 1), was isolated by Johann Andreas Buchner.10 Named after the Latin for 
its source, Salix alba, salacin can be hydrolyzed then oxidized to yield salicylic acid, a 
process first discovered by Raffaelle Piria in 1838.10 Salicylic acid possesses potent anti-
inflammatory properties, and thanks to the design of its de novo synthesis by Hammond 
Kolbe, salicylic acid was produced on an industrial scale beginning in 1874.10 
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 Motivated by his father’s intolerance of salicylic acid due to its relatively severe 
gastrointestinal side-effects and bitter taste, Felix Hoffmann, a chemist working for Bayer 
in Germany, developed the derivative acetylsalicylic acid in 1897.8 The drug was 
introduced to the market in 1899 under the trade name Aspirin, derived from A for acetyl, 
spir for the meadowsweet tree Spiraea ulmaria in which salicylic acid is naturally 
produced, and in for the then-common suffix of medicines.10 Though aspirin possesses 
some gastrointestinal side-effects similar to, though less severe than, that of salicylic 
acid, it has several effective therapeutic properties including the resolution of 
inflammation, reduction of fever, curing of headaches, and inhibition of platelet 
aggregation.8,11 
 
 
 
Figure 1. Compounds for the therapeutic treatment of inflammation. (A) Salicin is a β-
glucoside alcohol naturally produced in the bark of willow trees. (B) The hydrolysis and 
subsequent oxidation of salicin produces salicylic acid, a monohydroxybenzoic acid that 
possesses potent anti-inflammatory properties. (C) Acetylsalicylic acid, introduced to the 
market as “aspirin,” is a derivative of salicylic acid that has similar therapeutic properties 
with fewer adverse side effects. 
 
 
For nearly fifty years, aspirin remained the only commercially available non-
steroidal anti-inflammatory drug (NSAID), until phenylbutazone, phenacetin, and 
phenazone were developed in 1940s as therapeutic treatments for arthritis and other 
painful inflammatory diseases.12 As a result of the development of animal models, the 
1950s and 1960s saw the syntheses of indomethacin and ibuprophen, both of which are 
still commonly used today.13 These two drug discoveries were followed by a large-scale 
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effort by many pharmaceutical companies to develop a range of new NSAIDs including 
numerous derivatives of ibuprofen, piroxicam, mefenamic acid, and diclofenac amongst 
others.12,14,15 Though great efforts were made in the development of these drugs during 
this time period, little was known with respect to how they worked. 
 Immense strides were subsequently made with respect to research involving the 
biology of inflammation and the bioactivities of NSAIDs. In 1971, Vane, Smith, and 
Willis defined the mechanism of action of these drugs as the inhibition of the enzymatic 
production of prostaglandins (PGs).16, 17 PGs were discovered in the 1930s as a depressor 
substance in seminal fluid, and since then their biological significance has become well 
characterized.18 These lipid-derived compounds are mediators of a wide range of normal 
physiological functions as well as several pathological processes.19 The biosynthesis and 
biological activities of these signaling molecules are the focus of the following section of 
this introduction. 
 The defensive response of inflammation is crucial to the healing process from 
damage caused by toxins, physical trauma, or infection. Inflammation, though, can lead 
to immunopathologic inflammatory processes, resulting in various types of inflammatory 
diseases. The critical role that inflammation plays in pathologic events makes its 
regulation crucial to the prevention and treatment of various diseases, hence the 
importance and prominence of drugs such as NSAIDs. 
 The therapeutic treatment of inflammation dates back thousands of years. The 
success of NSAIDs as a treatment for inflammatory conditions such as RA and 
osteoarthritis (OA) highlight their pharmacological importance. Still, there is room for 
progress. The fact that aspirin was used for nearly one hundred years before its 
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mechanism of action was determined is telling of this. Ongoing research into the 
mechanisms that generate and regulate the inflammatory response are clearly needed for 
the benefit of those who suffer from inflammatory diseases. 
 
Eicosanoids 
 Metabolites of polyunsaturated fatty acids serve as potent signaling molecules that 
regulate various cellular responses through receptor-mediated pathways.19,20 One such 
class of mediators are metabolized from arachidonic acid (Figure 2), which is derived 
from the essential fatty acid linoleic acid supplied in the diet.20 The twenty-carbon 
molecule arachidonic acid contains four non-conjugated carbon-carbon double bonds at 
positions C-5, C-8, C-11, and C-14. As the Greek word for twenty is eikosi, arachidonic 
acid-derived mediators are referred to as eicosanoids. Eicosanoids are hormone-like 
molecules with potent signaling effects at low concentrations.19 However, unlike 
hormones, they are not transported by the circulatory system due to their biochemically 
unstable nature and thus act locally as autocrine or paracrine mediators of physiological 
and pathological functions.21 
 
 
 
Figure 2. Arachidonic acid. Metabolized from the essential fatty acid linoleic acid, 
arachidonic acid is a 20-carbon carboxylic acid with four cis double bonds. Signaling 
molecules that are derived from arachidonic acid are known as eicosanoids. 
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Arachidonic acid metabolism is a critical process that is mediated by a multitude 
of enzymes. Stored in cells as a component of the membrane bilayer, arachidonic acid is 
esterified at the sn-2 position of the glycerol moiety of phospholipids.22 Phospholipase A2 
(PLA2) hydrolyzes the acyl group at this sn-2 position, yielding free arachidonic acid.23 
Once released from the membrane, arachidonic acid is metabolized along one of several 
routes, forming distinct classes of eicosanoids. Cytochrome P450 (CYP) enzymes utilize 
arachidonic acid as a substrate to form epoxyeicosatrienoic acids (EETs), 
hydroxyeicosatetraenoic acids (HETEs), and dihydroxyeicosatrienoic acids (DHETs).24 
The LTs, lipoxins (LXs), and eoxins (EXs) arise from lipoxygenase (LOX) metabolism,25 
and prostanoids including PGs and thromboxane (TX) are arachidonic acid derivatives 
formed via the cyclooxygenase (COX) pathway.26,27 These classes of eicosanoids are 
discussed here, with particular emphasis placed on the prostanoids. 
 
Prostanoids 
Prostanoids are structurally unique among the eicosanoids, in that they possess a 
five- or six-membered ring within their carbon chain, whereas the other classes consist of 
linear carbon chain molecules. Synthesis of the prostanoids is initiated by the release of 
arachidonic acid from the lipid bilayer, an activity of cytosolic PLA2 (cPLA2), which is 
translocated to the membrane as a result of the mobilization of intracellular calcium.28,29 
In this way, cPLA2 plays a substrate-limiting role in the regulation of prostanoid 
synthesis. The membrane-anchored enzyme COX then catalyzes the committed step in 
prostanoid synthesis. This heme-dependent bis-oxygenation and cyclization of 
arachidonic acid forms the lipid endoperoxide-hydroperoxide intermediate PGG2.26 A 
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separate peroxidase site within the same enzyme then catalyzes the reduction of the 
hydroperoxide, giving PGH2.30 PGH2 does not accumulate but is quickly converted into 
biologically relevant mediators by specific terminal synthases. 
 
Cyclooxygenase 
The mechanism by which COX oxygenates arachidonic acid to PGG2 has been 
well-characterized (Figure 3).31-33 COX-bound arachidonic acid is positioned by 
hydrogen-bonding interactions between the carboxyl group of the substrate and Arg-120 
of the enzyme. The first chemical step of the mechanism is performed by a heme-
generated tyrosyl radical at position 385, which oxidizes arachidonic acid by abstracting 
the pro-S hydrogen at position C-13, developing a carbon radical at C-11. Oxygen 
insertion then occurs at C-11 on the opposite side of hydrogen abstraction, generating an 
11(R)-hydroperoxyl radical. This then adds to C-9, forming a cyclic peroxide and a 
carbon radical at C-8. A second cyclization reaction occurs as the radical at C-8 adds to 
C-12, generating a radical that is delocalized over C-13 to C-15. Finally, a second 
molecule of oxygen is added to C-15, producing a 15-hydroperoxyl radical that abstracts 
a hydrogen atom from Tyr-385, giving rise to PGG2. From here, PGG2 is transferred to 
the peroxidase site within the same enzyme where the C-15 hydroperoxide is reduced to 
the corresponding hydroxyl group, forming PGH2. 
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Figure 3. Chemical mechanism of the cyclooxygenase reaction. The reaction is initiated 
at the cyclooxygenase site of COX. Abstraction of the pro-S hydrogen at position C-13 
by a Tyr-385 radical is followed by O2 addition to C-11, forming an 11(R)-hydroperoxyl 
radical. An endoperoxide is then formed by reaction of the oxygen radical with C-9, 
centering the radical at position C-8. The cyclization reaction is completed by bond 
formation of C-8 to C-12, centering the radical at position C-15. The addition of a second 
molecule of oxygen to C-15 is followed by addition of a hydrogen atom from Tyr-385, 
forming PGG2. Finally, the reduction of the hydroperoxide at C-15, catalyzed at the 
peroxidase site of COX, results in the formation of PGH2. 
 
 
The membrane-anchored enzyme, COX, is located on the lumenal surface of the 
endoplasmic reticulum (ER) and the inner membrane of the nuclear envelope.34 There are 
two isoforms of COX, denoted COX-1 and COX-2. Although the two enzymes catalyze 
the same reactions and their amino acid sequences are about 65% identical, they differ in 
their expression pattern and biological function.35 COX-1 is typically a constitutive 
enzyme, expressed in a wide range of tissues and is assumed to maintain homeostatic 
levels of the primary prostanoids, which regulate biological processes such as gastric 
mucosal maintenance, renal blood flow, and platelet function.36 COX-2, on the other 
hand, is an inducible enzyme whose expression is up-regulated by a series of 
inflammatory stimuli, including pro-inflammatory cytokines, lipopolysaccharide (LPS), 
epidermal growth factors (EGF), and hormones.37 The induction of COX-2 expression is 
associated with pain, fever, inflammation, neurological disorders, and several types of 
cancer.36 The product of COX, PGH2, serves as a substrate for several terminal synthases 
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that catalyze the formation of PGD2, PGE2, PGF2, PGI2 (prostacyclin), and TXA2 (Figure 
4).38-42 The activities of these enzymes are summarized below. 
 
 
 
Figure 4. The prostanoid cascade. The prostanoids are lipid mediators that include the 
prostaglandins PGD2, PGE2, and PGF2α, prostacyclin (PGI2) and thromboxane (TXA2). 
The formation of prostanoids is catalyzed by one of several terminal synthases that utilize 
PGH2 as a substrate. 
 
 
PGD Synthase 
PGD synthase (PGDS) catalyzes the isomerization of the 9,11-endoperoxide 
group of PGH2, resulting in 9-hydroxy and 11-keto groups on the prostane ring. There are 
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two types of PGDS enzymes including the lipocalin type (L-PGDS) and the 
hematopoietic enzymes (H-PGDS).43,44 L-PGDS activity requires a sulfhydryl-containing 
compound such as glutathione (GSH), dithiothreitol (DTT), 2-mercaptoethanol (βME), or 
cysteine and is predominately expressed in the central nervous system, by epithelial cells, 
and by Leydig cells in the testis.43,44 H-PGDS is a cytosolic GSH transferase (GST) 
enzyme that specifically requires GSH as a cofactor for its activity and is expressed in 
immune and inflammatory cells.43,45 
 
PGE Synthase 
Similarly to PGDS, PGE synthase (PGES) isomerizes the endoperoxide of PGH2, 
but the catalysis results in the keto and hydroxyl groups in positions that are opposite to 
that of PGD2. There are three PGES enzymes, including a cytosolic protein (CPGES) and 
two membrane-bound proteins (MPGES1 and MPGES2).46-48 CPGES, similarly to H-
PGDS, is a member of the cytosolic GST family of proteins, and it is identical to the heat 
shock protein 90 (Hsp90)-binding protein, p23.48 CPGES is a constitutive enzyme that is 
expressed in most cells and displays a marked preference for COX-1-derived PGH2 over 
that of COX-2, suggesting that CPGES produces homeostatic levels of PGE2.48 
The integral membrane protein MPGES1 is a GSH-dependent enzyme whose 
expression is induced by pro-inflammatory stimuli, such as LPS, interleukin-1β (IL-1β), 
and tumor necrosis factor-α (TNF-α).49 It is co-localized with COX in the same 
subcellular compartments, the perinuclear membrane, and the ER.34 Since its localization 
and regulation are both coupled with that of the inducible COX-2, MPGES1 is associated 
with the induced production of PGE2.50 
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The third PGES enzyme, MPGES2, is a membrane-anchored protein that, unlike 
CPGES and MPGES1, is not dependent on GSH.47 While the enzyme can utilize GSH as 
a cofactor, it can also use other thiols such as βME, DTT, or a native cysteine residue 
within the active site to catalyze the isomerization of PGH2.51 While MPGES2 is a 
constitutive enzyme, it displays no preferential functional coupling to either COX-1 or 
COX-2.52 
 
PGF Synthase 
PGF2 prostanoids are widely distributed in tissues throughout the body and can be 
formed through metabolism of PGH2, PGD2, or PGE2 (Figures 4 and 5). The PGH2 
isomerase 9,11-endoperoxide reductase, whose activity results in the formation of 
hydroxyl groups at both the C-9 and C-11 positions of the cyclopentane ring, produces 
PGF2α in the presence of nicotinamide adenine dinucleotide (NADH) or NADH 
phosphate (NADPH).43 This membrane-associated protein is GSH-dependent and is a 
member of the GST family of proteins.53 
Another method by which PGF2α is formed is via reduction of the keto group of 
PGE2 by PGE 9-ketoreductase, which is a cytosolic enzyme dependent on NADH or 
NADPH, and possesses a high sequence similarity to aldo-keto reductase (AKR) 
superfamily members.43 Similarly, the keto group of PGD2 may be reduced by PGD 11-
ketoreductase, a NADH- or NADPH-dependent enzyme with high homology to the AKR 
superfamily.53 Unlike PGE 9-ketoreductase, however, reduction of PGD2 by PGD 11-
ketoreductase results in the formation of 9α,11β-PGF2. 
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Figure 5. Synthesis of PGF2. The formation of PGF2α is catalyzed by the isomerization 
of PGH2 by 9,11-endoperoxide reductase or by the reduction of PGE2 by PGE 9-
ketoreductase. The formation of 9α,11β-PGF2 is catalyzed by the reduction of PGD2 by 
PGD 11-ketoreductase. 
 
 
PGI and TX Synthases 
The unstable prostanoid PGI2 is metabolized from PGH2 by PGI synthase (PGIS), 
a membrane-bound hemoprotein belonging to the CYP superfamily and located in 
endothelial and smooth muscle cells.41 The catalytic activity of PGIS is different from the 
previously discussed prostanoid synthases, in that it catalyzes the rearrangement of the 
endoperoxide of PGH2, forming an oxygen-containing heterocycle, as opposed to the 
traditional five-membered prostane ring structure.54 
Another unstable prostanoid, TXA2, is synthesized from PGH2 by the heme-
dependent, membrane-bound, CYP family member TX synthase (TXS), which is 
expressed in platelets and macrophages.55 Like PGIS, the TXS isomerization of PGH2 
results in the generation of an unstable oxygen-containing heterocycle.54 
 
Prostanoid Signaling 
 The biological signaling effects of prostanoids are carried out by specific binding 
to cell-surface G protein-coupled receptors (GPCRs). These include the D prostanoid 
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(DP) receptors DP1 and DP2 for PGD2, EP1, EP2, EP3, and EP4 for PGE2, FP for PGF2, 
IP for PGI2, and TP for TXA2.56 All of the prostanoid receptors are class A rhodopsin-
like receptors with the exception of DP2, which belongs to the leukocyte chemoattractant 
receptor family.57 The cellular responses that prostanoids elicit are dependent upon the 
type and condition of cell in which they are produced. As such, they are mediators of a 
wide range of biological responses including vascular permeability, platelet aggregation, 
smooth muscle tone, pain, and fever.58-62 
 Prostanoids are molecules with an array of normal physiological signaling effects. 
For instance, a major mediator of sleep-wake processes is PGD2, in that it promotes 
physiological sleep and is a regulator of body temperature during sleep.63 Prostanoids 
also have important signaling effects related to reproduction, in that PGE2 softens the 
cervix and causes uterine contraction during labor, and PGF2α induces labor.56 Bone 
health is also a regulatory signaling function of prostanoids, given that PGE2 stimulates 
born resorption by osteoclasts.56 
Also, the maintenance of cardiovascular (CV) homeostasis is a central role of 
prostanoid signaling. The mediators PGD2, PGE2, and PGI2 are all vasodilators, while 
TXA2 is a vasoconstrictor.64 The importance of prostanoid signaling in CV health is 
highlighted by the important balance of PGI2 and TXA2, which are anti-thrombotic and 
pro-thrombotic mediators, respectively.65,66 As is the case with PGI2, 9α,11β-PGF2 also 
inhibits TXA2-induced platelet aggregation.53 
Prostanoids not only regulate normal biological processes but are also mediators 
involved in pathology. By activating their corresponding receptors, these lipid mediators 
have a direct effect on the production of chemokines, cytokines, and growth factors, as 
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well as expression levels of several pro-inflammatory enzymes.56 PGs in general, and 
PGE2 and PGI2 in particular, are detected in nearly all experimental models of 
inflammation, as well as in the synovial fluid of arthritic patients.67 In addition to PGE2 
and PGI2 being predominant pro-inflammatory signaling molecules, PGE2 is a potent 
pyretic agent; both PGF2α and 9α,11β-PGF2 cause contraction of bronchial, vascular, and 
arterial smooth muscle, and many of the prostanoids exert immuno-suppressive effects.68-
71
 PGE2 in particular has been implicated in increased susceptibility to infection, 
including several forms of cancer.72 
Playing yet another role in pathology, prostanoids not only propagate pathological 
processes – they can stimulate their resolution. A subset of prostanoids called 
cyclopentenone PGs (cyPGs) are non-enzymatic dehydration products of PGD2 and PGE2 
(Figure 6), resulting in the PGJ2 and PGA2 series, respectively, of which some possess 
anti-inflammatory, anti-neoplastic, and anti-viral properties.73 Electrophilic centers on the 
cyclopentenone rings of these cyPGs can form Michael adducts with sulfhydryl groups of 
intracellular regulatory proteins, modulating their function.74 For instance, 15-deoxy-
∆
12,14
-PGJ2 (15d-PGJ2) can bind to peroxisome proliferator-activated receptor γ (PPARγ), 
IκB kinase (IKK), or nuclear factor-κB (NF-κB) in vitro, each event resulting in the 
inhibition of the DNA binding activity of NF-κB, and having the effect of down-
regulating several pro-inflammatory genes.75-77 It should be noted, however, that a great 
amount of uncertainty remains regarding the significance, or even the existence, of cyPGs 
in vivo.78,79 
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Figure 6. Cyclopentenone prostaglandins. Spontaneous dehydration of PGE2 leads to the 
formation of the cyPG PGA2. Multiple steps of dehydration and isomerization of PGD2 
lead to the formation of the PGJ2 series of cyPGs. These lipid mediators have been 
implicated as signaling molecules that promote the resolution of inflammation. 
 
 
 Prostanoids play a delicate and complex role in the regulation of normal 
biological processes, the propagation of pathological events, and the resolution of such 
events. They are clearly important lipid mediators involved in a multitude of signaling 
pathways. Their importance is highlighted by the common therapeutic inhibition of COX 
enzymes. As summarized in the previous section of this introduction, NSAIDs are widely 
used as therapeutics for the treatment of pain, inflammation, and fever. The 
pharmaceutical mechanism of action of these small molecules involves the inhibition of 
COX, which subsequently inhibits primary prostanoid synthesis.16 
Since the isoform COX-2 has been associated with inflammation and several 
forms of cancer, COX-2-selective drugs (coxibs) such as celecoxib and rofecoxib were 
developed to better target the synthesis of specific prostanoids, particularly PGE2.80,81 
17 
 
Since drugs that target the COX enzymes are relatively non-specific for the inhibition of 
prostanoid production, treatment can lead to adverse gastrointestinal and cardiovascular 
side effects, which is described in more detail later in this introduction.82,83 In order to 
minimize such side effects, the specific targeting of the terminal prostanoid synthases 
immediately downstream of the COX enzymes holds promise as an alternative to 
treatment with NSAIDs and coxibs, but such drugs are not currently available. Though 
prostanoid research has progressed substantially for over half a century, much more 
progress is yet to be made. 
 
Leukotrienes 
 Another pathway by which arachidonic acid may be metabolized is by way of 
LOX enzymes, which are non-heme, iron-containing dioxygenases. Of particular interest 
is the enzyme 5-LOX, which catalyzes the formation of LTs (Figure 7), potent mediators 
of inflammation that are associated with acute and chronic inflammatory diseases such as 
asthma, rhinitis, and atherosclerosis.84,85 There are several isoforms of LOX including 5-, 
12-, and 15-LOX, named for the carbon position of arachidonic acid to which they add 
molecular oxygen, and they are present in leukocytes, platelets, and endothelial cells, 
respectively.86-88 Since 5-LOX synthesizes LTs and generates potent mediators of the 
allergic response, it has become the most widely studied of the isoforms with respect to 
inflammation research. 
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Figure 7. The leukotriene cascade. Arachidonic acid is metabolized by the non-heme, 
iron-containing dioxygenase 5-LOX, resulting in the formation of LTA4. This fatty acid 
serves as a substrate for LTA4 hydrolase and LTC4 synthase in the ultimate synthesis of 
LTB4, LTC4, LTD4, and LTE4, which are potent mediators of the allergic response. 
 
 
The 5-LOX cascade of arachidonic acid metabolism requires the formation of a 
multi-protein complex at the nuclear membrane that is induced by several immune and 
inflammatory signals.89 Similarly to the initiation of the COX pathway, cPLA2 is 
phosphorylated and translocated to the membrane along with 5-LOX as a result of the 
mobilization of intracellular calcium, at which point arachidonic acid is released from the 
lipid bilayer by cPLA2.28,90 Upon 5-LOX translocation to the membrane, the membrane-
bound 5-LOX-activating protein (FLAP) acts as a scaffold, theoretically playing the role 
of delivering arachidonic acid to 5-LOX.89,91 
5-LOX converts arachidonic acid to the unstable lipid epoxide LTA4 in a two-step 
process with 5-hydroperoxyeicosatetraenoic acid (5-HPETE) as an intermediate.92 LTA4 
is subsequently metabolized along one of two routes, being utilized as a substrate by 
either LTA4 hydrolase (LTA4H) or LTC4 synthase (LTC4S). LTA4H is a widely 
distributed protein in almost all mammalian cells that converts LTA4 to the chemotactic 
agent LTB4 via epoxide hydrolysis.93 Though LTB4 is generally considered to be a 
proinflammatory compound, LTA4H may also play a role in the resolution of 
inflammation, in that it degrades the chemotactic tripeptide Pro-Gly-Pro (PGP).94 
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LTC4S, which catalyzes the addition of the tripeptide GSH to the epoxide of 
LTA4 to form LTC4, has been observed in eosinophils, mast cells, and monocytes.95 The 
tripeptide moiety of LTC4 may subsequently undergo successive hydrolysis steps to 
generate LTD4 and LTE4. This class of LTs, called cysteinyl-leukotrienes (Cys-LTs) and 
previously known as the slow-reacting substance of anaphylaxis, is highly implicated in 
inflammatory diseases including asthma.96 While there continues to be uncertainty as to 
which enzymes catalyze the formation of LTD4 and LTE4 in vivo, the γ-glutamyl residue 
of LTC4 can be cleaved by γ-glutamyl transpeptidase (GGT) forming LTD4, and the 
remaining glycyl moiety of LTD4 can then be hydrolyzed by several dipeptidases, 
forming LTE4.97-102 
 Prior to hydrolysis, LTC4 is exported from the cell by multidrug resistance protein 
(MRP) 1 and MRP2.103 LTB4 is also typically exported from the leukocyte, but the 
mechanism of its secretion is not fully understood.104 The signaling effects of LTs are 
carried out by binding to rhodopsin-class receptors located at the plasma membrane of 
structural and inflammatory cells, including B LT receptor 1 (BLT1) and BLT2 for LTB4 
and Cys-LT receptor 1 (CysLT1) and CysLT2 for the Cys-LTs.105,106 
 LTs are lipid mediators that contribute to a variety of inflammatory and allergic 
diseases. LTB4 is a chemoattractant and activator of neutrophils, monocytes, and 
lymphocytes,105,107,108 LTD4 attracts eosinophils,109 and all Cys-LTs increase vascular 
permeability.109 Recent evidence suggests, however, that LT signaling also facilitates the 
host response against various types of infection,110 and they may even play are role in 
anti-inflammation signaling.111 
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 LTs represent an important class of arachidonic acid metabolites. They have a 
clear role in the initiation and propagation of inflammatory diseases and the allergic 
response, particularly with respect to asthma. This is underlined by the fact that asthma is 
therapeutically treated with 5-LOX inhibitors, such as zileuton, which is sold under the 
trade name Zyflo.96 Similarly, asthma and seasonal allergies are controlled using CysLT1 
antagonist drugs like montelukast and zafirlukast, whose trade names are Singulair and 
Accolate, respectively.64 Since the protein FLAP is essential to the initiation of LT 
synthesis, several FLAP inhibitors are currently in clinical development for the treatment 
of inflammation.50,112 Research regarding LT synthesis and signaling represents fertile 
ground for scientists with respect to developing treatments for allergic and inflammatory 
diseases. 
 
Lipoxins and Eoxins 
 A third pathway of arachidonic acid metabolism involves LOX enzymes in trans-
cellular biosynthesis. LXA4 and LXB4 may be produced via two different pathways 
involving such cell-cell interactions (Figure 8). In the first, 5-LOX catalyzes the 
conversion of arachidonic acid to LTA4 similarly to the first step of LT synthesis, at 
which point LTA4 is transferred to adherent permeabilized platelets and is converted to 
either LXA4 or LXB4 by the oxygenation activity of 12-LOX.113 In the second pathway, 
arachidonic acid is first oxygenated by 15-LOX in endothelial cells, producing 15(S)-
HPETE.114 This is subsequently taken up by polymorphonuclear cells (PMNs) or 
monocytes, converted to a 5,6-epoxytetraene intermediate by 5-LOX, and hydrolyzed by 
LXA4 hydrolase or LXB4 hydrolase, generating LXA4 or LXB4, respectively.115  
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Figure 8. Synthesis of lipoxins. Products of LOX metabolism, lipoxins are arachidonic 
acid derivatives produced by trans-cellular biosynthesis. They have been implicated as 
anti-inflammatory lipid mediators. 
 
 
Another class of LX called aspirin-triggered LX (ATL) is formed in endothelial 
cells following the acetylation of COX-2 (Figure 9). Therapeutic treatment with aspirin 
irreversibly acetylates Ser-516 of COX-2, resulting in arachidonic acid conversion to 
15(R)-HETE, as opposed to PGG2.116 This is then taken up by adherent leukocytes and 
oxygenated by 5-LOX, forming the 15-epimeric-LXs (15-epi-LXs) 15-epi-LXA4 and 15-
epi-LXB4.117 
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Figure 9. Aspirin-triggered lipoxins. Acetylation of COX-2 results in the trans-cellular 
formation of aspirin-triggered lipoxins, which may serve biologically as anti-
inflammatory and pro-resolution signaling molecules. 
 
 
Less is known of LX-receptor interactions, as compared to prostanoid- and LT-
receptor interactions. However, it is known that LXA4 and the ATLs bind to the GPCR 
formyl peptide receptor-like 1 (FPRL-1 or ALX) and that LXs act as partial agonists of 
the receptor CysLT1.118,119 LXs are known as anti-inflammatory and pro-resolution 
mediators. At nanomolar concentrations, they stimulate macrophages to ingest and clear 
neutrophils,120 and their signaling can elevate the levels of the anti-inflammatory cytokine 
transforming growth factor-β1 (TGF-β1), which down-regulates several pro-
inflammatory genes.121 LXs reduce the proliferation of fibroblasts, thereby counteracting 
the fibrotic response and improving tissue remodeling, and they have been observed to 
provide beneficial effects in various experimental models of infection, inflammation, and 
inflammatory diseases.122-128 
A relatively recently recognized class of eicosanoids is the EXs (Figure 10). 
Similar to the metabolism of arachidonic acid by 15-LOX described above, the synthesis 
of EXs is initiated in eosinophils, mast cells, or nasal polyps by the oxygenation activity 
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of 15-LOX, giving rise to 15(S)-HPETE.129 The resulting hydroperoxide is then 
dehydrated either spontaneously or by the 12-LOX activity of 15-LOX, giving rise to the 
lipid epoxide 14,15-LTA4, or so-called EXA4.130 EXA4 may then be utilized as a 
substrate by LTC4S, which catalytically adds GSH to the epoxide, forming EXC4.131 
Similarly to LTC4, EXC4 can be further metabolized to EXD4 and EXE4, lipid mediators 
that have similar signaling effects as the Cys-LTs, though less potent.131 
 
 
 
Figure 10. Synthesis of eoxins. Arachidonic acid is metabolized by 15-LOX to the 
epoxide EXA4, with 15(S)-HPETE as an intermediate. Similar to LTA4, EXA4 serves as a 
substrate for LTC4S for the synthesis of EXC4, which has similar pro-inflammatory 
signaling properties as LTC4. 
 
 
 LXs and EXs represent less well-characterized classes of eicosanoids. They 
clearly contribute to inflammatory, as well as anti-inflammatory, responses in vitro. 
Being relatively unrecognized yet important classes, they highlight the need for continued 
eicosanoid research. 
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Cytochrome P450-derived Eicosanoids 
 The primary chemistry of the membrane-bound, heme-containing CYP enzymes 
involves the oxidation of exogenous compounds, including toxins and drugs, as well as 
carcinogens.132 Though less well-characterized than the previously discussed eicosanoids, 
CYP metabolites of arachidonic acid represent yet another class of these lipid mediators 
(Figure 11). Oxygenation and hydroxylation of arachidonic acid by CYP enzymes give 
rise to EETs, HETEs, and DHETs, which have anti-inflammatory and anti-thrombotic 
signaling properties.133-135 
 
 
 
Figure 11.  Cytochrome P450-derived eicosanoids. A variety of cytochrome P450 
enzymes may utilize arachidonic acid as a substrate for the production of various lipid 
mediators that may serve as anti-inflammatory and anti-thrombotic signaling molecules. 
 
 
 EETs derive their anti-inflammatory role by inhibiting IKK or by binding to 
PPARγ, having the effect of down-regulating several pro-inflammatory signaling 
pathways downstream of NF-κB, similar to the bioactivity of 15d-PGJ2 described 
above.135,136 In addition, EETs inhibit platelet aggregation resulting from vascular 
injury.137 HETEs are anti-inflammatory mediators with respect to the fact that they inhibit 
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LT biosynthesis, and they are anti-thrombotic in that they have been demonstrated to 
inhibit TX-induced platelet aggregation.138,139 
 As with LXs and EXs, the EETs, HETEs, and DHETs represent classes of 
eicosanoids that are clearly in need of further research. They highlight the important and 
complex nature of lipid mediators, particularly with respect to those derived from 
arachidonic acid. 
 The eicosanoids constitute a widespread and complex family of lipid mediator 
molecules derived from arachidonic acid. The potent signaling activities of these 
mediators include a multitude of normal biological processes, as well as the initiation and 
propagation of pathological events. As eicosanoid research has progressed, the 
importance of these molecules has been established. 
 Pathways of polyunsaturated fatty acid oxygenation analogous to that of 
arachidonic acid metabolism have relatively recently given light to new classes of lipid 
mediators that possess anti-inflammatory and pro-resolving properties.140 These so-called 
protectins and resolvins include metabolites of the omega-3 fatty acids eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA).141 While these mediators are not 
technically eicosanoids, in that they are not derived from arachidonic acid, they do 
highlight the expanding frontier of research regarding lipid mediator signaling pathways 
of the inflammatory response. It proves that continued efforts in this field are obviously 
important to further the understanding of the biology of inflammation. 
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The MAPEG Superfamily 
 
Glutathione Transferases 
 GSTs are enzymes with a wide array of activities principally functioning in the 
metabolic detoxification of xenobiotic and endogenous compounds.142 GST activity 
mainly involves the nucleophilic addition of the reduced tripeptide GSH (Figure 12) to 
compounds containing an electrophilic carbon, nitrogen, or sulfur atom.143-145 In addition 
to GSH conjugation, however, GSTs catalyze reactions as thiol transferases, peroxidases, 
and isomerases, and they also possess non-catalytic activity including ligand binding.145-
147
 GST activity has arisen independently at least four separate times in evolutionary 
history, resulting in four distinct GST families classified as cytosolic, mitochondrial, 
bacterial, and microsomal, that are divergent in sequence and structure.148,149 
 
 
 
Figure 12. Glutathione. γ-L-Glutamyl-L-cysteinylglycine is the major low-molecular 
weight thiol in cells of eukaryotes and gram-negative bacteria and is the primary 
substrate of the glutathione transferases. 
 
 
The Cytosolic Family 
The ancient family of cytosolic GSTs is ubiquitous in all aerobic organisms and is 
the most abundant of the GST families.145 It is divided into seven classes, including 
Alpha, Mu, Pi, Sigma, Theta, Omega, and Zeta, based on sequence similarity and 
immunological reactivity.145 Recently, a novel class of cytosolic GSTs termed Nu has 
been described, consisting of unique structural and functional properties.150 Even though 
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each monomer of the cytosolic GSTs is catalytically independent, nearly all are active 
only as dimers, with heterodimerization restricted to subunits belonging to the same 
class.151,152 All cytosolic GSTs, with the exception of the aforementioned Nu class, 
display a high level of structural conservation with a common three-dimensional fold in 
addition to the dimeric structural formation. Each subunit is composed of two domains, 
with the N-terminal GSH-binding thioredoxin domain consisting of β strands and α 
helices. The C-terminal domain is all-helical and contains a binding site for hydrophobic 
substrates.144,145,153  
 
The Mitochondrial Family 
The mitochondrial family of GSTs, also referred to as the Kappa class, has 
homologues in eukaryotes and bacteria and is located in mitochondria and 
peroxisomes.149 As with the cytosolic family of GSTs, the mitochondrial GSTs possess a 
thioredoxin GSH-binding domain.154,155 Unlike the C-terminal alpha-helical domain of 
the cytosolic GSTs, though, the equivalent alpha-helical domain is inserted into the 
thioredoxin domain of mitochondrial GSTs, underlining the divergent evolution of these 
two families from a common ancestor.144,149,154 
 
The Bacterial Family 
The family of bacterial fosfomycin-resistance proteins (Fos) are found in plants, 
animals, and bacteria.149 The divalent metal-binding Fos proteins, related to glyoxylases 
and extradiol dioxygenases, are divided into three classes inculding FosA, FosB, and 
FosX, depending on their utilization of GSH, other sulfhydryl-containing compounds, or 
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H2O as the primary substrate, respectively.156-158 The conserved structure of these 
enzymes is unique from those of the cytosolic and mitochondrial families, underlining 
another independent evolutionary route of GST activity.149 
 
The Microsomal Family 
What was once termed the microsomal family is now known as a widespread 
superfamily of proteins called the “membrane-associated proteins in eicosanoid and 
glutathione metabolism” (MAPEG).159,160 This is something of a misnomer, however, 
since hydrophobicity plots and several determined crystal structures suggest that all 
members possess multiple membrane-spanning regions, making them integral membrane 
proteins.161-166 They exist in eukaryotes as well as prokaryotes, and six mammalian 
members of the superfamily have been identified including microsomal GST 1 (MGST1), 
MGST2, MGST3, LTC4S, FLAP, and MPGES1.46,161,167-171 The MAPEG superfamily is 
discussed in further detail below. 
 
MAPEG Discoveries 
 
MGST1 and LTC4S 
 The mammalian MAPEG members were discovered in the 1980s and 1990s, with 
MGST1 the first to be identified. The membrane-bound GST was first isolated in 1982 
from rat liver, constituting 2.5 – 3% of the overall microsomal protein.167 Differences 
from cytosolic GSTs in molecular weight and substrate specificity, in addition to the fact 
29 
 
that antibodies that react with cytosolic GSTs did not react with MGST1, demonstrated 
the identification of the first microsomal GST. 
Three years later LTC4S was identified when it was observed that the microsomal 
fraction of rat basophilic leukemia (RBL) cells produced LTC4 when in the presence of 
LTA4 and GSH.168 Because MGST1 is also capable of catalyzing the addition of GSH to 
LTA4 (Figure 13), it was initially uncertain as to whether or not LTC4S and MGST1 
were the same protein. However, LTC4S could be chromatographically separated from 
MGST1. Also, LTC4S was unable to catalyze the addition of GSH to the common 
laboratory GST substrate 1-chloro-2,4-dinitrobenzene (CDNB), a catalytic function of 
MGST1. Further, the LTC4S catalytic addition of GSH to LTA4 proved to be kinetically 
different than that of MGST1. Finally, the inhibition kinetics by S-hexylglutathione of the 
LTC4 synthesis reaction differed between the two enzymes, indicating that LTC4S was 
not MGST1 but a unique microsomal protein. 
 
 
 
Figure 13. Glutathione transferase activities of microsomal glutathione transferase 1 and 
leukotriene C4 synthase. Both MGST1 and LTC4S are capable of catalytically adding 
GSH to LTA4, while only MGST1 is capable of utilizing CDNB as a secondary substrate. 
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FLAP 
 The identification of FLAP is an interesting story. The enzyme 5-LOX converts 
arachidonic acid to LTA4 in a two-step process with 5-HPETE as an intermediate, as 
described in the previous section of this introduction.92,172,173 It was observed in 1989 that 
the orally active compound MK-886 inhibited LTA4 synthesis, and it was initially 
assumed that this molecule bound to 5-LOX. However, it was subsequently realized that, 
while LT synthesis is inhibited by MK-886 in whole human PMN leukocytes, it has no 
inhibitory effect on broken cell preparations or purified 5-LOX.174 The following year, 
the cellular target of MK-886 was identified using an 125I radio-labeled photo-affinity 
MK-886 analogue. Subsequently, MK-886-linked agarose gels were utilized as affinity 
matrices to isolate FLAP, the true target of MK-886.169 
 
MGST2 and MGST3 
 The remaining three mammalian members of the MAPEG superfamily, MGST2, 
MGST3, and MPGES1, were identified in the 1990s. A TBLASTN search of GenBank 
utilizing the amino acid sequence of FLAP revealed a gene product with 33% and 44% 
sequence identity to FLAP and LTC4S, respectively. Northern blot analysis showed that 
the mRNA of this protein, MGST2, is expressed in tissues throughout the body but that it 
differs from FLAP and LTC4S in distribution and expression level. MGST2 displays 
GST activity toward CDNB and LTA4, and it is also capable of reducing the 
hydroperoxide of 5-HPETE to 5-HETE in the presence of GSH (Figure 14).170,171 
The amino acid sequence of MGST2 was then utilized in a TBLASTN search of 
GenBank to reveal MGST3, a clone 20, 22, 27, and 36% identical to FLAP, MGST1, 
31 
 
LTC4S, and MGST2, respectively. Similarly to MGST2, Northern blot analysis revealed 
that the mRNA expression for MGST3 has a wide tissue distribution. The enzyme does 
not display GST activity toward CDNB, but it does catalytically add GSH to LTA4 and is 
capable of reducing 5-HPETE in the presence of GSH.171 
 
 
 
Figure 14. Glutathione-dependent peroxidase activity of MGST2 and MGST3. Both of 
the enzymes MGST2 and MGST3 catalyze the reduction of 5-HPETE to 5-HETE in the 
presence of GSH. 
 
 
MPGES1 
Similarly to the identification of MGST2 and MGST3, the amino acid sequence 
of MGST1 was utilized in a TBLASTN search of GenBank to reveal a gene product with 
38% sequence identity with MGST1.46,175 Northern blot analysis showed that the mRNA 
of this protein, MPGES1, is expressed in placenta, prostate, testis, mammary gland, and 
bladder. In addition, the mRNA is highly expressed in A549 and HeLa cancer cell lines. 
When A549 cells are grown in the presence of IL-1β, a significant induction of MPGES1 
is observed.171 Because COX-2 is also induced in A549 cells in the presence of IL-1β and 
converts arachidonic acid to PGH2, it was hypothesized that MPGES1 might utilize PGH2 
as a substrate.171,176-178 As such, the membrane fraction of recombinant MPGES1 was 
shown to catalyze the GSH-dependent oxido-reduction of PGH2 to PGE2 (Figure 15).171 
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Figure 15. PGE synthase activity of MPGES1. MPGES1 catalyzes the oxido-reduction 
of the endoperoxide of PGH2 in the presence of GSH, giving rise to PGE2. 
 
 
MAPEG Families 
 Through the use of multiple sequence alignments and phylogenetic calculations, 
the MAPEG superfamily can be divided into six families (Figure 16) named for the 
mammalian members that each contains.161 In addition, there are ancient prokaryotic 
subfamilies belonging to the MGST2, FLAP, and LTC4S families, as well as two distinct 
subfamilies belonging to Escherichia coli and Synechocystis sp. Insect members are 
similar to the MGST1 and MPGES1 families, while MAPEG members from fish are 
found in all six mammalian families. Though the evolutionary tree clearly divides the 
MAPEG superfamily, some families can be grouped together according to sequence 
similarity. Group I consists of MGST2, FLAP, and LTC4S, group II is occupied only by 
MGST3, group III is comprised of the unique bacterial enzymes, and group IV consists of 
MGST1 and MPGES1.160 
 
 
33 
 
 
Figure 16. The MAPEG superfamily. The superfamily of membrane-associated proteins 
in eicosanoid and glutathione metabolism can be broken up into several families 
belonging to one of four groups, based on phylogenetic analysis. The figure is adapted 
from one of reference 160. 
 
 
MAPEG Structures 
 Initial structural analyses of the MAPEG superfamily utilizing sequence 
alignments along with hydropathy plots suggested that the proteins contained multiple 
membrane-spanning regions.159,161,179-181 Subsequently, the three-dimensional crystal 
structures of MGST1 and MPGES1 were determined by electron microscopy of two-
dimensional crystals, and those of FLAP and LTC4S were determined by X-ray 
diffraction.162-166 The first of these to be determined was MGST1, and the structure 
revealed a homotrimer with four transmembrane (TM) helices per monomer. The N- and 
C-termini protrude from the lumenal boundary of the membrane, and each subunit 
contains one large cytosolic loop. MGST1 was crystallized in the presence of GSH, and 
the structure reveals three molecules of GSH bound at the interface of neighboring 
subunits.162 These characteristics have proven to be conserved among the other members 
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of the MAPEG superfamily (Figure 17), with the exception of FLAP, which has not been 
shown to bind GSH.163-166 The structure of each of these proteins is discussed in more 
detail below. 
 
 
 
Figure 17. The conserved structure of the MAPEG superfamily. The homotrimeric 
structures of (A) MGST1, (B) FLAP, (C) LTC4S, and (D) MPGES1 are shown in 
salmon, slate, and wheat highlighting individual subunits. Dotted lines represent 
approximate boundaries of the lipid bilayer. All of the crystal structures reveal four TM 
helices per monomer, the carboxy and amino termini protruding into the lumenal space of 
the perinuclear membrane (bottom), and extended loops exposed to the cytosolic space 
(top). All of the proteins were crystallized in the presence of GSH (green sticks) with the 
exception of FLAP, which has not been shown to bind GSH. 
 
 
MGST1 Structure 
The crystal structure of rat MGST1 in complex with GSH (Figure 18) was 
determined to 3.2 Å resolution by electron diffraction of two-dimensional crystals.162 As 
noted above, MGST1 adopts a homotrimeric conformation with a total of twelve TM 
helices, with TM II forming the core region of the enzyme. TM II is connected to TM I 
by a large, flexible cytosolic loop and to TM III by a short lumenal loop. TM III, then, is 
connected to TM IV by a short proline-rich loop on the cytoplasmic side of the 
membrane. The binding site for the primary substrate of MGST1, GSH, is located at the 
interface of neighboring subunits.162,182 This location is in agreement with 
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hydrogen/deuterium (H/D) exchange mass spectrometry (MS) data, which also suggest 
conformation dynamics among TM I, TM II, and TM III upon GSH binding.183 The 
crystal structure reveals three occupied GSH binding sites, however only one site is 
catalytically active at a time.162,184-187 In addition to the GSH site, H/D exchange kinetic 
data suggest two distinct secondary substrate binding sites: one for hydrophilic 
compounds and the other for hydrophobic compounds.183 
 
 
 
Figure 18. Crystal structure of MGST1. MGST1 is a homotrimeric integral membrane 
protein consisting of a total of twelve TM helices. Individual subunits are colored in 
salmon, slate, and wheat. Three molecules of GSH are bound at the interface of 
neighboring subunits and are represented by green sticks. H/D exchange kinetic analysis 
reveals conformational dynamics induced by ligand binding and two overlapping 
secondary substrate-binding sites, highlighted in cyan: one for electrophilic substrates (A) 
and another for hydrophobic substrates (B). 
 
 
FLAP Structure 
The crystal structure of human FLAP in complex with the LT synthesis inhibitor 
MK-591 (Figure 19) was determined to 4.0 Å by X-ray diffraction.165 As with MGST1, 
FLAP is a homotrimeric integral membrane protein with four TM helices per monomer, 
in which the N- and C- termini protrude into the lumen, TM I and TM II as well as TM 
III and TM IV are connected by cytosolic loops, and TM II and TM III are connected by 
a short lumenal loop. A structural comparison with MGST1, however, reveals that the 
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GSH binding site is not conserved within FLAP. In fact, co-crystallization of FLAP with 
GSH fails to produce electron density for GSH in the corresponding putative GSH 
binding site. Inhibitor MK-591 is bound within the plane of the nuclear membrane, 
making contacts with residues on TM I and TM II of one subunit and TM IV of the 
neighboring subunit. 
 
 
 
Figure 19. Crystal structure of FLAP. Like MGST1, FLAP is a homotrimeric protein 
with four TM helices per monomer. Unlike MGST1, FLAP has no known catalytic 
function and has not been shown to bind GSH. The protein was crystallized in the 
presence of the LT synthesis inhibitor MK-591, shown in cyan sticks bound at the 
interface of neighboring subunits. 
 
 
LTC4S Structure 
The X-ray crystal structure of human LTC4S in complex with GSH (Figure 20) 
was determined to 3.3 Å, and at the same time, the apo and GSH-bound forms were 
determined to 2.00 and 2.15 Å, respectively, by two separate research groups.163,164 As 
with MGST1 and FLAP, LTC4S is a homotrimeric integral membrane protein with four 
TM helices, two cytosolic loops, and one lumenal loop per monomer. Unlike the former 
proteins, however, LTC4S contains a fifth, C-terminal helix that, along with the N-
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terminus, protrudes beyond the lumenal membrane boundary. Three molecules of GSH 
bind in a U-shaped conformation, making contacts with residues on TM I and TM II of 
one subunit and TM II, TM III, and TM IV of the neighboring subunit. The sulfhydryl 
group of each GSH is exposed to the lipid bilayer, coming within 3.2 Å of Arg-104, 
which possibly plays the role of shifting its pKa to activate thiolate formation. In each of 
the published studies, an n-dodecyl-β-D-maltoside (DDM) detergent molecule was 
observed bound within the bilayer space, making contacts with residues of TM I and TM 
II of one subunit and TM IV of its neighbor. This DDM-binding pocket has been 
proposed as the putative LTA4 substrate-binding site. 
 
 
 
Figure 20. Crystal structure of LTC4S. The overall structure of LTC4S is conserved 
amongst the other determined structures of the MAPEG superfamily. However, in 
addition to the four TM helices of each subunit of the homotrimeric LTC4S, a fifth α-
helix extends into the lumenal space of the endoplasmic reticulum. Three molecules of 
GSH, shown in green sticks, are bound at the interface of neighboring subunits in a U-
shaped conformation. Three molecules of the detergent DDM, shown in cyan sticks, are 
bound within a hydrophobic cleft overlapping the GSH-binding site and have been 
proposed as occupying the LTA4 substrate-binding sites. 
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MPGES1 Structure 
The crystal structure of human MPGES1 complexed with GSH (Figure 21) was 
determined by electron diffraction of two-dimensional crystals to 3.5 Å.166 Similarly to 
the other MAPEG members, MPGES1 is a homotrimer with four TM helices per subunit, 
with the N- and C- termini extending into the lumenal space of the ER. Each monomer 
also contains one elongated cytosolic loop, one short cytosolic loop, and one short 
lumenal loop. As with LTC4S, GSH is bound in a U-shaped conformation within the 
plane of the membrane, making contacts with TM I and TM II from one monomer and 
TM II, TM III, and TM IV of its neighbor. Another similarity with LTC4S is that the 
GSH sulfhydryl comes within 3.8 Å of Arg-126 and is oriented toward the lipid bilayer, 
but unlike LTC4S the thiol moiety of GSH is not exposed to the lipid bilayer. Three key 
residues within the membrane region along TM IV have been proposed as the entrance 
for the PGH2 substrate binding site.188 The structure of MPGES1 is described in greater 
detail in the following section. 
 
 
 
Figure 21. Crystal structure of MPGES1. Consistent with the other MAPEG members, 
MPGES1 is a homotrimeric integral membrane protein composed of twelve TM helices. 
Like LTC4S, three GSH molecules (green sticks) are bound at the interface of 
neighboring subunits in a U-shaped conformation. Mutagenesis and inhibition kinetics 
analyses reveal the putative entrance to the active site along TM IV, highlighted in cyan. 
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MAPEG Functions 
 
Cytoprotection 
MGST1 is a widely expressed enzyme, and it is present at especially high levels 
in the liver, where it constitutes up to 3% of the total microsomal protein.167 It efficiently 
catalyzes the conjugation of GSH to xenobiotic and endogenous electrophiles, such as the 
common laboratory substrate CDNB as well as polyhalogenated unsaturated 
hydrocarbons. It is a rather inefficient GST, however, when utilizing epoxides such as 
LTA4 as substrates.189-191 The reaction rate of GST and GSH-dependent peroxidase 
activity of MGST1 is enhanced by electrophilic reagents such as N-ethylmaleimide 
(NEM), which covalently modify a cytosolic cysteine residue on the enzyme.192-194 
MGST1 is also activated by, and provides cellular protection from, oxidative stress as it 
catalyzes the reduction of hydrophobic peroxides derived from lipids and fatty acids.195-
198
 Taken together, these facts suggest a cellular protective role for MGST1, particularly 
with respect to oxidative damage to membranes. 
 Less is known of the cellular functions of MGST2 and MGST3. However, it is 
known that both enzymes catalyze the GSH-dependent reduction of 5-HPETE to 5-
HETE, and that MGST2 adds GSH to electrophiles such as CDNB, suggesting that both 
enzymes may play a role in cellular detoxification.170,171 
 
Eicosanoid Biosynthesis 
Several members of the MAPEG superfamily are involved in the synthesis of 
eicosanoids. Since this topic is detailed in the previous section, it is only briefly 
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mentioned here, with respect to the MAPEG members implicated. Involved in the 
synthesis of the pro-inflammatory LTs are FLAP and LTC4S. The LT pathway of 
arachidonic acid metabolism is dependent on the presence of FLAP, acting as a scaffold 
for 5-LOX, which catalyzes the conversion of arachidonic acid to LTA4.89,91 The 
determined crystal structure of FLAP suggests that its binding site within the bilayer is 
ideal for capturing laterally-diffusing arachidonic acid, and it is assumed that arachidonic 
acid is presented to 5-LOX by FLAP, however the structural basis for this process is 
unknown.165,199-201 The 5-LOX product LTA4 is subsequently metabolized along one of 
two routes. LTA4H catalyzes the hydrolysis of LTA4 to LTB4, while LTC4S catalytically 
adds GSH to LTA4, giving rise to LTC4, the first member of the potent Cys-
LTs.93,95,168,202 
Two other members of the MAPEG superfamily may potentially play roles in the 
5-LOX pathway of arachidonic acid metabolism. MGST2 catalyzes the addition of GSH 
to LTA4 in vitro, but the role of MGST2 as an LTC4 synthase in vivo has not been 
established.170,171 While MGST1 does not catalyze the synthesis of LTC4 as rapidly as 
does LTC4S, it is capable of tightly binding the LT within the plane of the 
membrane.183,203 The physiological function for this, however, remains uncertain. 
In addition to LT synthesis, the MAPEG superfamily plays a role in the 
production of PGE2. The COX-2-derived PGH2 serves as a substrate for MPGES1 in the 
formation of inducible PGE2, which is a predominant mediator of pain, fever, and 
inflammation.50 The role of MPGES1 in the production of PGE2 and its implication in 
pathologic events is detailed in the following section of this introduction. 
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 The MAPEG superfamily represents a unique set of GST proteins. The GSH 
conjugating and GSH-dependent peroxidase activities of MGST1, MGST2, and MGST3 
impart important detoxification properties to these family members. In addition, their 
integral membrane structures make them particularly effective in providing 
cytoprotection to membranes from oxidative damage. 
 In addition to detoxification, the MAPEG superfamily plays an important role in 
arachidonic acid metabolism. FLAP, LTC4S, and MPGES1 are crucial to the syntheses 
of LTs, Cys-LTs, and PGE2, respectively, and their structures make them ideal for 
binding unstable hydrophobic ligands and substrates within the bilayer. Since these lipid 
mediators are important pro-inflammatory signaling molecules, FLAP, LTC4S, and 
MPGES1 represent promising therapeutic targets for the treatment of inflammatory 
disease. 
 
Microsomal Prostaglandin E Synthase 1 
 At physiological conditions, the chemically unstable endoperoxide of PGH2 
rapidly decomposes into a mixture of the prostanoids PGD2 and PGE2 (Figure 22) with a 
half-life on the order of several minutes.204 Being potent biologically active signaling 
molecules, the synthesis of prostanoids must be tightly controlled. As such, several 
prostanoid synthases exist that utilize PGH2 as a substrate, as summarized in the 
Eicosanoid section of this introduction. 
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Figure 22. Decomposition of PGH2. Under physiological conditions, the endoperoxide of 
PGH2 undergoes spontaneous oxido-reduction, resulting in the formation of PGD2 and 
PGE2. 
 
 
With regard to PGE2 synthesis, there are three PGES enzymes that catalyze the 
isomerization of PGH2 resulting in a keto group at position C-9 and a hydroxyl group at 
C-11. These enzymes include the cytosolic CPGES and the membrane-bound proteins 
MPGES1 and MPGES2. It is generally accepted that CPGES and MPGES2 produce 
homeostatic levels of PGE2, while MPGES1 synthesizes the inducible form of the 
prostanoid.46-48 In this section, particular emphasis is placed on the structural and 
functional properties of MPGES1, as well as its physiological and pathological roles in 
biology. 
 
MPGES1 Catalytic Function 
 MPGES1 is a GSH-dependent PGH2 isomerase, having a KM value for GSH of 
0.71 mM and KM and kcat/KM values for PGH2 of 0.16 mM and 310 mM-1 s-1, 
respectively.205 Given that the reaction is an oxido-reduction, GSH is not consumed. 
MPGES1 is also capable of utilizing PGG2 as an alternate substrate (Figure 23) with 
similar kinetics, producing 15-hydroperoxy-PGE2, which can then be reduced by the 
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peroxidase activity of COX giving PGE2, though this route of PGE2 production is not 
likely to occur in vivo.205,206 
 
 
 
Figure 23. Substrates of MGPES1. MPGES1 catalyzes the oxido-reduction of the 
endoperoxide bridge of both PGG2 and PGH2 in vitro. However, the utilization of PGG2 
as a substrate is unlikely to occur in vivo. 
 
 
In addition to catalyzing the isomerization of PGG2 and PGH2, MPGES1 
catalyzes the conjugation of GSH to CDNB with a specific activity of 0.8 µmol min-1  
mg-1.205 This common GST activity, while relatively low compared to a typical GST, 
highlights the close evolutionary relationship of MPGES1 to the MGSTs of the MAPEG 
superfamily. Another common GST activity that MPGES1 possesses is the GSH-
dependent reduction of hydroperoxides, in that it reduces cumene hydroperoxide and 5-
HPETE with specific activities of 0.17 µmol min-1 mg-1 and 0.043 µmol min-1 mg-1, 
respectively.205 Since the catalytic rates are relatively low for MPGES1 when utilizing 
CDNB, cumene hydroperoxide, or 5-HPETE as substrates, these GST and GSH-
dependent peroxidase activities are unlikely to be functions of the enzyme in vivo, but 
they do highlight the evolutionary relationship of MPGES1 to the GSTs. 
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MPGES1 Chemical Mechanism 
 The chemical mechanism for the catalytic formation of PGE2 by MPGES1 
(Figure 24) has been proposed based on the crystal structure of the enzyme.166 Because 
MPGES1 also catalyzes the GSH-dependent peroxidase of lipid hydroperoxides, a GSH-
dependent peroxidase-like mechanism is favored, as opposed to a concerted acid-base 
mechanism, and involves GSH thiolate attack on an oxygen atom of PGH2. Thiolate 
formation is stabilized by Arg-126, which is within 3.8 Å of the GSH sulfhydryl. The 
chemical reaction begins with thiolate attack on oxygen at position C-9 of the PGH2 
endoperoxide. This is followed by proton donation by Arg-126 to the oxygen at C-11, 
forming the hydroxyl group. Finally, Arg-126 abstracts a proton from carbon C-9, 
forming the carbonyl as the oxygen-sulfur bond is broken, and the GSH thiolate is 
regenerated. 
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Figure 24. Chemical mechanism of MPGES1. The formation of the thiolate form of 
GSH, denoted GS¯ , is stabilized by residue Arg-126. The reaction is initiated by GS¯  
attack on the oxygen at position C-9 of PGH2, followed by protonation of the oxygen at 
position C-11 by Arg-126. A proton from C-9 is then abstracted by Arg-126, forming a 
carbonyl and breaking the oxygen-sulfur bond, which regenerates GS¯ . 
 
 
The corresponding arginine residue in LTC4S, Arg-104, is critical for thiolate 
formation, suggesting that arginine may play a conserved role in MAPEG catalysis.207 
However, mutation of Arg-126 to either alanine or glutamine converts MPGES1 from a 
GSH-dependent isomerase into a GSH-dependent reductase that produces PGF2α from 
PGH2, suggesting that Arg-126 is important for catalysis but not necessary for thiolate 
formation.208 Though the crystal structure favors Arg-126 as both the proton donor and 
acceptor in the reaction, other residues may play these roles in the mechanism. Since Tyr-
28 and Tyr-130 are within 3.6 and 7.1 Å of the GSH thiol, respectively, they are 
reasonable candidates for proton donation to oxygen at C-11 and proton abstraction from 
carbon C-9 of PGH2.166 This suggests that there could be alternatives to the proposed 
mechanism that may involve a single tyrosine, a combination of tyrosine residues, or a 
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combination of tyrosine and arginine. Clearly, additional structure-function studies 
combining crystallography with mutagenesis are needed to improve the understanding of 
the mechanism. 
 
MPGES1 Structure 
 Membrane proteins encompass 20-30% of the proteome of most organisms.209 
Pharmacologically, membrane proteins represent about 40% of all human drug targets, 
which are often GPCRs, being that they are therapeutically attractive due to their 
fundamental role in signal transduction.210 Even so, structural information of membrane 
proteins is relatively lacking. This is highlighted by the fact that membrane proteins 
account for only about 1% of all entries in the Protein Data Bank (PDB).211 In fact, even 
though crystal structures of soluble proteins were first determined in the 1950s, it was 
nearly thirty years before the same could be said of a membrane protein.212,213 While 
crystallography of membrane proteins is challenging due to the hydrophobicity of the 
protein surface and the fact that they tend to be flexible and unstable, significant progress 
has been made in determining the structures of the MAPEG proteins.162-166  
The three-dimensional structure of MPGES1 (Figure 25) was determined by 
electron diffraction of two-dimensional crystals induced in the presence of 
phospholipids.166 The 3.5 Å resolution structure of the human enzyme, complexed with 
the essential cofactor GSH, gives insight into the dynamic behavior of this integral 
membrane protein. As summarized in the previous section, MPGES1 possesses the 
conserved structure of the MAPEG proteins, in that it is a homotrimeric integral 
membrane protein with each subunit contributing four TM helices. 
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Of the twelve-helical bundle, TM II forms the core of the protein, which is 
surrounded by the remaining helices. A proline residue at position 81 gives TM II a slight 
kink, resulting in a cone-shaped cavity opening toward the cytoplasmic portion of the 
enzyme. Extended cytosolic loops, connecting TM I to TM II partially cover this 
opening. A short lumenal loop connects TM II to TM III, and TM III and TM IV are 
connected by a short cytosolic loop. The amino termini protruding from the lumenal side 
of the membrane are flexible, and so the first ten residues are disordered in the structure. 
The N-terminus of TM I is in close proximity to the C-terminus at the end of TM IV of 
the neighboring subunit. 
 
 
 
Figure 25. Structural analysis of MPGES1. MPGES1 is a homotrimeric integral 
membrane protein, with each subunit colored here in salmon, slate, and grey. The dotted 
lines denote the approximate boundaries of the lipid bilayer. The enzyme consists of a 
total of twelve TM helices, with the amino and carboxy termini protruding into the 
lumenal (bottom) space of the endoplasmic reticulum. Three molecules of GSH (green 
sticks) are bound in a polar pocket at the interface of neighboring subunits, and the 
binding site is partially covered by extended cytosolic (top) loops. 
 
 
The effects of site-directed mutagenesis, coupled with analysis of the crystal 
structure, highlight important molecular contacts.50,166,214 Side chain interactions between 
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polar and acidic residues of TM II and basic residues of TM III, toward the bottom of the 
cavity mentioned above, provide stabilization to the core of the structure. Several polar 
residues along the cytoplasmic face of TM II, toward the center of the cavity, provide 
contacts to GSH that are crucial to its binding. Also in this region is a salt bridge between 
His-72 and Glu-77 of neighboring TMs II. There is an additional salt bridge in this 
vicinity, connecting TM I and TM II of the same monomer, between Lys-26 and Asp-75. 
The cofactor GSH binds at the interface of neighboring subunits in a U-shaped 
conformation (Figure 26), similar to that observed for LTC4S,163,164 making contacts with 
TM I and TM II of one subunit and TM II, TM III, and TM IV of its neighbor.166 In 
addition to the polar interactions with TM II mentioned above, the carboxylate groups at 
either end of the GSH molecule make salt bridge contacts with Arg-38 of TM I and Arg-
70 of TM II. The sulfhydryl group of GSH is oriented toward the lipid bilayer, stabilized 
by Arg-126, but makes no contact with the membrane as it is blocked by TM I and TM 
IV of neighboring subunits. This is in correlation with the apo-structure of LTC4S, which 
also displays this “closed” conformation.164 This is, however, in contrast to the GSH-
complexed structure of LTC4S in which a V-shaped opening between TM I and TM IV is 
occupied by a DDM molecule, exposing the GSH thiol.163,164 This suggests that there is a 
dynamic opening of these helices that allows substrate access to GSH, which may also be 
true for the structurally homologous MPGES1. 
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Figure 26. GSH binding of MPGES1. The subunits of MPGES1 are colored salmon, 
slate, and grey. Dotted lines represent the boundaries of the lipid bilayer. (A) MPGES1 
binds three molecules of GSH (green sticks) in a U-shaped conformation within the plane 
of the membrane. (B) The bound GSH molecule makes contacts with TM I and TM II of 
one subunit and TM II, TM III, and TM IV of its neighbor. (C) The sulfhydryl of the 
GSH molecule is oriented toward the lipid bilayer, but it makes no contact with the 
bilayer, as it is obscured by TM I of one subunit and TM IV of the adjacent subunit. 
 
 
MPGES1 as a Drug Target 
 Under normal physiological conditions, MPGES1 expression is relatively low and 
has been observed in placenta, prostate, testis, mammary gland, and bladder.46 However, 
the enzyme is dramatically induced in response to several pro-inflammatory stimuli 
including LPS, IL-1β, and TNF-α, similarly to COX-2 induction.50 The down-regulation 
of MPGES1, much like that of COX-2, can be brought about with the administration of 
glucocorticoids, which suggests a functional coupling between these two inducible 
enzymes.49 
 As discussed previously, there are two COX isozymes. The isoform COX-1 is a 
constitutive enzyme that produces homeostatic levels of the primary prostanoids, while 
COX-2 is an inducible enzyme whose up-regulation results in the production of 
prostanoids causative of inflammation.36,37 Basal levels of production of PGE2 are 
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thought to contribute to the maintenance of the gastric mucosa by maintaining the mucus 
bicarbonate barrier and inducing growth factors including the vascular endothelial growth 
factor (VEGF).215 Therapeutic treatment with NSAIDs such as aspirin and ibuprofen 
inhibits both COX isozymes, prevents production of all primary prostanoids including 
PGE2, and subsequently leads to adverse gastrointestinal side effects.82,215  
 Since COX-2 contributes to the induced formation of PGE2 leading to 
inflammation, NSAID development in the 1990s focused on the selective inhibition of 
this enzyme. The hypothesis entailed maintaining basal levels of PGE2 while reducing 
induced levels of PGE2 in an effort to avoid such side effects observed with traditional 
NSAIDs. Two such coxibs developed include celecoxib and rofecoxib whose trade names 
are Celebrex and Vioxx, respectively.80,216 Unfortunately, the long-term selective 
inhibition of COX-2 leads to adverse cardiovascular side effects due to a decreased 
production of PGI2 relative to TXA2, which are inhibitors and inducers of platelet 
aggregation, respectively.217 Subsequently, it has been suggested from meta-analysis 
studies of randomized trials that long-term use of traditional, non-selective NSAIDs is 
also associated with an increased risk of adverse cardiovascular events.218 Because the 
principal function of MPGES1 is the production of induced PGE2, and since the enzyme 
is immediately downstream of COX-2 in the inducible PGE2 pathway, it represents a 
promising therapeutic target for the treatment of inflammatory diseases. 
 
MPGES1 Mouse Knockout Studies 
 Most knowledge of the physiological and pathological roles of MPGES1 has been 
obtained through gene knockout (KO) experiments with mice. Mice lacking MPGES1 
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were generated by targeted homologous recombination on an inbred background.219 The 
lack of any observable phenotype as compared to wild-type (WT) mice indicates that 
MPGES1 does not produce PGE2 as a mediator involved in development or essential 
biological processes. However, when tested in inflammation models including collagen-
induced arthritis (CIA) and delayed-type hypersensitivity, the mice show marked 
reduction in inflammatory responses.219,220 Under a model experiment for pain known as 
the writhing test, in which dilute acetic acid is injected intraperitoneally, the KO mice 
display a decrease in pain perception similar to that of a control of WT mice treated with 
NSAIDs.219 
 In two separate studies, MPGES1-deficient mice showed a decrease in fever 
response from LPS injection as compared to WT controls.220,221 Yet another study 
demonstrated that MPGES1 KO mice exhibit a decreased incidence in neuropathic 
pain.222 Finally, unlike COX-2 KO mice, MPGES1 KO mice display no decrease in anti-
thrombotic PGI2 production.223 These experiments highlight the promise of targeting 
MPGES1 to treat inflammatory disease. 
In light of these promising results, however, there may be complications that arise 
by targeting MPGES1 therapeutically. For instance, one study has demonstrated that 
mice deficient in MPGES1 exhibit an increase in blood pressure when administered 
synthetic mineralocorticoid while given a high-salt diet, a well-established model of 
hypertension.224 Other studies have revealed that PGE2 may play a role in the resolution 
phase of inflammation. For example, PGE2 down-regulates several pro-inflammatory 
genes by dissociating nuclear trafficking subunits of NF-κB in RA synovial fibroblasts.225 
Also, MPGES1-derived PGE2 displays a resolution role in mouse models of 
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neuroinflammation.226 On the other hand, the expression of MPGES1 rapidly drops to 
basal levels during the resolution phase in mouse CIA models, while COX-2 expression 
is maintained.227 Inhibiting COX-2 during this phase has the effect of perpetuating 
inflammation, suggesting that maintaining COX-2 expression while inhibiting MPGES1 
activity should hasten the resolution of inflammation brought about by arthritis.227 
Despite the uncertainty of the role of PGE2 as a mediator of resolving inflammation, 
MPGES1 has been the focus of drug development for the treatment of inflammatory 
disease, and several MPGES1-specific inhibitors have been developed. 
 
MPGES1 Drug Development 
 Several drug leads (Table 1) have emerged from both academia and the 
pharmaceutical industry. One example developed by Pfizer Inc. in St. Louis, MO, is the 
oxicam compound PF-9184, a selective MPGES1 inhibitor with an IC50 value of 16.5 
nM.228 In RA synovial fibroblasts induced with IL-1β, PF-9184 decreases PGE2 
production without inhibiting COX-2. Unfortunately, MPGES1 inhibition by this 
compound results in the shunting of PGH2 to the PGFS pathway, which could possibly 
result in unwanted side effects when used in animal models or as a drug. Another 
example of a drug lead is the carbazole benzamide AF3442 synthesized by the Angelini 
Research Center in Rome, Italy, which specifically inhibits MPGES1 with an IC50 value 
of 60 nM.229 In this case, the compound significantly reduces PGE2 formation in human 
monocytes induced with LPS with no evidence of shunting PGH2 to alternate synthase 
pathways. 
 
 
53 
 
Table 1. Drug leads targeting MPGES1. Several compounds that selectively inhibit 
MPGES1 have emerged as drug leads in recent years. These compounds, developed by 
both the pharmaceutical industry and academia, inhibit the isomerization activity of 
MPGES1 with IC50 values in the nanomolar range. 
 
 
 
 
 Merck Frosst, formerly in Quebec, Canada, developed several compounds 
targeting MPGES1. For instance, the phenanthrine imidazole MF63 is a potent, orally 
available MPGES1 inhibitor with an IC50 value of 1.3 nM.230 Utilizing animals including 
mice with a knock-in (KI) of the human enzyme as well as guinea pigs, oral 
administration of MF63 selectively decreases PGE2 production without effecting the 
production of other prostanoids, as compared to controls, in an LPS-induced air pouch 
model. In addition, MF63 substantially decreases hyperalgesia, pyresis, and chronic 
osteoarthritic pain induced by LPS without causing gastrointestinal toxic effects. 
Subsequently, the Merck Frosst group has made progress in developing mono- and 
disubstituted phenanthrene imidazoles as well as trisubstituted ureas as potent and 
selective MPGES1 inhibitors to be utilized in pre-clinical studies.231,232 
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 As a result of these inhibitor studies, it has come to light that inter-species 
differences of MPGES1 have a profound effect on inhibitor potencies. For instance, the 
compounds PF-9184 and MF63 display IC50 values in the nanomolar range against the 
human enzyme but are relatively ineffective against the mouse orthologue.228,230 A 
similar effect has been observed for the rat enzyme.188 It was subsequently demonstrated 
that the differences in potencies could be attributed to three key amino acid residues 
along TM IV of the enzyme that act as gate keepers for the entrance of the active site.188  
This obstacle to pre-clinical trials was overcome in the aforementioned Merck Frosst 
studies by generating mice that express human MPGES1 instead of the mouse enzyme, as 
well as by using guinea pigs whose MPGES1 orthologue more closely represents the 
human enzyme.230-232 This solution to inter-species differences in pre-clinical studies still 
presents difficulties in drug development, however, in that it complicates the evaluation 
of relevant off-target effects in the animal models. 
 
MPGES1 and Cancer 
 The induced production of PGE2 is highly correlated with cancer cell growth and 
survival, involving several signaling mechanisms that increase proliferation and 
invasiveness and inhibit apoptosis.233 COX-2 is highly expressed in various cancer cell 
lines, is generally assumed to be the major source of PGH2 production in cancer cells, 
and is therefore likely to play a major role in the production of PGE2 in cancer.36 Because 
MPGES1 is co-regulated with COX-2 and is the terminal enzyme in inducible PGE2 
synthesis, it represents a potential target for the treatment of cancer.234 
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 Initial studies of mouse cancer models with genetic deletions of MPGES1 have 
shown promise. In a colorectal cancer model, mice with mutations in the adenomatous 
polyposis coli (APC) gene were compared to MPGES1 KO mice containing the same 
APC mutations.235,236 MPGES1 KO mice display a significant suppression in intestinal 
cancer growth, even when induced by azoxymethane injections. In a separate study, 
shRNA was utilized to knock-down the MPGES1 gene of two cancer cells lines.237 The 
prostate cancer cell line DU145, which constitutively expresses MPGES1, and the non-
small lung cancer cell line A549, in which MPGES1 is inducible, both show slower 
colony growth in clonogenic assays. In addition, when the cells are injected into nude 
mice, the MPGES1 knock-down cells exhibit delayed tumor growth as compared to 
injection with WT cells. 
In addition to the knock-down study mentioned above, MPGES1 knock-down and 
overexpression in Lewis lung carcinoma (LLC) cells have also revealed the role of 
MPGES1 in the progression of cancer.238 The MPGES1 knock-down cells display a 
reduction in proliferation and invasiveness, while the overexpression of MPGES1 confers 
an increase in proliferation and invasiveness. Also, tumor growth is attenuated in WT 
mice subcutaneously injected with the LLC MPGES1 knock-down cells, as compared to 
LLC cells over-expressing the enzyme. In addition, when WT LLC cells are grafted onto 
MPGES1 KO mice, tumor growth is decreased as compared to grafting onto WT mice. 
Though in the relatively early stages of research, these studies suggest that PGE2 
production by MPGES1 plays a role in the progression of colon, prostate, and lung 
cancers. 
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 MPGES1 is a GSH-dependent PGH2 isomerase whose oxido-reduction activity 
gives rise to PGE2. The other catalytic activities of this enzyme highlight its evolutionary 
relationship to other MAPEG members, as well as to the other GST families. The 
catalytic mechanism of MPGES1 has been proposed based on its crystal structure, 
however uncertainties remain. The structure does, however, underline the homology of 
MPGES1 with other MAPEG members including MGST1, FLAP, and LTC4S. PGE2 
production is important for a wide range of normal biological functions, but it has also 
been associated with pathological processes including inflammation. The co-regulation of 
MPGES1 with COX-2 highlights its role in the production of induced PGE2 synthesis and 
gives it promise as a target to treat inflammation and perhaps several forms of cancer. 
Initial animal model studies, including KO and knock-down experiments, as well as 
administration of orally available MPGES1-specific inhibitors, are only just beginning to 
deliver on the potential of that promise. 
 
Hydrogen/Deuterium Exchange Mass Spectrometry of Membrane Proteins 
 The understanding of a protein’s function on a molecular level is often aided by 
the determination of its three-dimensional structure. Two common techniques often 
employed in structural biology include nuclear magnetic resonance (NMR) and X-ray 
crystallography. Both methods are well-recognized techniques that provide high-
resolution structural information of proteins, protein-ligand interactions, and protein-
protein interactions.212,239 Both of these methods, however, suffer from obstacles that 
hinder their utility. A major challenge of X-ray crystallography is the difficulty in 
crystallizing certain proteins including many membrane proteins, as well as those that are 
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intrinsically disordered.240 In addition, analyses can only be made in the non-native solid-
state. NMR suffers from the fact that many proteins are simply too large for analysis, and 
the technique requires relatively high concentrations of protein to be successful.241 
 Backbone amide H/D exchange MS has emerged as a useful tool for the study of 
protein structure and dynamics, as a complementary or alternative technique to NMR and 
crystallography. A clear advantage of this method is the ability to perform structural 
analyses in nearly any solution condition or protein concentration. The phenomenon of 
protein H/D exchange was first described by Kaj Ulrik Linderstrøm-Lang in the 1950s 
when he measured the extent of deuteration of D2O-solubilized proteins utilizing density 
gradient tubes.242 The first MS analysis of H/D exchange came in 1993 when horse 
cytochrome c was incubated in D2O as a function of time, proteolyzed by pepsin, and 
subsequently analyzed using fast atom bombardment (FAB) MS.243 The advent of 
electrospray ionization (ESI) and matrix-assisted laser desorption/ionization (MALDI) in 
the late 1980s made MS an analytical tool amenable to intact proteins.244,245 As such, the 
first structural dynamics study of a whole protein in solution utilizing H/D exchange 
coupled to LC and ESI-MS appeared in 1994 when the technique was used to observe 
deuterium incorporation for apo- and holo-myoglobin.246 
 
H/D Exchange Theory 
 Hydrogen exchange is both acid- and base-catalyzed.247 At physiological pH, the 
reaction is predominantly base-catalyzed, in that an amide nitrogen proton is first 
abstracted by hydroxide ion and subsequently protonated by a solvent proton. The 
kinetics of H/D exchange are modulated by factors including pH, polypeptide 
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conformation, solvent exposure, and structural dynamics that alter the chemical 
environment of reactive sites on the protein.248 Rapid H/D exchange kinetics, having an 
intrinsic exchange rate of about 10 s-1,249 is indicative of solvent exposure (Figure 27), 
while slow kinetics indicate either solvent protection or involvement in hydrogen 
bonding. The exchange of hydrogen for deuterium of hydrogen-bonding backbone 
amides is mediated by structural fluctuations that disrupt the hydrogen bonds, resulting in 
temporary solvent access. Taken together, measuring the rate of deuterium incorporation 
as a function of time reveals aspects of conformation, as well as conformational changes 
due to structural perturbations. 
 
 
 
Figure 27. The Linderstrøm-Lang model of H/D exchange. Amide protons that are 
exposed exchange with deuterons in the solvent with a half-life on the order of 
milliseconds. Those amide protons that are buried or are involved in hydrogen bonding 
exchange with a half-life on the order of seconds to years. Structural perturbations in 
folded regions allow solvent access and incorporation of deuterium. In this way, kinetic 
analysis of H/D exchange reveals aspects of structural conformation, as well as 
conformational dynamics. 
 
 
H/D Exchange MS Methodology 
 The most common method of H/D exchange MS involves continuous labeling 
(Figure 28).250 In this procedure, purified native protein in a buffered solution made with 
H2O is diluted in deuterated solvent and incubated at room temperature and neutral pH 
for time periods ranging from a few seconds to several hours. This “in-exchange” process 
is quenched by acidification to pH 2.5 by dilution with ice-cold buffer made with H2O, 
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reducing the rate of exchange by several orders of magnitude for backbone amide 
nitrogens.251 The exchange kinetics of other sites on the protein are significantly less 
reduced, and those sites therefore “back-exchange” with hydrogen in the solvent, 
resulting in labeling that is exclusive to backbone amide nitrogens. The remainder of the 
procedure is performed at 0 °C, which reduces the rate of exchange by an additional order 
of magnitude. After proteolysis by an acidic protease such as pepsin, the resulting 
peptides are analyzed by reversed-phase LC-MS utilizing an ESI source in positive mode, 
observing deuterium incorporation as an increase in average mass for each peptide. Due 
to the relative lack of cleavage specificity of pepsin, all analyzed peptides are sequenced 
by MS/MS prior to H/D exchange kinetic analysis. 
 
 
 
Figure 28. H/D exchange MS experimental method. (A) Incubation of a protein in 
deuterated solvent results in the incorporation, or “in-exchange,” of deuterium at multiple 
sites. Quenching the incorporation and diluting the protein in solvent lacking deuterium 
results in the loss, or “back-exchange,” of deuterium at all sites except for those of 
backbone amide nitrogens. This leads to deuterium labeling that is exclusive to the 
backbone of the protein and can be exploited for making structural analyses. (B) The H/D 
exchange assay involves a range of D2O incubation times followed by quenching and 
proteolysis. Each resulting peptide is subsequently analyzed for deuterium incorporation 
as a function of time by LC-MS. 
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 For each experimental time point, the number of deuterons incorporated onto the 
backbone amide nitrogens of each peptide is calculated from its mass spectrum (Figure 
29), using the centroid of the resulting isotopic envelope. The number of incorporated 
deuterons is then plotted as a function of time and fit to a sum of first-order exponential 
rate terms. H/D exchange kinetic rates are generally divided into three phases including 
fast (~ 10 s-1), intermediate, and slow, with slow exchange defined as no deuterium 
incorporation throughout the time course of the experiment (typically several hours). As 
mentioned above, fast exchange kinetics is indicative of protein conformation. In fact, all 
three phases of exchange can be utilized to analyze structural perturbations of a protein as 
a result of experimental conditions that cause some conformational change. 
 
 
 
Figure 29. H/D exchange kinetic analysis. (A) The incorporation of deuterium for each 
peptide is observed in a series of mass spectra as an increase in average mass. (B) The 
number of deuterons incorporated onto each peptide is plotted as a function of time and 
fit to a sum of first-order exponential rate terms. Perturbing the structure of the protein 
results in significant changes in H/D exchange kinetics, illustrated by the red and black 
traces, which represent two different experimental conditions. These changes in kinetics 
as a result of structural perturbations are used to make conformational determinations. 
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H/D Exchange MS of Membrane Proteins 
Structural studies of membrane proteins are inherently difficult due to their 
typically low overexpression in heterologous expression systems.252 In addition, micelle 
or surfactant solubilization as a substitute for the native lipid bilayer commonly results in 
degradation and precipitation of membrane proteins.253 With respect to LC-MS, many 
hydrophobic peptides do not readily elute from reversed-phase columns, and detergents 
tend to suppress ionization from the electrospray source,254 as detailed below. With 
respect to H/D exchange, deuterium incorporation kinetics for membrane proteins are 
somewhat different than those for soluble proteins due to limited solvent access of the 
membrane- or micelle-embedded regions. 
Despite these challenges, progress has been made in the field of membrane 
protein H/D exchange MS. For instance, the H/D exchange kinetics of short 
transmembrane peptides within the lipid bilayer have been analyzed with respect to 
structural topology and conformational flexibility.255,256 The method has also been 
successfully utilized to analyze the interaction between membrane-associated proteins 
and their ligands,257 as well as their interactions with the bilayer itself.258 There are even a 
few examples of H/D exchange MS studies of intact integral membrane proteins that 
clearly reveal the extent of conformational dynamics within the bilayer, which are 
summarized here. 
 
H/D Exchange MS of MGST1 
 The detoxification enzyme MGST1, a homotrimeric protein with a total of twelve 
TM helices, responds to chemical and oxidative stress.162 It is involved in multiple roles 
62 
 
of cellular protection by functioning as a GSH-dependent peroxidase with lipid 
hydroperoxides and as a GST with various electrophilic species including epoxides. H/D 
exchange MS of MGST1 solubilized in the detergent Triton X-100 reveals the location of 
the cytoplasmic GSH binding site (Figure 30), as well as the structurally-overlapping 
binding site for hydrophobic substrates.183,194 The method was also used to determine that 
GSH binding induces a significant conformational change amongst several TM helices.194 
In addition, it was observed that a cytoplasmic cysteine residue acts a stress sensor that 
responds to chemical modification by pre-organizing the aforementioned TM helices, 
resulting in enzyme activation.194 
 
 
 
Figure 30. H/D exchange MS of MGST1. The detoxification enzyme MGST1 is a 
homotrimeric integral membrane protein with a total of twelve TM helices. Three 
molecules of GSH are bound, shown in green sticks. Covalent modification of a cytosolic 
cysteine residue by electrophilic compounds activates the enzyme by pre-organizing 
regions of the TM helices, highlighted in pink, as revealed by H/D exchange kinetic 
analysis. 
 
 
H/D Exchange MS of CcO 
 The redox-driven proton pump cytochrome c oxidase (CcO) is the terminal 
electron acceptor in the respiratory chains of aerobic organisms that catalyzes the 
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reduction of O2 to H2O.259 The enzyme consists of four subunits donating a total of 
twenty-two TM helices. H/D exchange MS of CcO solubilized in DDM demonstrates that 
distinct redox-linked conformational changes in the catalytic cycle of CcO involve the 
opening and closing of specific proton pathways (Figure 31) and provide protons 
alternative access to opposite sides of the membrane.260 In addition, this method coupled 
to mutagenesis reveals the structural location of a gate that controls directional proton 
flow to either the active site or the exiting pathway of the enzyme.261 
 
 
 
Figure 31. H/D exchange MS of CcO. CcO is an integral membrane protein with a total 
of twenty-two TM helices. The proton pump is the terminal electron acceptor in the 
respiratory chains of a variety of organisms. Several redox-dependent conformational 
changes that occur during the catalytic cycle are revealed by H/D exchange, highlighted 
in pink. 
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H/D Exchange MS of Bacteriorhodopsin 
 The light-driven proton pump bacteriorhodopsin is an integral membrane protein 
with seven membrane-spanning helices that undergoes a conformational change upon 
absorbing a photon, resulting in an electrochemical gradient.262 The protein, solubilized 
in a mixture of 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) and 2[(3-
cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate (CHAPSO), was 
denatured by the addition of sodium dodecyl sulfate (SDS), and the structure of the 
unfolded state was monitored by H/D exchange MS to probe the hydrogen-bonded side-
chain interactions within the plane of the membrane (Figure 32).263 The results confirm a 
double-mutant cycle analysis, which indicates that most hydrogen-bond interactions 
within the bilayer or micelle are only modestly stabilizing.263 
 
 
 
Figure 32.  H/D exchange MS of bacteriorhodopsin. Bacteriorhodopsin is a light-driven 
proton pump with a total of seven TM helices. The hydrogen-bonding interactions of 
several membrane-embedded residues, highlighted in pink, were analyzed by H/D 
exchange and confirmed to be only modestly stabilizing. 
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H/D Exchange MS of β2AR 
 The β2-adrenergic G protein-coupled receptor (β2AR) plays a critical role in the 
signaling of many biological processes including glycogenolysis, gluconeogenesis, 
potassium uptake, and smooth muscle relaxation.264 The seven-TM helix protein is a 
therapeutic target for diseases including asthma.265 H/D exchange MS of the DDM-
solubilized protein reveals the dynamic flexibility of regions within the bilayer (Figure 
33).266 In addition, the structural perturbations induced by the binding of an inverse 
agonist indicates that several small secondary elements are functionally important 
regions.266 
 
 
 
Figure 33. H/D exchange MS of β2AR. β2AR is a GPCR involved in a multitude of 
biological processes and has a total of seven TM helices. H/D exchange kinetic analysis 
reveals several small secondary regions, highlighted in pink, that are involved in the 
binding of an inverse agonist, shown in cyan sticks. 
 
 
H/D Exchange MS of GGCX 
 A key regulator of blood coagulation that is essential for hemostasis, γ-glutamyl 
carboxylase (GGCX) is an integral membrane protein predicted to have five TM 
helices.267 GGCX was analyzed by H/D exchange MS solubilized in phospholipid bilayer 
66 
 
nanodiscs,268 which offer a controllable, stable, and monodisperse bilayer similar to that 
of the native phospholipid membrane.269 The uniformly-sized bilayer was used to 
perform global topography analysis of GGCX, but the significance of the H/D exchange 
kinetic analysis is yet to be interpreted. Still, the nanodisc technique represents a unique 
method for addressing the challenges of performing structural studies of membrane 
proteins in physiologically relevant conditions.268 
Taken together, these studies reveal the diverse utility of H/D exchange MS 
analyses. With respect to membrane proteins, the technique offers a solution to making 
the conformational determinations of proteins that were once nearly impossible. From 
global topography determinations to identifying ligand-binding sites to revealing the 
dynamic functions of proteins, H/D exchange has proven to be crucial to observing 
structural dynamics within the bilayer.  
 
Challenges of Membrane Protein H/D Exchange MS 
 Because spectral analyses are performed on peptides of varying length, one of the 
difficulties in H/D exchange MS studies has been in the ability to identify individual 
amide sites of deuterium incorporation. One method by which spatial resolution has been 
improved upon involves multiple analyses, altering digestion conditions to obtain 
peptides that overlap in amino acid sequence. These adjustments include changing 
digestion time, varying protease concentration, adding denaturants, or utilizing multiple 
acidic proteases with differing specificities.270 
 Another method by which resolution may be improved is by utilizing MS/MS 
fragmentation. This has been a much less fruitful method due to the phenomenon of 
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proton migration, or “scrambling,” of the ionized peptides caused by collision-induced 
dissociation (CID), resulting in randomization of deuterium incorporation on the parent 
ion. Alternative fragmentation methods such as electron capture dissociation (ECD) and 
electron transfer dissociation (ETD) occur more rapidly than CID, impart relatively low 
internal energy to the parent ion, and have in some cases minimized the scrambling 
phenomenon.271-273 
 A challenge of membrane protein MS in general, and indeed membrane protein 
H/D exchange MS in particular, involves detergents. The use of detergents is crucial to 
various membrane protein protocols with respect to solubilization and stabilization. The 
presence of detergents in MS analyses, however, can cause suppression of ionization 
from the ESI source, adduct formation, and interference with peptide ion signals.254,274,275 
Still, these difficulties can be surmounted by utilizing detergents that are compatible with 
the electrospray source. Detergents that are anionic like SDS and cationic like laurel 
dimethylamine oxide, as well as non-ionic polyoxyethylenes including Tween 20 and 
Triton X-100, tend to suppress peptide ionization.254 However, zwitterionic detergents 
like CHAPS and nonionic saccharides including n-dodecyl-β-D-glucoside and DDM 
display limited ionization suppression and adduct formation and have proven useful in 
membrane protein H/D exchange analyses.260,266 
An alternative to using an ESI-compatible detergent is to remove the detergent 
from the sample prior to MS analysis. With respect to H/D exchange MS, this can be 
performed either before or after the proteolysis step. Common protocols for the removal 
of detergents prior to proteolysis include dialysis, desalting chromatography,276 or 
removal by polystyrene or cyclodextrin.277,278 Such methods, however, commonly result 
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in protein precipitation. Less common protocols utilize organic solvent extraction,279 
detergent precipitation by acetone or trichloroacetic acid,280 or protein isolation by 
polyacrylamide gel electrophoresis.281 These methods, however, inherently involve the 
denaturation of proteins and poor recovery of hydrophobic peptides. 
Detergent removal may also be performed after the proteolysis step of the H/D 
exchange MS protocol utilizing chromatography or organic solvent extraction.282-284 
While the proteolysis of hydrophobic regions of a membrane protein typically results in 
shorter, more soluble peptides, these detergent removal techniques tend to suffer the same 
problems as whole-protein detergent removal in the form of peptide precipitation and 
poor hydrophobic peptide yields. 
One alternative to these methods includes the use of cleavable detergents like 
acid-labile surfactants (ALS). After hydrolysis by acidification, the hydrophobic portion 
of the ALS is easily removed by centrifugation, eliminating ionization suppression from 
the ESI source.285,286 While this method has advantages over those previously mentioned, 
precipitation of hydrophobic peptides can still occur, resulting in potentially valuable data 
loss. Yet another alternative, nonionic detergent extraction with chlorinated solvents, has 
recently shown promise as a method of detergent removal that has displayed minimal 
effect on ESI-MS analysis.287 While persisting as one of the main challenges of 
membrane protein H/D exchange MS, effective detergent use or removal continues to be 
an active area of research. 
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Prospects for H/D Exchange MS 
 One of the promising prospects for H/D exchange MS is its potential for 
automation. In this regard, initial studies involve completely automated protein de novo 
sequencing of proteolytic peptides by MS/MS, which has been aided greatly with the 
advent of powerful computational tools.288 The deuterium labeling protocol itself has 
been automated with the use of robotics,289 and several software packages have been 
developed that reduce the labor-intensive task of data processing.290 The high-throughput 
potential of H/D exchange MS for the screening of conformational changes induced by 
inhibitor binding presents a potentially significant aid in the understanding of the 
structure-function relationship. 
It is conceivable that H/D exchange kinetic data could be used as constraints in 
computational modeling and docking studies, aiding in structure prediction. In addition, 
structural studies of membrane proteins utilizing MS coupled with alternative labeling 
methods represent an as-yet untapped area of H/D exchange research. These labeling 
methods include hydroxyl radical foot-printing, oxidative methionine labeling, and 
electrophysiology-coordinated photo-labeling, which have been successfully used in the 
analysis of protein-protein interactions,291 conformational dynamics in the native lipid 
environment,292 and structural studies within living cells,293 respectively. It is feasible that 
studies in similar conditions could be performed utilizing H/D exchange as an alternative 
to these techniques. 
 Kinetic analysis of H/D exchange has been used for decades to probe the 
structural properties of proteins. The advent of the soft ionization techniques of ESI and 
MALDI allowed these analyses to be performed using MS on whole proteins. The results 
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have revealed the utility of H/D exchange MS as a method for observing a wide range of 
conformational events. Its application to the structural characterization of membrane 
proteins has proven to be quite successful where traditional methods such as NMR and 
X-ray crystallography continue to be challenging. In addition, the determination of the 
conformational dynamics of catalysis in nearly any solution condition represents a unique 
application of H/D exchange. 
While challenges of membrane protein MS remain, particularly with regard to the 
use of detergents, progress continues to be made. The potential of the technique for 
automation and its application to high throughput systems represent exciting avenues for 
structure-function research. The virtually un-tapped field of membrane protein 
conformation in physiologically relevant systems represents a possible new frontier in 
H/D exchange MS studies. While already proving its potential, the future prospects of 
this method for scientific research are particularly exciting. 
 
Purpose of These Studies 
 The terminal prostanoid synthase MPGES1 plays an important role in the 
pathology of inflammation. Since its identification as a promising therapeutic target over 
ten years ago, an extraordinary amount of research has been invested into the enzyme. 
From its identification to its functional characterization to its structural determination to 
the discovery of drug leads, studies of MGPES1 continue to aid inflammation research. 
The purpose of this study is to analyze the structure of MPGES1 and to make 
observations of its dynamic physical interactions with various ligands in the hope of 
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furthering the understanding of the function of this enzyme and to ultimately aid in the 
discovery of new treatments for inflammatory disease. 
 
Structure-based Drug Design 
 In the past, drug discovery often began with the identification of a lead compound 
that was typically a natural ligand of a protein or was discovered through the random 
screening of compounds in in vitro or in vivo assays.294 Using standard medicinal 
chemistry, the lead structure is systematically modified through iterative cycles of 
syntheses of new compounds, which are then assayed for biological activity to derive a 
structure-activity relationship with respect to some measure of therapeutic efficiency.295 
Then emerged high through-put screening (HTS), a method of mechanized testing and 
rapid assay systems allowing researchers to quickly detect biological activities of 
extremely large libraries of compounds of diverse structures.296 This method is used 
extensively today. 
 Still, another method of drug discovery is structure-based drug design, or rational 
drug design, a method used in the pharmaceutical industry and academia since the late 
1980s.297 This method first involves the identification of a protein target that plays a 
critical role in an important physiological or pathological pathway, followed by the 
determination of that target’s structure, often by crystallography or NMR. Proteins bind 
their ligands in specific conformations, and the affinity and specificity of binding is 
dependent on the chemistry and topographies of their complimentary surfaces. Structural 
information regarding the conformation of the protein-ligand complex, as well as the 
molecular interactions between the protein and ligand, are used to rationally modify the 
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ligand to produce novel analogs that are more potent and/or specific. One famous 
example of the successful use of this approach is the design of HIV protease inhibitors as 
AIDS antivirals.298 
 By analyzing the structure of MPGES1, and by observing the conformational 
dynamics associated with interactions of MPGES1 with various ligands, it is the aim of 
this study to better understand the relationship between the structure and the function of 
the protein, as well as to gain knowledge regarding the mechanism by which the enzyme 
is inhibited. 
 
Structural Topology of MPGES1 
 At the initiation of this project, no crystal structure existed for MPGES1. In fact, 
at that time the only MAPEG superfamily member with a determined crystal structure 
was MGST1.162 As a means of predicting the structure of MPGES1, a sequence 
alignment with MGST1 was performed to locate homologous TM helices, and several 
computational algorithms for predicting membrane-spanning regions of membrane 
proteins were utilized. In order to provide physical evidence in support of these 
prediction methods, backbone amide H/D exchange MS was chosen as a technique to 
analyze the local and global protein topology of detergent-solubilized MPGES1. 
Monitoring the selective exchange of hydrogen for deuterium along the protein backbone 
is a sensitive technique that probes the solvent-accessibility of different regions of a 
protein, and it also reveals structural motion as a result of various experimental 
conditions. As summarized in the previous section, H/D exchange kinetic analysis has 
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become a well-established method for assessing protein structure, and it has been used 
successfully in the prediction of the overall topology of integral membrane proteins.250 
Here, the membrane-spanning regions of MPGES1 are determined utilizing H/D 
exchange MS kinetic analysis of the enzyme solubilized in two different, structurally 
distinct detergents. As this effort was nearing completion, the three-dimensional crystal 
structure of MPGES1 was determined by electron microscopy of two-dimensional 
crystals in the presence of phospholipids.166 This allowed for a direct comparison of the 
determined crystal structure with the H/D exchange topology determinations, as well as 
with the topologies predicted computationally and by the MGST1 sequence alignment. 
The results demonstrate that the overall topology is in agreement amongst these 
techniques, revealing a protein with four membrane-spanning regions per subunit. In 
addition, the MPGES1 protein structure is only slightly perturbed as a function of 
solubilization agent, i.e. phospholipids or the structurally dissimilar detergents CHAPS or 
DDM, and the structural perturbation is most likely due to interactions between the 
enzyme and the head groups of the corresponding solubilizing compound. 
 
Location of Inhibitor Binding Sites 
In addition to the determination of protein topology, H/D exchange kinetic 
analysis has been used successfully in observing ligand binding events and assessing 
protein biopharmaceutical comparability.299,300 The second aim of this project addresses 
inhibitor binding by MPGES1. Although the structure of the protein complexed with 
GSH has been determined, there is yet to be determined an apo-structure or inhibitor-
bound structure of the enzyme.  
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In light of this, backbone amide H/D exchange MS was utilized to map the 
binding sites of different types of inhibitors of MPGES1. The results reveal two spatially 
distinct binding sites, which include the cofactor site as well as a hydrophobic cleft 
composed of TM helices of neighboring subunits predicted to harbor the substrate-
binding site. Analysis of the H/D exchange behavior of the cofactor site confirms the 
atypical observation that MPGES1 and the closely related MGST1 bind the common 
cofactor/primary substrate GSH in differing locations and conformations. In addition, 
H/D exchange kinetics of inhibitors competitive for PGH2 binding reveal a site within a 
hydrophobic environment capable of binding a hydrophobic ligand. This knowledge of 
the locations of the binding sites for these inhibitors could in principal be used as a 
preliminary guide in structure-based drug design. 
 
Inhibition by 15d-PGJ2 
The cyPG 15d-PGJ2 is a dehydration product of PGD2 that binds to PPARγ with 
an EC50 value in the low micromolar range,79 which may impart the anti-inflammatory 
signaling properties associated with this mediator, as described in the Eicosanoid section 
of this introduction.  In addition, this lipid mediator has been reported to irreversibly 
inhibit the pro-inflammatory enzyme MPGES1 with an IC50 value of 0.3 µM, which may 
also contribute its anti-inflammatory properties.301 The chemical properties of 15d-PGJ2 
are likely dominated by the electrophilic α,β-unsaturated carbonyl group on the 
cyclopentenone ring that results in the formation of Michael adducts with sulfhydryl-
containing nucleophiles including GSH and cellular proteins.302,303 As such, this 
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prostanoid represents a unique inhibitor of MPGES1, unlike those that bind to the 
cofactor site or those that are synthesized as pharmacologically active inhibitors. 
As a naturally occurring inhibitor, 15d-PGJ2 may form a covalent adduct or 
involve allosteric binding to MPGES1, and the final aim of this project involves the 
elucidation of its mechanism of inhibition. A series of biochemical and MS experiments 
suggest that 15d-PGJ2 inhibits MPGES1 by covalent adduction of the enzyme at a 
cytosolic cysteine residue, as well as by binding to the PGH2 substrate-binding site. 
Inasmuch as GSH is the most abundant low molecular weight thiol in most cells, it is 
likely that the most physiologically relevant 15d-PGJ2 species is that of the GSH 
adduct.304 However, stable forms of this conjugate display no inhibitory effect on 
MPGES1 in vitro. Still, since the GSH adduct of 15d-PGJ2 is likely the predominant form 
of the prostanoid in vivo, its chemical structure, as well as its spontaneous kinetics of 
formation, were determined by MS/MS fragmentation, two-dimensional NMR 
spectroscopy, and spectrophotometry. 
 Inflammation research has been, and continues to be, an important field of study. 
Though relatively new to the field, MPGES1 has garnered much interest due to its 
promise as a therapeutic target. In the pursuit of furthering the understanding of the 
function of this enzyme, as well as in aiding in the development of new drug leads, this 
study focuses on the structure and conformational dynamics of MPGES1. By gaining 
insight into the global topology of the protein, locating inhibitor binding sites, and 
analyzing protein interactions with endogenous inhibitors, this study assists in this worthy 
pursuit. 
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Materials 
 Buffer salts and common chemicals were of the highest quality commercially 
available. Detergents were from Affymetrix Anatrace, Santa Clara, CA. GSO3¯  (1) and 
MK-886 (4) were obtained from Sigma, St. Louis, MO. The NovaSAID compound (2) 
was a generous gift from NovaSAID AB, Stockholm, Sweden. MF63 (3) was synthesized 
by the Synthesis Core at the Vanderbilt Instituted of Chemical Biology. Prostaglandins 
including PGD2, PGE2, 11β-PGE2, PGH2, and 15d-PGJ2, as well as malondialdehyde 
were obtained from Cayman Chemical, Ann Arbor, MI. Oasis HLB extractions cartridges 
were obtained from Waters, Milford, MA. 
 
Methods 
 
Native Protein and C59A Mutant Expression 
The human MPGES1 gene with C-terminal hexa-histidine tag was subcloned into 
a pET-21b vector. For experiments involving the native enzyme, silent mutations were 
performed for R40, R74, and R123 to correct for codon bias. For experiments involving 
MPGES1 with Cys-59 mutated the Ala, standard PCR was used with the forward primer 
GGC CCC CAG TAT GCC AGG AGT GAC CCC and the reverse primer GGG GTC 
ACT CCT GGC ATA CTG GGG GCC on the native gene with
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described above. The resulting mutant enzyme is hereafter referred to as MPGES1 C59A. 
Both native enzyme and MPGES1 C59A were expressed and prepared by the same 
protocol, detailed below. 
Rosetta 2 (DE3) E. coli competent cells were transformed with the expression 
vector and cultured in a minimal medium (20 mM Na2HPO4, 20 mM KH2PO4, 90 mM 
NaCl, 200 mM NH4Cl, 130 µM CaCl2, 1 mM MgSO4, 0.4% glucose, 0.3% casamino 
acids) at 37 ºC and 250 rpm. The cell culture was cooled to 15 ºC when an OD600 of 0.7 
was reached, and expression was induced by the addition of 2 mM IPTG. The cells were 
cultured further at 15 ºC and 200 rpm for 36 to 40 hours. Cells were harvested by 
centrifugation at 6,500 × g, 4 ºC, for 5 minutes and stored at -20 ºC. Frozen cell pellets 
were resuspended in cold lysis buffer (50 mM KH2PO4, 300 mM KCl, 1 mM GSH, 1 mM 
DTT, 1 mM EDTA, 10% glycerol, pH 8.0). Lysozyme was added to 0.2 mg/mL and 
stirred for 2 hours at 4 ºC. Cells were subsequently lysed further, utilizing sonication 
(60% power, 50% duty cycle, 2 minutes on, 4 minutes off) on ice, until no longer 
viscous. Cellular debris was cleared by centrifugation at 10,000 × g, 4 ºC, for 30 minutes. 
 
Enzyme Preparation 
The membrane fraction of the above cleared lysate was isolated using 
ultracentrifugation at 100,000 × g, 4 ºC, for 2 hours. Pellets were washed with 50 mM 
KH2PO4, pH 8.0, and resuspended in cold extraction buffer (50 mM KH2PO4, 300 mM 
KCl, 1 mM GSH, 5 mM imidazole, 10% glycerol, 0.5% DDM, pH 8.0). The enzyme was 
solubilized by gently stirring at 4 ºC, overnight. The solubilized enzyme was added to Ni-
NTA agarose (~5 mL per 25 g of wet cells), equilibrated with extraction buffer, and was 
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incubated by inverting at 4 ºC for 1 hour. Resin was applied to a gravity column and was 
washed with a similar buffer, containing 35 mM imidazole. MPGES1 was then eluted 
with a similar buffer, containing 250 mM imidazole. The elution was concentrated to 
~1.5 column volumes and then dialyzed, MWCO 6-8 kDa, against 1 L cold ion exchange 
buffer (50 mM KH2PO4, 1 mM GSH, 20% glycerol, 1% polyoxyethylene(10)dodecyl 
ether, pH 7.0) at 4 ºC overnight. The dialyzed protein was then applied to sulfopropyl 
sepharose (~3 mL per 25 g of wet cells), equilibrated with ion exchange buffer, in a 
gravity column. The resin was washed with a similar buffer, containing 1% CHAPS, and 
was eluted with a linear KCl gradient, 0-200 mM, in a similar buffer, containing 0.5% 
CHAPS. The extent of purification of the protein was subsequently estimated by SDS 
PAGE. Purified MPGES1 was concentrated in an Amicon ultrafiltration system, MWCO 
10 kDa, to 1 mg/mL and was then dialyzed, MWCO 10 kDa, against 200 mL cold MS 
buffer (50 mM KH2PO4, 300 mM KCl, 1 mM GSH, 1 mM DTT, 7.5% glycerol, 1% 
CHAPS, pH 7.0) at 4 ºC overnight. 
For preparation of the DDM-solubilized enzyme, CHAPS was replaced with 
equal concentration (w/v) amounts of DDM at the sulfopropyl sepharose chromatography 
step, as well as in all subsequent steps. For preparation of the glutathione sulfonate 
(GSO3¯ )-bound enzyme, GSH was replaced with equimolar amounts of GSO3¯  at the 
sulfopropyl sepharose chromatography step, as well as in all subsequent steps. For 
analyses involving 15d-PGJ2, DTT was not included in either the last chromatography 
step or final dialysis. Instead, these buffers were purged with argon. Inasmuch as 
MPGES1 is unstable when the GSH cofactor-binding site is unoccupied, apo-MPGES1 
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experiments were not possible. As such, in all described experiments MPGES1 is 
complexed with either GSH or GSO3¯ , as noted. 
 
Preparation of 9-(S-Glutathionyl)-15d-PGJ2 
 The conjugation of GSH to 15d-PGJ2 was initiated by the addition of 1.5 mL of 
10 mM GSH in 100 mM KH2PO4, pH 7.0, to 500 µg of 15d-PGJ2 at 40 °C for 30 
minutes. The reaction was stopped by the addition of 100 µL of 70% H2SO4, after which 
the sample was applied to a 6cc Oasis hydrophilic-lipophilic balance (HLB) solid-phase 
extraction cartridge that was previously activated with methanol and hydrated with 50 
mM ammonium acetate, pH 3. The sample was washed with 50 mM ammonium acetate, 
pH 3, and eluted with methanol. After evaporation under nitrogen, the sample was 
reconstituted in 15% CH3CN and 0.01% formic acid and stored on dry ice. It was 
subsequently purified by HPLC, monitoring at 308 nm, using a Beckman 5 µ, 80 Å C18 
column (4.6 mm x 25 cm), and eluted at 1 mL/min with a gradient of 15% to 95% 
CH3CN and 0.01% formic acid over a 30-minute period. After collecting the 9-(S-
glutathionyl)-15d-PGJ2 peak at approximately 20 minutes on dry ice, the sample was 
dried under vacuum and stored desiccated at -80 ºC. 
 
Preparation of 9-(S-Glutathionyl)-11-hydroxy-15d-PGJ2 and 11-Hydroxy-15d-PGJ2 
The 9-(S-glutathionyl)-11-hydroxy-15d-PGJ2 adduct of 15d-PGJ2 was prepared 
by adding 40 µL of a 25 mM solution of 15d-PGJ2 in DMSO to 160 µL of 6.3 mM GSH 
in 100 mM KH2PO4, pH 7.0, and incubating at 22 °C for one hour. The adduct was then 
reduced by the addition of 10 µL of a 1 M suspension of NaBH3CN in THF and storing 
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overnight at 4 ˚C. The reaction was subsequently diluted ten-fold in 20 mM Tris, pH 8.0. 
The product was purified by diethylaminoethyl weak anion exchange chromatography, 
washing with 20 mM Tris, pH 8.0, and eluting with 100 mM KH2PO4, pH 7.5, containing 
1 M KCl, 1% glycerol, and 1% CHAPS. The 11-hydroxy-15d-PGJ2 was prepared as 
above without the reaction with GSH. 
 
Structure of 9-(S-Glutathionyl)-15d-PGJ2 and 9-(S-Glutathionyl)-11-hydroxy-15d-PGJ2 
The structure of the glutathionyl adduct of 15d-PGJ2 was determined by LC-
MS/MS, as well as by 2D NMR spectroscopy. For MS analysis, the borohydride-reduced 
GSH adduct was prepared as described above. In addition, a cysteine adduct was 
prepared as described above, replacing GSH with equimolar L-cysteine. Analysis was 
performed by reversed-phase LC-MS/MS, using a Phenomenex Synergi 2.5 µ, Hydro-
RP, 100 Å C18 column (100 x 2.00 mm), and eluting at 0.2 mL/min with a gradient of 
15% to 95% CH3CN and 0.01% formic acid over a 30 min period. Ions of m/z 300 to 
1300 were detected on a ThermoFinnigan TSQ triple-quadrupole mass spectrometer 
using positive electrospray ionization. The PG adduct was identified with a mass 
corresponding to the monoisotopic mass of GSH or cysteine plus the monoisotopic mass 
of reduced 15d-PGJ2, and the site of adduction was determined by MS/MS fragmentation. 
The diasteroselectivity of the reaction of GSH with 15d-PGJ2 was determined by 
2D NMR spectroscopy at high field. NMR data were acquired either using a 22.1 T 
Bruker magnet equipped with a Bruker AV-III console or a 14.9 T Bruker magnet 
equipped with a Bruker AV-III console. All spectra were acquired in 3 mm NMR tubes 
using a Bruker 5 mm TCI cryogenically cooled NMR probe.  Chemical shifts were 
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referenced internally to CD3OD (3.30 ppm) or D2O (4.70 ppm), which also served as the 
2H lock solvents.  For 1D 1H NMR, typical experimental conditions included 32K data 
points, 13 ppm sweep width, a recycle delay of 1.5 seconds and 32 scans. For samples 
acquired in D2O, water suppression using pre-saturation was implemented in order to 
reduce the signal of residual H2O. For 2D 1H-1H COSY and DQF-COSY, experimental 
conditions included 2048 x 512 data matrix, 13 ppm sweep width, recycle delay of 1.5 
seconds and 4 scans per increment. The data were processed using squared sine-bell 
window function, displayed in either the magnitude mode (COSY) or absolute intensity 
mode (DQF-COSY). Similar experimental parameters were used to acquire 2D 1H-1H 
nuclear Overhauser effect (NOESY) experiments which were acquired with a mixing 
time of 400 ms. The data were processed using a pi/2 shifted squared sine window 
function displayed in absolute intensity mode. Multiplicity-edited HSQC experiments 
were acquired using a 1024 x 256 data matrix, a J(C-H) value of 145 Hz which resulted 
in a multiplicity selection delay of 34 ms, a recycle delay of 1.5 seconds and 16 scans per 
increment along with GARP decoupling on 13C during the acquisition time (150 ms). The 
data were processed using a pi/2 shifted squared sine window function and displayed with 
CH/CH3 signals phased positive and CH2 signals phased negative. 
 
Kinetics of the Spontaneous Reaction of GSH with 15d-PGJ2 
The kinetics of the approach to equilibrium were determined at 25 ˚C under 
pseudo-first-order conditions with a fixed concentration of 40 µM 15d-PGJ2 and a 
variable excess concentration of GSH ranging between 0.5 to 5.0 mM in 100 mM 
KH2PO4, pH 7.0. Reactions were initiated by the addition of 10 µL of a 4.0 mM stock 
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solution of 15d-PGJ2 in 20 mM KH2PO4, pH 7.0, to 990 µL of GSH in the same buffer. 
The formation of the glutathionyl adduct was observed spectrophotometrically as an 
exponential decrease in absorbance at 250 nm. The concentration dependence of kobs was 
used to determine the rate constants for the forward (k1) and reverse (k-1) reactions from 
eq. 1: 
 
kobs = k1[GSH] + k-1      (Eq. 1) 
 
In addition, the equilibrium constant for formation (Kf) of 9-(S-glutathionyl)-15d-
PGJ2 was calculated by determining the final concentrations of reactants and products at 
equilibrium under four different initial reactant concentrations. Two reactions were 
initiated by the addition of 25 µL of 2 mM 15d-PGJ2 stock solution in 100 mM KH2PO4, 
pH 7.0, to 475 µL of 105 µM or 211 µM GSH in the same buffer, giving an initial 15d-
PGJ2 concentration of 100 µM and initial concentrations of GSH of 100 µM or 200 µM, 
respectively. Two additional reactions were initiated by the addition of 50 µL of the same 
15d-PGJ2 stock solution to 450 µL of 111 or 222 µM GSH, giving a 15d-PGJ2 
concentration of 200 µM and GSH concentrations of 100 or 200 µM, respectively. Each 
reaction mixture was incubated at 4 °C overnight. After equilibrating to 22 ˚C for one 
hour the samples were analyzed by HPLC, monitoring the absorbance at 316 nm, using a 
Phenomenex Synergi 2.5 µ, Hydro-RP, 100 Å C18 column (100 x 2.00 mm), and eluting 
at 0.2 mL/min with a gradient of 15% to 95% CH3CN and 0.05% trichloroacetic acid 
over a 30 min period.  
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Glutathione Transferase Enzyme Activity Assays 
Glutathione transferase activity of native MPGES1 and MPGES1 C59A utilizing 
CDNB as a secondary substrate was verified using the method previously described.205 
Reactions were initiated at 22 °C by the addition of 10 µL of 200 mM CDNB in 
acetonitrile to 990 µL of 100 mM KH2PO4, pH 6.5, containing 4 mM GSH, 1 µM 
enzyme, and either 0.1% DDM or 1% CHAPS, and were followed over the course of 
thirty minutes spectrophotometrically at 340 nm. The background spontaneous reaction 
was also assayed in the same conditions, lacking enzyme. 
 Glutathione transferase activity of native MPGES1 and MPGES1 C59A utilizing 
15d-PGJ2 as a secondary substrate was analyzed using a similar spectrophotometric 
assay. Reactions were initiated at 22 °C by the addition of 5 µL of 2.5 mM 15d-PGJ2 in 
100 mM KH2PO4, pH 7.0, to 495 µL of 100 mM KH2PO4, pH 7.0, containing 1 mM 
GSH, 1 µM enzyme, 10% glycerol, and 1% CHAPS. The reaction was followed by 
iterative scans of 440 – 220 nm, monitoring the decrease in absorbance at 250 nm, over 
the course of several hours. The background spontaneous reaction was also assayed in the 
same conditions, lacking enzyme. 
 
Prostaglandin E Synthase Activity and Inhibition Assay by Mass Spectrometry 
The isomerization of PGH2 to PGE2 and its inhibition were verified with a method 
adapted from that of reference 48, and the detection of PGE2 by LC-MS/MS was 
performed as previously published.305 Reactions were initiated at 0 ˚C by the addition of 
100 µL of a 100 nM enzyme stock solution in reaction buffer (100 mM KH2PO4, pH 7.5, 
containing 2.5 mM GSH, 1% glycerol and 1% CHAPS) to 6.7 µL of 75, 150, or 300 µM 
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PGH2 in acetone. After a one-minute incubation on ice, unreacted PGH2 was decomposed 
to malondialdehyde (MDA) and 12-(S)-hydroxy-8,10-trans-5-cis-heptadecatrienoic acid 
(12-HHT) by the addition of 400 µL of 25 mM FeCl2 in 50 mM citric acid, pH 3.0, which 
included 0.5 µM 11β-PGE2 as an internal standard. After solid-phase extraction, the 
resulting prostaglandins were reconstituted in 5% CH3CN and analyzed by reversed-
phase LC-MS/MS, with a Phenomenex Synergi 2.5 µ, Hydro-RP, 100 Å C18 column 
(100 x 2.00 mm), and eluted at a flow rate of 0.2 mL/min with 32% CH3CN and 0.01% 
formic acid. Single-reaction monitoring (SRM) of the transition m/z 351 to 271 was 
utilized for PGE2 detection on a ThermoFinnigan TSQ triple-quadrupole mass 
spectrometer using negative electrospray ionization. To verify inhibition, the procedure 
was repeated, pre-incubating on ice with inhibitors of the following concentrations: 1 
mM MK-886 (4) from a 10 mM stock in DMSO; 100 µM MF63 (3) from a 1 mM stock 
in DMSO; 100 µM NovaSAID compound (2) from a 1 mM stock in DMSO; 5 mM 
GSO3¯  (1) from a 400 mM stock in 100 mM KH2PO4, pH 7.0; and 100 µM 15d-PGJ2 
from a 1 mM stock in DMSO. The IC50 value for 1 was determined utilizing the 
aforementioned procedure, by adding 100 µL of 1 µM enzyme, pre-incubated with 1 
ranging in concentrations from 0.004 to 37.5 mM, to 3 µL of 300 µM PGH2. 
 
Prostaglandin E Synthase Activity and Inhibition Assay by Fluorescence 
 The inhibition kinetics of MPGES1 by 15d-PGJ2 were determined with a method 
adapted from a previously described technique.194 The enzyme, complexed with GSO3¯ , 
was combined with the inhibitor by addition of 10 µL of solutions of the 15d-PGJ2 
ranging in concentrations from 0.1 µM to 5 mM in reaction buffer lacking GSH to 90 µL 
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of a 1.1 µM enzyme solution in reaction buffer lacking GSH, giving a final enzyme 
concentration of 1 µM and a final inhibitor concentration range of 0.01 to 500 µM. An 
additional incubation was initiated by the addition of 40 µL of a 5 mM stock solution of 
15d-PGJ2in reaction buffer lacking GSH to 60 µL of 1.7 µM enzyme, giving final 
concentrations of 2 mM and 1 µM, respectively. After a one-hour incubation on ice, 2.5 
µL of a 100 mM stock solution of GSH in 100 mM KH2PO4, pH 7.0, were added to the 
pre-incubated protein, mixed, and incubated at 0 ºC for five minutes. The reaction was 
subsequently initiated by the addition of 100 µL of each sample to 5 µL of 100 µM PGH2 
in acetone
 
and incubated at 22 ºC for one minute. Un-reacted PGH2 was decomposed to 
MDA and 12-HHT by the addition of 200 µL of 50 mM FeCl2 in 500 mM KH2PO4, pH 
2.0. To form a fluorescent complex of MDA in solution, 500 µL of 15 mM thiobarbituric 
acid (TBA) in 80 mM KH2PO4, pH 2.0, was added to the reaction mixture and heated to 
80 °C for thirty minutes. Precipitate was removed by centrifugation, and the resulting 
fluorescent MDA-TBA complex was detected with a Horiba Fluorolog fluorescence 
spectrometer, tuned to excitation and emission wavelengths of 530 nm and 550 nm, 
respectively. The same method was used to examine the inhibition of MPGES1 by 11-
hydroxy-15d-PGJ2 and 9-(S-glutathionyl)-11-hydroxy-15d-PGJ2. 
 
Covalent Modification of MPGES1 by 15d-PGJ2 
The site of adduction of the enzyme by 15d-PGJ2 was determined by LC-MS/MS 
sequencing. The covalent modification was initiated by the addition of 2 µL of 25 mM 
15d-PGJ2 in DMSO to 100 µL of 1 mg/mL (60 µM) purified native enzyme in 50 mM 
KH2PO4, pH 7.0, containing 300 mM KCl, 7.5% glycerol, 1% CHAPS, and either 1 mM 
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GSH or 1 mM GSO3¯ . After an overnight incubation at 4 ºC, the Michael adduct was 
reduced with NaBH3CN, as described above for the glutathionyl adduct. For MS analysis, 
10 µL of the pre-incubated protein was diluted five-fold in H2O at 22 °C, after which 50 
µL of ice-cold 100 mM KH2PO4, pH 2.3, was added, dropping the pH to 2.5. The protein 
was then digested on ice for five minutes by the addition of 2 µL of 10 mg/mL (290 µM) 
pepsin in H2O. The resulting peptides were separated by HPLC on an ice-cold 
Phenomenex Jupiter 5 µ, 300 Å C18 column (50 x 1.00 mm), and eluted at 0.3 mL/min 
with a 30-minute gradient of 2-50% CH3CN and 0.4% formic acid. Ions of m/z 300 to 
1500 were detected on a ThermoFinnigan TSQ triple-quadrupole mass spectrometer 
using positive electrospray ionization. Peptides containing the reduced adduct were 
identified as those with a mass shift corresponding to the monoisotopic mass of reduced 
15d-PGJ2, and were verified by MS/MS sequencing. 
In order to determine the regiochemistry of enzyme adduction on 15d-PGJ2, the 
procedure from the previous paragraph was repeated on a ThermoFinnigan LTQ ion trap 
mass spectrometer using positive electrospray ionization. The peptide identified as 
containing the PG adduct was subject to MS3 fragmentation, selecting for the y-ion 
containing the adducted Cys-59 residue. 
 
Peptide sequencing by Tandem Mass Spectrometry 
 Prior to H/D exchange MS analyses, both the native enzyme and MPGES1 C59A 
were sequenced by LC-MS/MS, essentially by the method previously described.194 The 
protein was first brought to a concentration of 0.2 mg/mL (12 µM) in ice-cold H2O. 
Digestion was performed on ice for five minutes by the addition of 2 µL of 10 mg/mL 
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(290 µM) pepsin in H2O. The resulting peptides were separated by reversed-phase HPLC 
on an ice-cold Phenomenex Jupiter 5 µ, 300 Å C18 column (50 x 1.00 mm), and eluted at 
a flow rate of 0.3 mL/min with a thirty-minute gradient of 2-50% CH3CN and 0.4% 
formic acid. Scans of m/z 300 to 1500 were utilized for peptide detection on a 
ThermoFinnigan TSQ triple-quadrupole mass spectrometer using positive electrospray 
ionization, and peptides were sequenced by data-dependent tandem MS/MS by CID. The 
putative identity of each peptide was determined from the parent ion m/z value using the 
MS analysis software MassXpert.306 Each putative identification was subsequently 
confirmed by database searching, making individual comparison of the MS/MS spectra to 
the corresponding theoretical fragmentation patterns, as generated by the 
ProteinProspector software MS-Product.307 
 
Amide Hydrogen/Deuterium Exchange Mass Spectrometry and Kinetic Analysis. 
Several kinetic analyses of backbone amide H/D exchange were performed on 
MPGES1. To make topology determinations, experiments were performed on native 
MPGES1 in complex with GSH and solubilized in either CHAPS or DDM micelles. To 
study inhibitor binding, H/D exchange experiments were conducted on native 
MPGES1•GSH unbound to any inhibitors and compared to MPGES1•1, as well as to 
MPGES1•GSH bound to each of the inhibitors 2, 3, and 4. Additionally, to monitor the 
structural interaction of MPGES1 with 15d-PGJ2, H/D exchange kinetic analyses were 
performed on the native enzyme, as well as the C59A mutant, in complex with either 
GSH or GSO3¯ , in the presence of 15d-PGJ2 and compared to identical solution 
conditions lacking 15d-PGJ2. 
88 
 
The H/D exchange MS assays were performed essentially as previously 
described.194 For studies involving the binding of inhibitors 2 – 4, overnight pre-
incubation at 4 °C was initiated by the addition of 4 µL of 5 mM inhibitor in DMSO to 
200 µL of 1 mg/mL (60 µM) purified MPGES1•GSH in 50 mM KH2PO4, pH 7.0, 
containing 300 mM KCl, 7.5% glycerol, and 1% CHAPS. The binding of inhibitor 1 was 
analyzed on 200 µL of 1 mg/mL (60 µM) purified MPGES1•GSO3¯  in the same buffer. 
For studies of 15d-PGJ2 binding, pre-incubation of the enzyme with the PG was initiated 
by the addition of 4 µL of 25 mM 15d-PGJ2 in DMSO to 200 µL of 1 mg/mL (60 µM) 
purified native enzyme or C59A mutant in 50 mM KH2PO4, pH 7.0, containing 300 mM 
KCl, 7.5% glycerol, 1% CHAPS, and either 1 mM GSH or 1 mM GSO3¯ , and was 
incubated overnight at 4 ºC. 
It is important to emphasize that all H/D exchange experiments, except when 
specifically mentioned, were performed on MPEGS1 solubilized in CHAPS detergent 
micelles. The detergent CHAPS was ultimately chosen in inhibitor-binding studies due to 
its minimal suppression of ionization from the electrospray source. Final inhibitor 
concentrations were as follows: 1 mM 1, 100 µM each of 2, 3, and 4, and 500 µM 15d-
PGJ2. 
Deuterium incorporation was initiated by a five-fold dilution of 10 µL of the pre-
incubated protein solution into D2O at 22 ºC. The incorporation was then quenched by a 
two-fold dilution in ice-cold 100 mM KH2PO4, pH 2.3. The protein was then digested on 
ice for five minutes by the addition of 2 µL of 10 mg/mL (290 µM) pepsin in H2O. The 
resulting peptides were separated by reversed-phase HPLC on an ice-cold Phenomenex 
Jupiter 5 µ, 300 Å C18 column (50 x 1.00 mm), and eluted at a flow rate of 0.3 mL/min 
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with a fifteen-minute gradient of 2-50% CH3CN and 0.4% formic acid. Scans of m/z 300 
to 1500 were utilized for peptide detection on a ThermoFinnigan TSQ triple-quadrupole 
mass spectrometer using positive electrospray ionization. Deuterium incorporation was 
observed as a shift in the centroid of the ion envelope (average mass) for each peptide. 
In order to correct for deuterium incorporation that occurs after the quenching step, a 
control for time point zero was performed, in which 10 µL of the protein solution was 
added to 50 µL of ice-cold 100 mM KH2PO4, pH 2.3, followed by addition of 40 µL of 
ice-cold D2O and pepsin digestion, as described above. A control sample accounting for 
the loss of deuterium that occurs during the chromatography step was also performed, in 
which the peptide was first fully labeled at all exchangeable backbone amide sites by 
diluting 10 µL of the protein solution five-fold in D2O and heating to 40 °C for four 
hours. This was followed by a two-fold dilution in ice-cold 100 mM KH2PO4, pH 2.3, 
and pepsin digestion, as described above. 
The kinetics of backbone amide H/D exchange behavior of each peptide were 
determined as previously described.194 The number of deuterons incorporated onto each 
peptide were calculated, correcting for the loss and gain of deuterium during the analysis, 
using eq. 2: 
 
D = N mt − m0%
m100% − m0%
 
 
 
 
 
 
 
 
 
 
 
 
     (Eq. 2) 
 
 
in which D is the number of deuterons incorporated, N is the total number of 
exchangeable backbone amide sites, mt is the average mass of the partially deuterated 
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peptide sample at time t, and m0% and m100% are the average masses of the non-deuterated 
and fully deuterated peptide control samples, respectively. 
The number of incorporated deuterons D were plotted as a function of time, on a 
logarithmic scale, and fit to an equation consisting of a sum of first-order exponential rate 
terms given by eq. 3: 
 
D = N − Σ
n=1
N
Ane
−knt
     (Eq. 3) 
 
in which An and kn are the amplitudes and rate constants of the nth phase of the exchange. 
The exchange amplitude at time zero (Afast) represents the number of hydrogens that 
exchange within the first 15 seconds. The value of Afast is the difference between the sum 
of the fitted amplitudes (A1 + A2 … + An) in the intermediate kinetic phases (> 15 s) and 
the total number of exchangeable sites in the peptide. 
Inasmuch as Afast is an extrapolated value and not a fitted parameter, no errors are 
reported. Given that the errors in the fitted amplitudes A1, A2, and A3 are typically < 10%, 
the errors in Afast are estimated to be < 20 – 30%. The kinetic data were used to identify 
regions of the enzyme involved in inhibitor binding and were guided by the following 
criteria. Peptides displaying significant changes in deuterium incorporation rates were 
those that exhibited an increase or decrease in the number of fast-exchanging (Afast) or 
slow exchanging sites, comprising 15% of the backbone amide protons in the peptide. 
For sites exchanging at intermediate rates, a 10-fold change in the rate of exchange for at 
least one amide site of the peptide was defined as significant. 
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CHAPTER III 
 
TOPOLOGY OF MICROSOMAL PROSTAGLANDIN E SYNTHASE 1 
 
Results 
 
Prediction of Transmembrane Helices of MPGES1 by Computational Methods 
 Hydropathy plots calculated from the Kyte-Doolittle algorithm, which 
progressively evaluates the hydrophilicity and hydrophobicity of a protein as a function 
of its amino acid sequence,308 were previously utilized to predict that the MAPEG 
superfamily members share a conserved secondary structure consisting of four TM 
helices.161 In the study described here, several contemporary computational methods 
optimized for predicting TM helices of integral membrane proteins from their amino acid 
sequence were used. These include TMPred, PHDhtm, and SOSUI, and the results of the 
prediction algorithms are illustrated as a sequence alignment in Figure 34. 
TMPred uses an algorithm based on the statistical analysis of a database of 
naturally-occurring integral membrane proteins to predict membrane-spanning regions.309 
The prediction reveals four TM helices, consisting of residues 15 –31, 81 –101, 97 –118, 
and 127 –146. PHDhtm, a multiple alignment-based neural network system for predicting 
the location and topology of TM helices,310 projects four membrane-embedded helices 
spanning the residues 16 – 33, 76 – 93, 98 – 117, and 128 – 145. SOSUI predicts 
secondary structure of membrane proteins utilizing an amphiphilicity index of polar 
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amino acids of the protein sequence to define membrane-water interfaces.311,312 This 
algorithm displays four TM helices ranging 12 – 34, 73 – 95, 99 – 120, and 129 – 151. 
 
 
 
Figure 34. Prediction of topology of MPGES1 by computational methods. Shown is a 
qualitative map of the four computationally predicted TM helices of MPGES1 as a 
function of amino acid sequence. Each color represents an individual computational 
method with TMPred in black, PHDhtm in blue, and SOSUI in red. 
 
 
Prediction of Transmembrane Helices of MPGES1 by Sequence Alignment with MGST1 
 Both MPGES1 and MGST1 belong to the MAPEG superfamily of integral 
membrane proteins, their activities are GSH-dependent, and the human enzymes share 
38% sequence identity. The three-dimensional structure of rat MGST1, to which human 
MPGES1 shares 36% sequence identity, was determined by electron microscopy of two-
dimensional crystals.162 The structure reveals that the enzyme forms a homotrimer with 
each subunit contributing four TM helices. ClustalW2, a general purpose computer 
program that produces biologically meaningful alignments of similar or divergent amino 
acid sequences,313 was used to predict homologous TM helices of MPGES1, which is 
shown in Figure 35. The alignment reveals a prediction of TM I spanning residues 12 – 
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37, TM II ranging 79 – 92, TM III including 96 – 112, and TM IV consisting of 127 – 
142. 
 
 
 
Figure 35. Prediction of topology of MPGES1 by sequence alignment. (A) The sequence 
alignment of human MPGES1 with rat MGST1, which share 36% sequence identity, 
reveals four TM helices, as indicated by the purple bars and boldface text. (B) The crystal 
structure of rat MGST1 was determined to 3.2 Å by electron microscopy of two-
dimensional crystals. The regions highlighted in purple correspond to the membrane-
embedded regions of the α-helices. 
 
 
Topology of MPGES1 by Amide H/D Exchange Kinetic Analysis 
 The analysis of H/D exchange kinetics was performed on 19 peptides, ranging in 
length from 3 to 16 residues, covering 90% of the entire protein sequence, and assayed 
over a period of 15 seconds to 8 hours. Two separate analyses were performed: one of 
MPGES1 solubilized in the detergent CHAPS, and the other of the enzyme solubilized in 
the detergent DDM, as shown in Figure 36. H/D exchange kinetics can be divided into 
three general types of rates: fast, intermediate, and slow. In general, fast rates (k ≥ 10 s-1) 
indicate solvent exposure, while slow rates (k ≤ 10-4 min-1) are indicative of amide 
nitrogens that are either protected from the solvent or are involved in hydrogen 
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bonding.248 In the case of membrane proteins, peptides that contain a low composition of 
rapid-exchanging amides and a high composition of slow-exchanging amides indicate 
regions that are membrane- or micelle-embedded.  
 
 
 
Figure 36. H/D exchange kinetic profiles for MPGES1 as a function of detergent. Shown 
are the average kinetic profiles for deuterium incorporation as a function of time for 
MPGES1 solubilized in either CHAPS (blue) or DDM (red), with the number of 
exchangeable amide protons for each peptide in parentheses. Complete kinetic data for all 
plots may be found in the Appendix (Figures 60-63). 
 
 
Membrane-spanning regions of MPGES1 were identified as peptides consisting of 
at least 80% slow-exchanging amides while having a maximum of 20% fast-exchanging 
sites (Figure 37). The results reveal that the micelle-embedded regions of MPGES1 are 
consistent between the two different detergent conditions, with the membrane-spanning 
regions encompassing residues 14 – 36, 84 – 103, 108 – 123, and 133 – 152. 
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Figure 37. Determination of topology of MPGES1 by H/D exchange MS. The extent of 
slow-exchanging kinetics is plotted as a function of amino acid sequence for MPGES1 
solubilized in either (A) CHAPS or (B) DDM detergent micelles. Highlighted in purple 
are regions that contain peptides that consist of at least 80% slow-exchanging amides, 
while having a maximum of 20% fast-exchanging amides, and are predicted to be 
micelle-embedded regions. Peptide 48-58 is not predicted to be membrane-embedded, as 
it contains >20% fast-exchanging amides. 
 
 
Discussion 
 
Comparison of Structural Prediction Methods for MPGES1 
 The results from the prediction algorithms reveal that MPGES1 contains four TM 
helices, in agreement with the Kyte-Doolittle prediction.161 The N-terminal region of the 
first membrane-spanning helix begins within the first twelve-to-sixteen amino acids of 
the peptide sequence and ends before the thirty-fifth. The prediction for the second TM 
region is more varied, in that it begins between amino acids R73 and P81 and ends 
between G93 and M101. The prediction algorithms are most consistent for the third TM, 
with the N-terminal end within F97 – A99, and the C-terminal end between Y117 and 
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K120. Finally, the fourth predicted TM is also well conserved amongst the prediction 
algorithms and begins within S127 – T129 and ends between L145 and H151. A 
limitation of the computational method, however, is particularly revealed in the case of 
the algorithm TMPred, which predicts TMs II and III to overlap in amino acid sequence. 
Clearly, the inclusion of complimentary methods to locate membrane-spanning regions of 
proteins is beneficial. 
Overall, when comparing the computational predictions with the MGST1 
sequence alignment and also with the H/D exchange kinetics, it is revealed that there is a 
high degree of consistency in the determination of the location of TM I (Figure 38). The 
membrane-spanning region of TM II is relatively uncertain, as the computational 
methods, sequence alignment, and H/D exchange results reveal a relatively broad range 
in the terminal ends of the helices. With regard to TM III and TM IV, the predictions 
made by computation and sequence alignment are highly conserved, while the 
determinations made from H/D exchange suggest membrane-spanning regions that are 
shifted to higher-numbered amino acid residues. 
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Figure 38. Comparison of prediction methods. Shown is a qualitative map indicating the 
locations of the TM helices of MPGES1 as a function of amino acid sequence by 
computational methods (black), sequence alignment with MGST1 (green), and H/D 
exchange MS (purple). The intensity of the text for the computational methods reflects 
the consensus between the three prediction algorithms. 
 
 
Comparison of Structural Predictions with MPGES1 Crystal Structure 
 During the course of this study, the crystal structure of human MPGES1 (Figure 
39) was determined to 3.5 Å by electron diffraction of two-dimensional crystals in a 
phospholipid bilayer.166 It is revealed that MPGES1 is structurally homologous to 
MGST1, being a homotrimeric protein with four TMs per monomer, as predicted 
computationally. The crystal structure allows for a comparison of the topology of the 
protein determined by crystallography from a phospholipid bilayer to that determined by 
H/D exchange kinetic analysis of detergent-solubilized protein. Also the accuracy of the 
predictions by computational methods, as well as by the MGST1 sequence alignment can 
be investigated. By mapping onto the structure the membrane-spanning regions as 
predicted by computation and sequence alignment, it is revealed that there is a high 
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degree of accuracy in the predictions. In particular, the large cytosolic loop regions are 
well predicted and highly conserved between the techniques. 
 
 
 
Figure 39. Transmembrane helices of MPGES1. The crystal structure of MPGES1 was 
determined by electron microscopy of two-dimensional crystals induced in the presence 
of phospholipids. The membrane embedded regions of MPGES1 as predicted by (A) 
computation, (B) MGST1 sequence alignment, and (C) H/D exchange kinetics are 
mapped onto the crystal structure in grey, green, and purple, respectively. The dotted 
lines represent the lipid bilayer boundaries, as determined from the crystal structure. 
 
 
The integral membrane regions determined by H/D exchange are largely 
consistent with the crystal structure, with the exception of TM III, which extends beyond 
the cytosolic membrane boundary in the crystal structure. This may be due to the 
difference in solubilization methods, i.e. phospholipid bilayer versus detergent micelle. 
The structure also gives insight into the relative inconsistency of the prediction for TM II. 
This helix forms the core of the protein, adopting a polar pocket that opens toward the 
cytosol, and makes little-to-no contact with the membrane bilayer, affecting the 
computational prediction as well as the H/D exchange kinetics. 
 The detergents CHAPS and DDM, depicted in Figure 40, differ with respect to 
their chemical structures, as well as to their critical micelle concentrations (CMC). While 
DDM contains a nonionic, polar saccharide head group, CHAPS is a zwitterionic bile 
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acid derivative. Their CMC values differ by an order of magnitude, with that of DDM 
being 0.01% (w/v, or 0.2 mM) and CHAPS being 0.5% (w/v, or 8 mM).314,315 
 
 
 
Figure 40. Detergents. The detergents used for the solubilization of MPGES1 for the 
H/D exchange experiments include (A) CHAPS and (B) DDM and are diverse in both 
their structures and chemical properties. 
 
 
Even with this variance in micelle conditions, the observations of fast- and slow-
H/D exchange kinetics reveal consistent determinations of the TM helices, suggesting 
that the protein is in similar conformations in each analysis. However, somewhat subtle 
differences in H/D exchange behavior do occur within peptides 2-13, 14-17, 60-68, 124-
129, and 141-152, as illustrated in Figure 41. When these peptides are mapped onto the 
crystal structure (Figure 42) it is revealed that they correspond to regions of TM helices 
at the membrane boundary. As such, the kinetic differences are likely the result of TM-
detergent head group interactions. 
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Figure 41. H/D exchange kinetic profiles for MPGES1 at the micelle boundary. Shown 
are the average kinetic profiles for deuterium incorporation as a function of time for 
MPGES1 solubilized in either CHAPS (blue) or DDM (red), with the number of 
exchangeable amide protons for each peptide in parentheses. Complete kinetic data for all 
plots may be found in the Appendix (Figures 60-63). 
 
 
 
 
Figure 42. H/D exchange kinetic behavior at the micelle boundary. (A) The amino acid 
sequence of MPGES1 is shown with grey bars indicating the TM helices, as determined 
by electron microscopy. Highlighted in purple are regions identified as being kinetically 
different as a function of detergent micelle. (B) The crystal structure of MPGES1 is 
shown, with dotted lines representing the membrane boundaries, as determined by 
electron microscopy. Regions highlighted in purple are the same as those highlighted in 
(A). 
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Conclusion 
 Multiple sequence alignments and hydropathy plots based on amino acid 
sequence are established methods for protein structure prediction. While these techniques 
are undoubtedly valuable for making topology predictions of membrane proteins, it is 
important to validate them with empirical evidence. Here it is shown that H/D exchange 
can be used as a complimentary tool to improve and verify structure prediction by 
utilizing experimental data. In particular, the method shows great promise in identifying 
membrane boundaries of integral membrane proteins by locating regions that interact 
with detergent and/or phospholipid head groups. 
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CHAPTER IV 
 
LOCATION OF INHIBITOR BINDING SITES IN THE HUMAN INDUCIBLE 
PROSTAGLANDIN E SYNTHASE MPGES1 
 
Results 
 
General Considerations 
The H/D exchange kinetics of 19 peptides, ranging in size from 3 to 16 residues 
and covering 90% of the 152 residue protein sequence of MPGES1, were monitored over 
periods of 15 seconds to 8 hours. A peptic peptide map of the protein used in this study is 
presented in Figure 58 in the Appendix. As mentioned previously, MPEGS1 is unstable 
in the absence of GSH or the structurally similar inhibitor glutathione sulfonate (GSO3¯ ), 
so it was not possible to determine the backbone H/D exchange kinetics of the apo-
enzyme. The most pertinent H/D exchange kinetic results are illustrated in the figures and 
tables within this chapter. The remainder of the kinetic data not specifically discussed is 
documented in the Appendix (Figures 64-67 and 74-78). 
 
Structural Studies of Inhibitor Binding 
 Known inhibitors of MPGES1 include those molecules that bind within the 
cofactor GSH site, such as GSO3¯ , 1, and those molecules that bind elsewhere, 
presumably the PGH2 substrate-binding site. The structures of four known inhibitors of 
human MPGES1 with their corresponding IC50 values are illustrated in Table 2. 
Compounds 2 – 4 are representative of pharmacologically active MPGES1 inhibitors of 
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varying potency.188,230,316 The structural interactions of inhibitors 1 – 4 with MPGES1 
were analyzed using the H/D exchange MS technique. 
 
 
Table 2. Inhibitors of MPGES1 used in H/D exchange kinetic analysis. Shown are the 
chemical structures and corresponding IC50 values for inhibitors used in this study. These 
include inhibitor 1, which binds in the GSH cofactor-binding site of MPGES1, and 
inhibitors 2 – 4, which bind within the PGH2 substrate-binding site. 
 
 
 
 
Binding of Glutathione Sulfonate (1) 
Although it is not possible to obtain H/D exchange data from apo-MPGES1, it is 
possible to probe the cofactor-binding site by comparing the H/D exchange behavior of 
the MPGES1•GSH complex to that of the MPGES1•1 complex. The results reveal that 
replacing GSH with 1 increased deuterium incorporation rates for eight of the nineteen 
peptides analyzed including peptides 18-23, 28-31, 32-39, 63-78, 78-83, 124-129, 130-
132, and 133-140 (Figures 43, 48, and Appendix Figures 64-67). There were no instances 
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of significant decreases in deuterium incorporation rates. The results indicate that the 
sulfonate group is sufficient to disrupt the native enzyme structure complexed with GSH. 
Several of these aforementioned peptides contain at least one residue that is in 
close proximity (5 Å) to the sulfur atom of GSH, as indicated by the crystal structure of 
MPGES1 (Figure 44). These residues include Y28, R110, H113, R126, and Q134. The 
remaining peptides that display an increase in H/D exchange rates, 18-23, 63-78, and 78-
83, are adjacent to the those peptides that do contain a residue close to the GSH sulfur 
and are located within the GSH binding pocket.166 Because the sulfhydryl group of GSH 
is surrounded by protein residues, it is perhaps not unexpected that the introduction of the 
three additional oxygen atoms of the sulfonate group is sufficient to disrupt the GSH 
binding site as indicated by the H/D exchange results. Given that the GSH binding pocket 
is in direct contact with membrane-spanning helices, it is reasonable to assume that 
adjoining or neighboring TM segments are affected by structural perturbations to the 
GSH binding site. 
It is a bit surprising, however, that there is no significant change to the H/D 
exchange behavior in peptide 108-123 in TM III as a result of introducing 1 to the GSH-
binding site (Figure 43D), which contains two residues (R110 and H113) in close 
proximity to the sulfhydryl group. This 16-residue peptide in TM III appears to be buried 
in the core of the protein and is not prone to exchange in the GSH-bound form, with the 
exception a single amide. This particular site exhibits no significant change in either the 
amplitude or the rate constant for exchange in the presence of 1 as compared to GSH 
(A1GSH = 1.07 ± 0.07, k1GSH = 0.26 ± 0.03 min-1 and A11 = 1.04 ± 0.03, k11 = 0.17 ± 0.02 
min-1). 
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Figure 43. H/D exchange kinetic profiles for MPGES1 at the cofactor site. Shown are the 
average kinetic profiles for deuterium incorporation as a function of time for MPGES1 
complexed with either GSH (black) or 1 (red), with the number of exchangeable amide 
protons for each peptide in parentheses. The amplitudes and rate constants for each 
peptide can be found in the Appendix (Figures 64-67).  
 
 
 
 
Figure 44. Stereoviews of the residues in close proximity to the sulfhydryl group of 
GSH. Shown is the three-dimensional structure of the MPEGS1•GSH complex.166 (Top) 
α-Helices near the GSH binding site with associated residues shown in stick 
representation with carbon, oxygen, nitrogen and sulfur shown in grey, red, blue, and 
yellow respectively. The model of GSH is shown in stick representation with carbon 
atoms shown in green. (Bottom) Residues near the sulfur of GSH. Those within 5 Å of 
the sulfur of GSH are labeled with distances.  
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Binding of inhibitors 2, 3, and 4 
The H/D exchange kinetic results of the MPGES1•GSH complex bound to 
inhibitors 2, 3, and 4 were compared with those of the GSH-complexed enzyme in the 
absence of inhibitors. All three inhibitors increased H/D exchange rates in some peptides 
and decreased them in others. The most significant observation of these experiments is 
that the changes in H/D exchange behavior are mainly limited to a set of spatially 
common peptides, as illustrated in Figures 45 and 46 and Table 3. Most of the affected 
peptides are relatively short and provide good spatial resolution of the inhibitor-binding 
site. Inhibitors 2 and 3 display significant effects on seven common peptides, while 
inhibitor 4 shares four common peptides with inhibitors 2 and 3. As indicated in Figures 
45 and 46, the effects of inhibitor binding on the H/D exchange kinetic behavior of a 
particular peptide varies. Nevertheless, the results do point to a common binding site for 
all three inhibitors. 
 
 
 
Figure 45. Qualitative map of the effect of inhibitor binding to MPGES1•GSH. Affected 
peptide segments are numbered for each inhibitor where orange indicates enhanced H/D 
exchange and blue signifies decreased exchange in the presence of the inhibitor. 
 
 
In the presence of GSH and 2, deuterium incorporation rates increase for peptides 
37-54, 78-83, 124-129, and 133-140 as compared to GSH alone. Additionally, 
incorporation rates decreased for peptides 104-107, 130-132, and 141-152. In the 
presence of GSH and 3, deuterium incorporation rates increased for peptides 37-54 and 
133-140. Deuterium incorporation rates decreased for peptides 28-31, 78-83, 104-107, 
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124-129, 130-132, and 141-152. In the presence of GSH and 4, deuterium incorporation 
rates increased for peptides 18-23, 124-129, and 133-140. Deuterium incorporation rates 
decreased for peptides 78-83 and 104-107. A few common effects on H/D exchange 
kinetics and many unique features of H/D exchange behavior associated with individual 
inhibitors are illustrated in Figure 46 and Table 3. 
 
 
 
Figure 46. Effects of inhibitor binding on the H/D exchange kinetic profiles of MPGES1. 
Shown are the average kinetic profiles for deuterium incorporation as a function of time 
for MPGES1•GSH, with the number of exchangeable amide protons for each peptide in 
parentheses, in the absence of an inhibitor (black), and in the presence of inhibitor 2 
(blue), 3 (red), and 4 (green). The rate constants and amplitudes derived from kinetic 
analysis are given in Table 3. 
 
 
 
 
 
 
 
 
 
 
 
108 
 
Table 3. Amplitudes and rate constants for amide H/D exchange in the analysis of 
inhibitor binding. Given are the data for selected peptides (from Figure 46) in the 
presence of GSH and inhibitors 2, 3 and 4. 
Peptide/ 
Inhibitor Afast (D) A1 (D) k1 (min
-1) A2 (D) k2 (min-1) 
A 37-54 (16)   
 
  
  none 3.9 5.90 ± 0.15 0.0601 ± 0.0054 6.18 ± 0.26 ≤ 1 x 10-4 
  2 9.1 3.54 ± 0.12 00194 ± 0.0028 3.09 ± 0.69 ≤ 1 x 10-4 
  3 7.9 6.16 ± 0.11 0.0270 ± 0.0020 1.93 ± 0.18 ≤ 1 x 10-4 
  4 3.5 7.34 ± 0.14 0.0792 ± 0.0049 5.19 ± 0.15 ≤ 1 x 10-4 
 
     
B 78-83 (4)      
  none 0.8 0.94 ± 0.02 0.00428 ± 0.00038 2.30 ± 0.13 ≤ 1 x 10-4 
  2 0 2.28 ± 0.04 0.0206 ± 0.0014 1.69 ± 0.18 ≤ 1 x 10-4 
  3 0 0.62 ± 0.18 0.609 ± 0.028 3.62 ± 0.02 ≤ 4.80 x 10-4 
  4 0 0.59 ± 0.08 0.749 ± 0.022 3.35 ± 0.03 ≤ 8.29 x 10-4 
 
     
C 104-107 (3)      
  none 0 0.37 ± 0.05 0.0365 ± 0.0021 2.56 ± 0.05 ≤ 4.90 x 10-4 
  2 0 3 ≤ 1 x 10-4   
  3 0 3 ≤ 1 x 10-4   
  4 0 3 ≤ 1 x 10-4   
 
     
D 124-129 (5)      
  none 0 0.99 ± 0.04 0.0227 ± 0.0022 4.00 ± 0.16 ≤ 1 x 10-4 
  2 0 1.54 ± 0.03 0.0182 ± 0.0017 3.02 ± 0.18 ≤ 1 x 10-4 
  3 0 5 ≤ 1 x 10-4   
  4 0 1.84 ± 0.04 0.0361 ± 0.0030 2.92 ± 0.10 ≤ 1 x 10-4 
 
     
E 130-132 (2)      
  none 0 0.90 ± 0.02 0.0454 ± 0.0046 0.75 ± 0.05 ≤ 1 x 10-4 
  2 0 0.78 ± 0.04 0.125 ± 0.019 1.21 ± 0.04 ≤ 1 x 10-4 
  3 0 0.48 ± 0.02 0.0172 ± 0.0031 1.37 ± 0.10 ≤ 1 x 10-4 
  4 0 0.85 ± 0.01 0.0202 ± 0.0013 0.95 ± 0.05 ≤ 1 x 10-4 
 
     
F 133-140 (6)      
  none 0 1.12 ± 0.03 0.00446 ± 0.00055 4.88 ± 0.03 ≤ 1 x 10-4 
  2 0 3.50 ± 0.06 0.00787 ± 0.00061 2.12 ± 0.06 ≤ 1 x 10-4 
  3 0.8 2.85 ± 0.06 0.00440 ± 0.00046 2.40 ± 0.06 ≤ 1 x 10-4 
  4 0 1.25 ± 0.11 0.0567 ± 0.0128 4.28 ± 0.11 ≤ 1.09 x 10-3 
 
 
 
There are several unique effects that are induced by particular inhibitors. The 
longest peptide analyzed (37-54), which contains 18 residues and 16 exchangeable sites, 
extends from the C-terminal end of TM I into the cytosolic loop, partially covers the GSH 
binding site. The exchange behavior of this particular peptide is profoundly affected by 
the presence of either of the two tight-binding inhibitors (2 or 3), as indicated in Figures 
47 and 48. The amplitudes of the rapidly exchanging sites increases from Afast = 4 in the 
MPGES1•GSH complex to Afast = 8 to 9 in the inhibitor-bound complexes. As indicated 
in Figure 47, the two tight-binding inhibitors appear to increase the conformational 
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dynamics of the cytosolic domain. In contrast, the MPGES1•GSH•4 complex behaves 
similarly to MPGES1•GSH in this region.  
Another striking difference amongst the inhibitors 2 – 4 is revealed in peptide 
124-129 (Figure 46). While inhibitors 2 and 4 provoke an increase in amplitude of 
exchange by about one deuteron relative to the MPGES1•GSH complex, inhibitor 3 
completely inhibits H/D exchange.  
In spite of these differences, all three inhibitors share common attributes as 
clearly observed in peptide 104-107 (Figure 46C) and peptide 133-140 (Figure 46F). All 
inhibitors prevent the relatively slow exchange in peptide 104-107, whereas, in peptide 
133-140 they enhance H/D exchange. The response of peptide 78-83 (Figure 46B) is a 
more complex situation in which all inhibitors decrease the exchange of one site (Afast) 
but have mixed effects on the second site. Finally, although the single exchange site in 
peptide 130-132 (Figure 46E) differs in a subtle manner from one inhibitor to another, the 
relative changes in amplitudes and rate constants are distinguishable (Table 3). 
Figure 47 reveals the common spatial distribution of the effects of the three 
inhibitors on the H/D exchange behavior of the MPGES1•GSH complex. The effects for 
all three compounds are primarily located in TM II, TM III, and TM IV toward the 
luminal side of the GSH binding site. There is also a clear distinction between 4 and the 
two tight-binding inhibitors, 2 and 3, which result in much more extensive changes in the 
H/D exchange behavior in the cytosolic loop and helices encompassing the substrate 
binding cleft. 
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Figure 47. The impact of inhibitor binding on the H/D exchange behavior of the 
MPGES1•GSH complex. The effects of inhibitors 2, 3 and 4 are shown in figures A, B, 
and C, respectively, with GSH shown in stick representation. Regions of enhanced 
exchange are shown in orange while those with decreased exchange are in blue. Only one 
potential binding site in the trimer is illustrated for clarity. 
 
 
Discussion 
 
Binding of 1 Suggests Differences in the Location of GSH in MPGES1 and MGST1 
Interestingly, very large differences in H/D exchange behavior were observed 
between the MPGES1•GSH and MPGES1•1 complexes. Previous comparisons of the 
GSH and 1 complexes of a soluble class Mu GST indicated very limited and highly 
localized differences in H/D exchange kinetics near the –SH/–SO3¯  groups,317  as 
opposed to the very broad regions observed for MPGES1. The results of this experiment 
also contrast with a previous comparison of the H/D exchange kinetics of another 
MAPEG homologue, MGST1,183,194 which shares 38% sequence identity with MPGES1. 
Like the soluble class Mu enzymes, the differences in H/D exchange behavior between 
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the MGST1•GSH complex and MGST1•1 are relatively small and localized near the 
GSH binding site, as determined by electron diffraction and as indicated in Figure 48. 
 
 
 
Figure 48. Comparison of the differential impact of GSH/1 binding on MPGES1. Shown 
are the kinetics of backbone H/D exchange of MGST1•GSH vs. MGST1•1 (left) and 
MPGES1•GSH vs. MPGES1•1 (right) and the location of the GSH binding site in the 
proteins as defined by three-dimensional electron diffraction from two-dimensional 
crystals. 162,166 The dotted lines indicate the approximate location of the cytosolic (top) 
and luminal (bottom) boundaries of the microsomal membrane. One binding site is 
shown for clarity. 
 
 
When comparing the crystal structure of MGST1 to those of the structurally 
homologous MAPEG members MPGES1 and LTC4S, the differences in location of the 
GSH binding sites and shape of the GSH molecules are obvious, as illustrated in Figures 
48 and 49. While the molecular density and electron density of GSH in MPGES1 and 
LTC4S co-localize in the protein within the plane of the bilayer,163,164,166 the density for 
GSH in the MGST1 structure is located in the cytosolic domain of the protein.162 
Moreover, the conformation of the GSH molecule is U-shaped in MPEGS1 and LTC4S 
but C-shaped in MGST1. This is a novel observation in which homologous proteins (~ 
112 
 
40% sequence identical) in the same superfamily appear to bind the common substrate 
(or cofactor) GSH in a different location and conformation. This difference was initially 
attributed, in part, to an ambiguity in the location of the GSH binding site in MGST1 due 
to the anisotropy in the resolution of the diffraction data from the two-dimensional 
crystals. However, comparison of the H/D exchange kinetic results of the enzymes bound 
to either GSH or 1 appear to confirm the different locations of the GSH binding sites, at 
least in the cases of  MGST1 and MPEGS1. 
 
Binding of Inhibitors 2, 3, and 4 Define a Consensus Hydrophobic Cleft 
Ago et al.,163 as well as Martinez Molina et al.,164 reported in 2007 the X-ray 
crystal structures of the GSH-bound LTC4S at resolutions of 3.3 and 2.15 Å, 
respectively. In each case, LTC4S was crystallized in the presence of the detergent DDM, 
and in each case, a detergent molecule was observed to be bound in an ordered fashion 
within a hydrophobic cleft comprised of TM Ia, TM IIb
 
and TM IVb adjacent to the GSH 
binding site (Figure 49A). The authors of both studies proposed this location to be the 
LTA4 substrate-binding site for LTC4S. 
A structural comparison of MPGES1 with LTC4S was used to locate the 
equivalent hydrophobic cleft within MPGES1, as illustrated in Figure 49B. 
Coincidentally, the majority of the peptides involved in inhibitor binding, as determined 
by H/D exchange MS, are localized within this hydrophobic cleft. The only exception is 
that of the large cytosolic loop connecting TM I to TM II. In this case, the loop becomes 
more flexible when the enzyme is inhibitor-bound, perhaps due to a conformational 
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change typically induced by substrate binding, and serving the purpose of facilitating 
product release into the cytosol. 
 
 
 
Figure 49. Definition of the hydrophobic cleft. The proposed substrate binding site is 
defined in (A) LTC4S by co-crystallization with GSH in the presence of the detergent 
DDM. The DDM (cyan) and GSH (green) molecules are shown in stick representation. 
DDM is thought to reside in the LTA4 binding site. The homologous cleft is defined in 
(B) MPGES1 by structural comparison of LTC4S with MPGES1. The hydrophobic cleft 
is located in (C) MPEGS1 by H/D exchange kinetics in the presence of inhibitors 2, 3 and 
4. The side chains of T131, L135 and A138 in TM IV are shown in stick representation. 
One binding site is shown for clarity. 
 
 
It has been recently noted that the efficacy of MPGES1 inhibitors is species 
dependent and defined, in part, by residues located on one face of TM IV.188 For 
example, inhibitor 2, which is very potent toward the human enzyme is ineffective 
against the rat orthologue. This interspecies difference has been ascribed by mutagenesis 
to three specific residues, T131, L135, and A138 on TM IV of the human enzyme. These 
critical residues are located within the hydrophobic cleft at the subunit interface where 
the backbone exhibits a significant enhancement in H/D exchange kinetics when the 
enzyme is bound to inhibitors 2, 3 or 4, as illustrated in Figures 46F, 47A and 49C. This 
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behavior suggests that the binding of these three inhibitors increase the conformational 
dynamics of the protein backbone in this section of TM IV. The H/D exchange results are 
clearly consistent with the mutagenesis analysis that identifies this region as crucial for 
inhibitor binding. 
It should be noted that it is not possible to conclusively determine from this data if 
any of the inhibitors 2, 3 or 4 displace GSH upon binding to the hydrophobic cleft. 
However, this possibility seems unlikely, particularly with respect to inhibitors 2 and 4. 
Compound 2 inhibits MPGES1 by a strictly competitive mechanism vs. the substrate 
PGH2, while compound 4 inhibits by a mixed-type mechanism with a predominant 
competitive component against PGH2.318 Moreover, both 2 and 4, along with 
pharmacologically similar inhibitors exhibit a predominantly noncompetitive component 
when GSH is the varied substrate. This information argues that inhibitors 2, 3, and 4 do 
not displace GSH in the inhibited complexes.    
 
Conclusion 
Backbone amide H/D exchange kinetics analysis is an excellent tool to map 
inhibitor-binding sites in purified integral membrane protein targets. Differences in the 
location of inhibitor sites and their individual impact on the conformational dynamics of 
proteins are easily distinguishable. The H/D exchange kinetics of MPGES1•GSH and 
MPGES1•1 reveal discrete differences in the exchange behavior of the complexes as 
compared to previous studies with the related enzyme MGST1. These observations 
suggest that there are fundamental differences in the mode of binding of GSH to 
MPGES1, in which it acts as a cofactor, and MGST1, in which it is a substrate. Finally, 
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since there is no crystal structure or NMR structure of MPGES1 bound to an inhibitor, 
the H/D exchange kinetic data reported here represent the only physical evidence for the 
location of an inhibitor binding site. 
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CHAPTER V 
 
OBSERVATION OF TWO MODES OF INHIBITION OF HUMAN MICROSOMAL 
PROSTAGLANDIN E SYNTHASE 1 BY THE CYCLOPENTENONE 
15-DEOXY-∆12,14-PROSTAGLANDIN J2 
 
 
Results 
 
Kinetics of the Spontaneous Reaction of 15d-PGJ2 with GSH 
The spontaneous reaction of GSH with 15d-PGJ2 (Figure 50) was previously 
reported,302 but not with respect to its kinetics. The kinetics of the approach to 
equilibrium for the reaction at pH 7.0 and 25 ˚C, determined under pseudo-first-order 
conditions with [GSH] >> [15d-PGJ2], gives rate-constants of k1 = 0.75 ± 0.02 M-1 s-1 and 
k
-1 = (2.0 ± 0.7) x 10-4 s-1 for the forward and reverse reactions, respectively. An 
equilibrium constant for the formation of the adduct is estimated from Kf = k1/k-1 ≈ 3800 
± 1000 M-1. Analysis by HPLC of reaction mixtures of GSH and 15d-PGJ2 at various 
concentrations reveals a similar value of Kf = 1700 ± 200 M-1. 
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Figure 50. Reaction of 15d-PGJ2 with GSH. GSH spontaneously adds to an electrophilic 
carbon on 15d-PGJ2 via Michael addition at room temperature and neutral pH. Reduction 
of the keto group on the cyclopentenone ring of the adduct prevents the retro-Micheal 
reaction. 
 
 
Regiochemistry of the Spontaneous Reaction of 15d-PGJ2 with GSH and L-Cys 
The reaction of 15d-PGJ2 with GSH or L-Cys results in one major peak on 
analysis by HPLC. Further analysis by LC-MS/MS fragmentation reveals position C-9 of 
15d-PGJ2 to be the predominant site of Michael adduction by both GSH and L-Cys, 
consistent with what was previously reported for GSH.302 However, both of these adducts 
are labile under the ESI conditions in the mass spectrometer. Reduction of the keto group 
of the 15d-PGJ2 adducts by NaBH3CN addition (Figure 50) results in stable compounds 
for more definitive analysis by MS/MS (Appendix Figure 79). This analysis shows 
positive evidence for adduction at position C-9 and no definitive evidence for adduction 
at positions C-13 or C-15. The observation of a single major species by HPLC and the 
absence of any MS/MS evidence for exclusive addition to C-13 or C-15 suggest that the 
major site of adduction is C-9. 
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Diastereoselectivity of the Reaction of GSH with 15d-PGJ2 
A previous study suggested that the stereochemistry of addition of GSH to 15d-
PGJ2 occurs on the si-face (bottom) of the 9-10 double bond of the cyclopentenone ring 
giving (9S)-S-glutathionyl-15d-PGJ2 (9S-GS-15d-PGJ2).302 However, examination of the 
addition utilizing molecular models suggests that the attack of the nucleophile from the 
si-face is significantly more hindered and less likely to occur than addition from the top 
(re-face). Therefore, the structure of the GSH adduct was reinvestigated utilizing high-
field NMR spectroscopy. 
 
 
 
Figure 51. Stereoselectivity of GSH addition. The spontaneous addition of GSH to 15d-
PGJ2 can theoretically result in the formation of two diastereomers. The stereochemistry 
at position C-8 would indicate, however, that the 9R species to be that which is 
predominately formed spontaneously, as a result of steric hindrance. 
 
 
A detailed NMR analysis of the purified adduct at 600 MHz and 900 MHz in D2O 
and CD3OD were consistent only with the 9R-GS-15d-PGJ2 diastereomer, which results 
from the re-face addition of GSH. The NMR assignments for this molecule were 
established using 2D 1H-1H COSY/DQF-COSY and NOESY along with 2D 1H-13C 
HSQC experiments. The stereochemistry of the GSH adduct was determined by analysis 
of the protons H7 (2.36, 2.27 ppm), H8 (3.06 ppm) , H9 (4.57 ppm), and H10  (2.81, 3.05 
ppm). In the one-dimensional 1H-NMR spectrum in CD3OD, H9 appears as two doublets, 
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which strongly suggests coupling between two protons and not three. These doublets 
were assigned to coupling between H9 to the two protons on C10, and this was confirmed 
in the 2D COSY. The COSY experiment shows two correlations between H9 and the two 
H10 protons and no correlation between H9-H8. The NOESY spectrum also reveals 
correlations between the C10 protons and H9, but gives no evidence of a correlation 
between H9-H8. The lack of a coupling between H8-H9 can be explained if the bond 
angle between these two protons approaches 90˚, which is unique to the 9R-GS-15d-PGJ2 
diastereomer. 
Upon switching the solvent from CD3OD to D2O, changes were observed in the 
chemical shifts for the protons H7 (2.41, 2.45 ppm), H8 (3.17 ppm), H9 (4.75 ppm), and 
H10 (3.03, 3.20pm). A triplet was observed for H9 in D2O, which is again consistent with 
coupling to two protons (H10). Results from both 2D COSY and DQF-COSY reveal 
coupling between H9 to H10 but no evidence of coupling between H8-H9. This was 
further supported by the 2D NOESY experiment, which also fails to show any correlation 
between H8-H9. The NMR spectra of 9-GS-15d-PGJ2 are provided in the Appendix 
(Figures 80-82). 
 
Covalent Modification of MPGES1 by 15d-PGJ2 
The inhibition studies of MPGES1 by 15d-PGJ2 by Quraishi et al. suggested that 
the inhibition is possibly due to a covalent modification of the enzyme.301 Analysis of the 
three-dimensional structure of MPGES1 determined by Jegerschöld et al. indicates that 
there are three buried cysteine residues and one surface-exposed cysteine (C59) per 
subunit of the homotrimeric protein.166 LC-MS/MS sequencing of the native MPGES1 
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enzyme covalently modified by the 15d-PGJ2 and digested with pepsin revealed that C59 
of the peptide 49-59 was the specific and exclusive site of adduction. Initial estimates 
utilizing TIC chromatographs of the adducted and un-adducted peptide 49-59 suggested 
that only about 20% of the C59 residues were modified by 15d-PGJ2. Since the GSH and 
L-Cys adducts of 15d-PGJ2 are labile under the ESI conditions of the mass spectrometer, 
further analyses were made of the modified enzyme stabilized by reduction with 
NaBH3CN. This analysis of MPGES1 complexed with GSH revealed that approximately 
80-90% of the enzyme is modified under the experimental conditions of the H/D 
exchange assay, while the MPGES1•GSO3¯  complex appears to be fully adducted. 
The regiochemistry of the protein adduct was determined by MS3 experiments on 
the peptic peptide containing C59 (residues 49-59). This peptide was subjected to MS3 
fragmentation selecting for the y-ion of the adducted C59 residue. The results, shown in 
Figure 84 in the Appendix, provide evidence only for site of adduction, at position C-9 of 
15d-PGJ2, consistent with what is observed for the GSH and L-Cys adducts. However, 
the absence of evidence for addition to C-13 or C-15 of 15d-PGJ2 does not exclude its 
occurrence. 
 
Considerations of the Catalytic Properties of Native MPGES1 and the C59A Mutant 
The catalytic and physical properties of native MPGES1 and MPGES1 C59A 
were analyzed and compared, particularly with respect to their GSH transferase and 
PGH2 isomerase activities. The MPGES1 C59A protein exhibits a catalytic activities 
toward GSH and PGH2 that are indistinguishable from those of the native enzyme. 
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Neither the native enzyme nor the C59A mutant catalyze the addition of GSH to 15d-
PGJ2. 
 
Inhibition of MPGES1 by 15d-PGJ2 
The native enzyme is inhibited by 15d-PGJ2 with an IC50 value of 0.6 µM (Figure 
52), consistent with that previously reported,301 while the C59A mutant is inhibited with 
an IC50 value of 12 µM (Figure 52B). Moreover, increasing the substrate concentration 
fails to rescue the activity of native MPGES1, following pre-incubation with 15d-PGJ2, 
suggesting that the inhibition is not competitive (Figure 53A), while the inhibition of 
MPGES1 C59A is reversible with increasing concentrations of PGH2 (Figure 53B). The 
inhibition of the native enzyme utilizing 11-hydroxy-15d-PGJ2 (11-OH-15d-PGJ2) as an 
inhibitor is similar to that of the C59A mutant, having IC50 values of 11 µM and 16 µM, 
respectively (Figure 52). Neither enzyme is appreciably inhibited by 9-GS-11-OH-15d-
PGJ2. 
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Figure 52. Inhibition of the isomerase activity of MPGES1. The inhibition of the native 
enzyme (panel A) and the C59A mutant (panel B) by 15d-PGJ2 (black), 11-OH-15d-PGJ2 
(blue), and 9-GS-11-OH-15d-PGJ2 (red). The IC50 values, 95% confidence range, and 
Hill coefficients are given the in the parentheses for MPGES1; [15d-PGJ2 (0.6 µM, 0.5 – 
0.8 µM, 0.91)], [11-OH-15d-PGJ2 (11 µM, 9 – 13 µM, 0.84) and 9-GS-11-OH-15d-PGJ2 
(>>1 mM) and for C59A MPGES1; [15d-PGJ2 (12 µM, 11 – 14 µM, 0.81)], [11-OH-15d-
PGJ2 (16 µM, 13 – 19 µM, 0.79) and 9-GS-11-OH-15d-PGJ2 (>>1 mM)].  
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Figure 53. Recovery of the isomerase activity of MPGES1. (A) Assay of native and 15d-
PGJ2-modified MPGES1 and (B) the C59A mutant in the absence and presence of 100 
µM 15d-PGJ2, at three different concentrations of the substrate, PGH2. 
 
 
H/D Exchange MS of Native MPGES1 and MPGES1 C59A 
The backbone H/D exchange kinetics of the native MPGES1 enzyme, complexed 
with GSH, and in the presence or absence of 15d-PGJ2 were compared. Kinetic plots for 
some selected peptides are shown in Figure 54. A complete set of the kinetic plots for all 
peptides along with the amplitudes and rate constants for the fits of the data are provided 
in the Appendix (Figures 84-93). These data reveal that peptides within proximity of, or 
containing, the residue C59 (peptides 37-54, 49-59, and 60-68) (Figure 55A) display 
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decreased deuterium incorporation rates when adducted with 15d-PGJ2. This was not 
unexpected, since 15d-PGJ2 is adducted to C59. In addition to these changes, however, 
peptides within the α-helical core of the protein (peptides, 78-83, 104-107, 124-129, 130-
132, 133-140, and 141-152) also display significant differences in H/D exchange 
behavior (Figures 54C, 54D, 55A). On further inspection, it was observed that these 
regions were spatially similar to those identified as constituting the hydrophobic substrate 
binding cleft by H/D exchange experiments of MPGES1•GSH in the presence of 
inhibitors competitive for PGH2 binding,319 as described in the previous chapter. 
 
                                         
 
Figure 54. H/D exchange kinetic profiles of MPGES1•GSH as a function of 15d-PGJ2. 
Shown are the selected kinetic data of the native enzyme (black) and C59A mutant (blue) 
of MPGES1 in complex with GSH in the absence of 15d-PGJ2 and the native (red) and 
the C59A mutant (green) enzyme in the presence of 15d-PGJ2. The number of 
exchangeable sites is given in parentheses. The amplitudes and rate constants for the fits 
of the data can be found in the Appendix (Figures 84-93). 
 
 
To further explore the possibility that MPGES1 binds 15d-PGJ2 in its substrate-
binding site, the above experiments were repeated with the MPGES1 C59A mutant. The 
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H/D exchange kinetics of the C59A mutant in complex with GSH are essentially the 
same as those of the native enzyme in the absence of 15d-PGJ2, as shown in Figure 54. 
However, the H/D exchange behavior of MPGES1 C59A in the presence of GSH and 
15d-PGJ2 are remarkably different than those of the native enzyme. In this case, regions 
in close proximity of A59 display no significant difference in deuterium incorporation 
rates. Regions within the CHAPS micelle (18-23, 78-83, 104-107, 124-129, 130-132, 
133-140, and 141-152), however, do display changes (Figure 55B), which are associated 
with the non-covalent binding of 15d-PGJ2 to the substrate-binding site. 
 
  
 
Figure 55. Structural impact of 15d-PGJ2 binding on MPGES1•GSH. H/D exchange 
results mapped to the secondary structural elements (A) in the native protein and (B) in 
the C59A mutant. The representation of the three-dimensional structure of MPGES1 was 
derived from PDB file 3DWW.166 GSH is shown in stick representation, and C59 and 
A59 are depicted with spheres. The blue and orange peptides indicate regions with 
decreased and increased rates of exchange, respectively, in the presence of 15d-PGJ2. A 
single binding site is shown for clarity. 
 
 
In order to eliminate contributions of the spontaneous adduction of 15d-PGJ2 to 
the cofactor GSH, the H/D exchange kinetic analysis of native MPGES1, as well as 
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MPGES1 C59A, complexed with GSO3¯  were performed in the absence and presence of 
15d-PGJ2 (Figures 56 and 57). Here, peptide 37-54 (Figure 57A) still displays an overall 
decrease in deuterium incorporation rates for the native enzyme, whereas peptides 49-59 
and 60-68 no longer display this large change in kinetics. This may be due to the fact that 
GSO3¯  binding distorts the structural conformation of MPGES1,319 complicating the data 
interpretation. Regions within the detergent micelle (peptides 78-83, 104-107, 130-132, 
and 141-152) still exhibit substantial changes in H/D exchange kinetics, suggesting that 
the enzyme binds 15d-PGJ2 within in the substrate-binding site, even in the absence of 
GSH. 
 
 
 
Figure 56. H/D exchange kinetic profiles of MPGES1•GSO3¯  as a function of 15d-PGJ2. 
Shown are the selected kinetic data of the native enzyme (black) and C59A mutant (blue) 
of MPGES1 in complex with GSO3¯  in the absence of 15d-PGJ2 and the native enzyme 
(red) and the C59A mutant (green) in the presence of 15d-PGJ2. The number of 
exchangeable sites is given in parentheses. The amplitudes and rate constants for the fits 
of the data can be found in the Appendix (Figures 84-93). 
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Figure 57. Structural impact of 15d-PGJ2 binding on MPGES1•GSO3¯ . H/D exchange 
results mapped to the secondary structural elements (A) in the native protein and (B) in 
the C59A mutant. The representation of the three-dimensional structure of MPGES1 was 
derived from PDB file 3DWW.166 GSH is shown in stick representation, and C59 and 
A59 are depicted with spheres. The blue and orange peptides indicate regions with 
decreased and increased rates of exchange, respectively, in the presence of 15d-PGJ2. A 
single binding site is shown for clarity. 
 
 
Discussion 
 
The Chemistry of 15d-PGJ2 
The formation of 15d-PGJ2 and its reactions with cellular nucleophiles has been 
studied by numerous investigators. The regiochemistry of the reaction of GSH, as well as 
L-Cys, with 15d-PGJ2 appears to occur predominantly at position C-9, as previously 
reported by others.302,320 This is also shown to be true for the adduction of MPGES1 at 
residue C59. The NMR results at 600 MHz and 900 MHz in D2O and CD3OD suggest 
that the nucleophile adds to the least hindered face of the 9-10 double-bond of the 
cyclopentenone ring to give the 9R-GS-15d-PGJ2 diastereomer. 
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The chemistry and kinetics of the reaction of GSH with 15d-PGJ2 are key to 
understanding the cellular concentration of the cyclopentenone and its potential anti-
inflammatory properties. The spontaneous reaction with GSH is relatively slow (~ 10-3 s-
1) at pH 7, 25 ˚C, and physiological concentrations of GSH (~ 4 mM). Once formed, the 
GSH adduct has a half-life of about one hour at room temperature in aqueous solution. It 
is clear from the chemical equilibrium, though, that virtually all 15d-PGJ2 is in the form 
of the 9-GS-adduct. The rates of GSH addition to 15d-PGJ2, as well as to its precursor 
PGJ2, are known to be catalyzed in vitro by soluble GSTs.320,321 However, the efficiency 
of the enzyme-catalyzed reactions, at least with respect to PGJ2, appears to be rather low 
with kcat/KM values of 100 to 300 M-1 s-1.320 The exact role of GSTs in the metabolic fate 
of PGJ2 and 15d-PGJ2 is not known. 
 
Inhibition of MPGES1 by 15d-PGJ2 
The anti-inflammatory properties of 15d-PGJ2 may be associated with its 
inhibition of MPGES1. The study detailed in the previous chapter showed that the 
binding of inhibitors competitive for the PGH2 substrate-binding site induces flexibility 
in the cytosolic loop connecting TM I to TM II. It was hypothesized that this increased 
flexibility aids in product release to the cytosol as a result of a normal conformational 
change induced by substrate binding. As defined in this chapter, the covalent 
modification of C59, which lies at the interface of the loop with TM II, by 15d-PGJ2 
results in a significant decrease in H/D exchange rates within the cytosolic loop. This 
suggests that the predominant mechanism of inhibition of MPGES1 by 15d-PGJ2 may 
involve the preclusion of product release from the active site (Figure 55). The H/D 
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exchange kinetic data also reveal that 15d-PGJ2 binds within the substrate-binding site, 
competing for PGH2 binding (Figures 55 and 57). Therefore, inhibition of MPGES1 by 
15d-PGJ2 may involve both the occlusion of substrate from the active site, as well as 
prevention of product release. 
Though it may be compelling to argue that the anti-inflammatory properties of 
15d-PGJ2 are partially due to its inhibition of MPGES1, the in vitro evidence refutes this. 
There are two mechanisms of inhibition: the covalent modification of residue C59 and 
the competitive inhibition revealed by the inhibition and H/D exchange experiments of 
the C59A mutant. The most efficient inhibition of the enzyme is via the covalent 
modification of C59 with an IC50 of 0.6 µM. Since the concentration of 15d-PGJ2 in the 
cell is not known, it is not practical to predict if the covalent modification of MPGES1 
occurs to any significant extent in vivo. Though the physical properties of the molecule 
suggest that the location of 15d-PGJ2 is likely to be concentrated in or near the membrane 
where the enzyme is also located, it is highly unlikely that a non-covalent, competitive 
inhibition of MPEGS1 by 15d-PGJ2 (IC50 ≈ 12 µM) has any biological relevance in vivo, 
since the concentration of free 15d-PGJ2 in the cell is likely to be well below the micro-
molar range.78 
 
Biological Consequences of 15d-PGJ2 
Although the potential biological effects of 15d-PGJ2 are interesting, such as those 
cited in this dissertation and elsewhere, the significance of the findings remains 
uncertain.79 The biological effects of 15d-PGJ2 formed in vivo are controversial 
considering that the formation, concentration, location, and metabolic fate of the 
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molecule are poorly understood.322 The concentration of 15d-PGJ2 in human urine has 
been estimated to be in the low pM range, suggesting that its level is insufficient to 
support biological activity.78 However, the level in urine probably does not reflect local 
cellular concentrations that could affect bioactivity. 
Finally, the transformation of PGD2 to 15d-PGJ2 appears to occur by spontaneous 
chemistry that is unregulated. This fact alone would suggest that 15d-PGJ2 does not likely 
play a regulatory role as an anti-inflammatory mediator. However, that does not 
necessarily preclude it from playing a role under pathological conditions. 
 
Conclusion 
The results reported here demonstrate that 15d-PGJ2 can act as an effective dual-
mode inhibitor of MPGES1 in vitro and define, from a chemical and physical standpoint, 
the interaction of the inhibitor with the enzyme. Although the currently available 
biological data do not rule out an anti-inflammatory role for 15d-PGJ2 in vivo, there is no 
positive physiological evidence to that effect, particularly with respect to MPGES1 
inhibition. The biological data that is currently available do not necessarily preclude an 
anti-inflammatory signaling role for 15d-PGJ2 in vivo, but the lack of knowledge 
regarding the in vivo concentration of 15d-PGJ2, its kinetic disposition, and homeostasis 
leave a significant amount of uncertainty. 
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CHAPTER VI 
 
CONCLUSION 
 
Discussion 
 Inflammation, while a protective immune response that is important to the healing 
process, is implicated in a variety of disease states including atherosclerosis, Alzheimer’s 
disease, RA, and cancer. The critical role that inflammation plays in pathologic events 
makes its regulation crucial to the prevention and treatment of inflammatory diseases, 
accounting for the prominence of anti-inflammatory drugs like NSAIDs. The definition 
of the mechanism of action of NSAIDs as the inhibition of the enzymatic production of 
PGs shed light on the role of eicosanoids as mediators of pain, inflammation, and fever. 
Metabolites of the polyunsaturated fatty acid arachidonic acid not only include the 
prostanoids, but LTs, LXs, EXs, and CYP-derived metabolites as well. These eicosanoids 
constitute a widespread family of signaling molecules that have all been shown on some 
level to be lipid mediators of the inflammatory response. Their synthesis is tightly 
controlled by a multitude of enzymes in tissues throughout the body. The delicate and 
complex role that the eicosanoids play in the regulation of normal biological processes, 
the propagation of pathological events, and the resolution of such events has been studied 
intensely. 
 One family of proteins involved in the synthesis of eicosanoids represents a 
unique set of GSTs known as the MAPEG superfamily. Three members in particular, 
FLAP, LTC4S, and MPGES1 are directly involved in the synthesis of LTs, Cys-LTs, and 
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inducible PGE2, respectively, and therefore represent promising targets for the 
therapeutic treatment of inflammation. 
 The focus of this dissertation, MPGES1, is a GSH-dependent isomerase that 
preferentially utilizes PGH2 produced by the inducible COX-2, an enzyme highly 
implicated in a variety of inflammatory diseases and several forms of cancer. As such, 
MPGES1 has been at the forefront of drug development by groups in the pharmaceutical 
sector, as well as in academia. Though the three-dimensional crystal structure of 
MPGES1 was determined by two-dimensional crystallography in 2008, questions have 
remained regarding its chemical mechanism and physical interaction with inhibitors. 
 The method of H/D exchange MS has emerged as a useful technique for the 
structural analysis of integral membrane proteins, such as MPGES1. Given that analyses 
may be performed in nearly any solution condition or protein concentration, an option not 
often available with techniques such as X-ray crystallography or NMR, H/D exchange 
MS was utilized to make structural and conformational dynamic determinations of 
MPGES1. The initial aim of this project took advantage of the use of structurally 
divergent detergent micelles to make topography determinations of the enzyme. The 
technique proved particularly successful in identifying the boundaries of micelles by 
locating regions of the protein that interact with detergent head groups. 
 In the absence of a crystal structure of MPGES1 bound to an inhibitor, H/D 
exchange MS was utilized to map the binding sites of different types of inhibitors of 
MPGES1 as the second aim of this project. The results reveal two spatially distinct 
binding sites, which include the cofactor site as well as a hydrophobic cleft, predicted to 
harbor the substrate-binding site. Analysis of the H/D exchange behavior of the cofactor 
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site confirms the unusual observation that MPGES1 and the closely related MGST1 bind 
the common cofactor/primary substrate GSH in differing locations. In addition, H/D 
exchange kinetics of inhibitors competitive for PGH2 binding reveal a site within a 
hydrophobic environment capable of binding a hydrophobic ligand. 
 The cyPG 15d-PGJ2 is an endogenous inhibitor of MPGES1 unlike those 
inhibitors that bind to the cofactor site or those that are synthesized as pharmacologically 
active inhibitors. Initial biochemical data has suggested that 15d-PGJ2 may form a 
covalent adduct or involve allosteric binding to MPGES1, and the final aim of this 
project involved the elucidation of its mechanism of inhibition. Further investigation of 
the interaction of 15d-PGJ2 using biochemical methods along with H/D exchange MS 
have revealed that covalent adduction of the enzyme at a cytosolic cysteine residue, as 
well as binding to the PGH2 substrate-binding site, account for its inhibitory activity. The 
GSH adduct of 15d-PGJ2, on the other hand, displayed no inhibitory effect on MPGES1. 
While 15d-PGJ2 can act as an effective dual-mode inhibitor of MPGES1 in vitro, there is 
no convincing physiological evidence to suggest that the anti-inflammatory role of this 
cyPG is due to its role as an inhibitor of MPGES1 in vivo. 
 
Future Studies 
 Though the IC50 values of inhibition for 15d-PGJ2 and 11-OH-15d-PGJ2 have 
been determined for native MPGES1 and MPGES1 C59A, they have only been done so 
for a single PGH2 substrate concentration. Varying the substrate concentration will alter 
the corresponding IC50 value, and these data can be used to kinetically define the 
mechanism(s) of inhibition. Plotting IC50 values as a function of substrate concentration 
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is a method that can be used to calculated the inhibition constant (Ki) of each inhibitor for 
each enzyme, and the slopes of the plots may be used to determine the mechanism of 
inhibition, whether it be competitive, uncompetitive, non-competitive, or a mixed-type of 
inhibition. 
 While there is a chemical mechanism of MPGES1 isomerase activity suggested 
from its crystal structure, uncertainty remains. To probe whether Arg-126 is the proton 
donor to oxygen at position C-11 of PGH2 and the proton acceptor from C-9, additional 
mutagenesis experiments, coupled with kinetic analysis, may be performed. As Tyr-28 
and Tyr-130 are reasonable candidates as proton donors and acceptors in the reaction, 
mutations of these residues may be made in conjunction with those of Arg-126. 
 The crystal structure of MPGES1 also suggests that the enzyme binds three 
molecules of GSH simultaneously, but this may be an artifact of crystallographic 
conditions. If the enzyme does bind three molecules of GSH, it is unclear if all three sites 
are simultaneously active. To address these uncertainties, a series of experiments could 
be designed, such as nano-flow electrospray MS and equilibrium dialysis to determine 
the number of occupied cofactor sites, and single turnover stopped flow kinetic analysis 
to monitor the GSH-binding affinity of each site, should they differ. 
 Additional structural analyses of MPGES1 are in need and are almost certain to 
come. While the structure of MPGES1 in complex with GSH has been revealing, it would 
certainly be beneficial to analyze structures of MPGES1 in the absence of GSH and/or 
bound to inhibitors that are competitive for PGH2 binding. These observations could 
reveal aspects of the mechanism of action of the enzyme, as well as aid in structure-based 
drug design. 
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 The studies described here have alluded to a possible mode of product release 
from MGPES1. It would be interesting to use alternative methods to define both the 
mechanism of product release and mechanism of substrate binding. As an alternative to 
H/D exchange MS, other structural dynamics-dependent labeling techniques coupled to 
MS could be utilized including hydroxyl radical foot-printing, oxidative methionine 
labeling, and electrophysiology-coordinated photo-labeling. 
 Finally, while several H/D exchange MS analyses have been made of MPGES1 
and MGST1, the other members of the MAPEG superfamily have not been investigated 
utilizing this technique. As an example, the method could feasibly be used to monitor the 
physical interaction of FLAP with 5-LOX, should there be one, at the committed step of 
LT biosynthesis. 
 
Conclusion 
 Inflammation research has come a long way since the reverend Edward Stone 
performed the first clinical trial of willow bark in fever patients in 1763. The discovery of 
naturally-occurring anti-inflammatory compounds eventually led to the discovery of the 
mechanism of action of NSAIDs. That discovery gave way to the revelation of 
eicosanoids as being lipid mediators of not just normal biological functions, but a 
multitude of pathological processes as well. Along with that came the investigations of 
the proteins involved in the syntheses of the eicosanoids. We are now at a stage of, not 
only observing these proteins, but utilizing their structural and functional properties as a 
means to target them for therapeutic purposes. To this end, it is my hope that the 
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conformational dynamics studies of MPGES1 described here have played their small role 
in the increasingly important field of inflammation research. 
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APPENDIX 
 
 
 
 
Figure 58.  MPGES1 peptic peptide map.  White bars, with corresponding residue 
numbers, represent peptides analyzed for deuterium incorporation.  Gray bars indicate the 
transmembrane helices, as determined by electron microscopy. 
 
 
 
138 
 
 
Peptide Afast (D) A1 (D) k1 (min-1) A2 (D) k2 (min-1) 
A 2-13 (10)   
 
  
  CHAPS 8.6 1.44 ± 0.10 0.536 ± 0.087   
  DDM 7.6 2.40 ± 0.11 0.321 ± 0.040   
      
B 14-17 (3)      
  CHAPS 0 0.74 ± 0.03 0.0971 ± 0.0142 2.29 ± 0.03 ≤ 1 x10-4 
  DDM 0 1.04 ± 0.04 0.101 ± 0.011 1.96 ± 0.04 ≤ 1 x10-4 
      
C 18-23 (5)   
 
  
  CHAPS 0 5 ≤ 1 x10-4   
  DDM 0 5 ≤ 1 x10-4   
      
D 23-27 (4)      
  CHAPS 0 4 ≤ 1 x10-4   
  DDM 0 4 ≤ 1 x10-4   
      
E 28-31 (3)      
  CHAPS 0 0.33 ± 0.03 0.141 ± 0.015 2.55 ± 0.02 ≤ 5.12 x10-4 
  DDM 0 0.67 ± 0.07 0.252 ± 0.035 2.40 ± 0.05 ≤ 4.94 x10-4 
      
F 32-39 (7)      
  CHAPS 0 1.05 ± 0.03 0.102 ± 0.009 5.90 ± 0.04 ≤ 1 x10-4 
  DDM 0 1.41 ± 0.03 0.0282 ± 0.0023 5.59 ± 0.03 ≤ 1 x10-4 
 
Figure 59. H/D exchange kinetic profiles for MPGES1 as a function of micelle, residues 
2 – 39. The total number of exchangeable sites for each peptide is given in parentheses. 
Deuterium incorporation as a function of time is plotted for the enzyme solubilized in 
either CHAPS (blue) or DDM (red) detergent micelles and fit to a sum of first-order rate 
terms, as described in the Materials and Methods chapter. 
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Peptide Afast (D) A1 (D) k1 (min-1) A2 (D) k2 (min-1) 
A 37-54 (16)   
 
  
  CHAPS 3.9 5.90 ± 0.15 0.0601 ± 0.0054 6.18 ± 0.26 ≤ 1 x10-4 
  DDM 3.4 6.61 ± 0.11 0.0161 ± 0.0022 6.00 ± 0.21 ≤ 1 x10-4 
      
B 49-58 (8)      
  CHAPS 0 1.37 ± 0.08 0.141 ± 0.025 6.44 ± 0.07 ≤ 1 x10-4 
  DDM 0.5 1.18 ± 0.03 0.0943 ± 0.0074 6.30 ± 0.03 ≤ 1 x10-4 
      
C 60-68 (7)   
 
  
  CHAPS 2.6 4.37 ± 0.08 0.0131 ± 0.0011   
  DDM 1.5 5.54 ± 0.09 0.0622 ± 0.0037   
      
D 63-78 (15)      
  CHAPS 0 5.11 ± 0.09 0.103 ± 0.006 10.00 ± 0.12 ≤ 1 x10-4 
  DDM 0 5.09 ± 0.12 0.0851 ± 0.0067 9.91 ± 0.18 ≤ 1 x10-4 
      
E 78-83 (4)      
  CHAPS 0.8 0.94 ± 0.02 0.00428 ± 0.00038 2.30 ± 0.13 ≤ 1 x10-4 
  DDM 0.9 1.10 ± 0.03 0.0116 ± 0.0014 2.00 ± 0.03 ≤ 1 x10-4 
      
F 90-92 (2)      
  CHAPS 0 2 ≤ 1 x10-4   
  DDM 0 2 ≤ 1 x10-4   
 
Figure 60. H/D exchange kinetic profiles for MPGES1 as a function of micelle, residues 
37 – 92. The total number of exchangeable sites for each peptide is given in parentheses. 
Deuterium incorporation as a function of time is plotted for the enzyme solubilized in 
either CHAPS (blue) or DDM (red) detergent micelles. 
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Peptide Afast (D) A1 (D) k1 (min-1) A2 (D) k2 (min-1) 
A 92-100 (6)   
 
  
  CHAPS 0 6 ≤ 1 x10-4   
  DDM 0 6 ≤ 1 x10-4   
      
B 104-107 (3)      
  CHAPS 0 0.37 ± 0.05 0.0365 ± 0.0021 2.56 ± 0.05 ≤ 4.90 x10-4 
  DDM 0 0.58 ± 0.08 0.0549 ± 0.0020 2.44 ± 0.08 ≤ 4.26 x10-4 
      
C 108-123 (15)   
 
  
  CHAPS 0 1.07 ± 0.07 0.261 ± 0.029 14.06 ± 0.05 ≤ 1 x10-4 
  DDM 0 1.52 ± 0.04 0.0497 ± 0.0046 13.25 ± 0.04 ≤ 1 x10-4 
      
D 124-129 (5)      
  CHAPS 0 0.99 ± 0.04 0.0227 ± 0.0022 4.00 ± 0.16 ≤ 1 x10-4 
  DDM 0.6 1.71 ± 0.05 0.103 ± 0.009 2.70 ± 0.15 ≤ 1 x10-4 
      
E 130-132 (2)      
  CHAPS 0 0.90 ± 0.02 0.0454 ± 0.0046 0.75 ± 0.05 ≤ 1 x10-4 
  DDM 0.3 1.03 ± 0.03 0.0517 ± 0.0051 0.70 ± 0.05 ≤ 1 x10-4 
      
F 133-140 (6)      
  CHAPS 0 1.12 ± 0.03 0.00446 ± 0.00055 4.88 ± 0.03 ≤ 1 x10-4 
  DDM 0 1.11 ± 0.04 0.0339 ± 0.0045 4.89 ± 0.06 ≤ 1 x10-4 
 
Figure 61. H/D exchange kinetic profiles for MPGES1 as a function of micelle, residues 
92 – 140. The total number of exchangeable sites for each peptide is given in parentheses. 
Deuterium incorporation as a function of time is plotted for the enzyme solubilized in 
either CHAPS (blue) or DDM (red) detergent micelles. 
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Peptide Afast (D) A1 (D) k1 (min-1) A2 (D) k2 (min-1) 
A 141-152 (11)   
 
  
  CHAPS 0.8 1.11 ± 0.11 0.254 ± 0.029 9.06 ± 0.06 ≤ 1 x10-4 
  DDM 0.7 2.75 ± 0.05 0.0649 ± 0.0038 7.60 ± 0.16 ≤ 1 x10-4 
 
Figure 62. H/D exchange kinetic profiles for MPGES1 as a function of micelle, residues 
141 – 152. The total number of exchangeable sites for each peptide is given in 
parentheses. Deuterium incorporation as a function of time is plotted for the enzyme 
solubilized in either CHAPS (blue) or DDM (red) detergent micelles. 
 
 
 
 
 
log IC50 0.2611  
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Figure 63. Determination of GSO3¯  IC50. The final concentration of total protein is 15 
µg/ml, PGH2 is 10 µM, GSH is 0.4 mM, and GSO3¯  from 0.004 to 37.5 mM. The number 
of replicate experiments is twelve. 
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Peptide Afast (D) A1 (D) k1 (min-1) A2 (D) k2 (min-1) 
A 2-13 (10)   
 
  
  GSH 8.6 1.44 ± 0.10 0.536 ± 0.087   
  1 8.7 1.31 ± 0.11 0.747 ± 0.132   
      
B 14-17 (3)      
  GSH 0 0.74 ± 0.03 0.0971 ± 0.0142 2.29 ± 0.03 ≤ 1 x10-4 
  1 0 0.95 ± 0.02 0.0127 ± 0.0011 2.06 ± 0.10 ≤ 1 x10-4 
      
C 18-23 (5)   
 
  
  GSH 0 5 ≤ 1 x10-4   
  1 0 3.00 ± 0.07 0.0115 ± 0.0012 1.70 ± 0.07 ≤ 1 x10-4 
      
D 23-27 (4)      
  GSH 0 4 ≤ 1 x10-4   
  1 0 4 ≤ 1 x10-4   
      
E 28-31 (3)      
  GSH 0 0.33 ± 0.03 0.141 ± 0.015 2.55 ± 0.02 ≤ 5.12 x10-4 
  1 0 1.90 ± 0.03 0.0127 ± 0.0009 1.16 ± 0.26 ≤ 1 x10-4 
      
F 32-39 (7)      
  GSH 0 1.05 ± 0.03 0.102 ± 0.009 5.90 ± 0.04 ≤ 1 x10-4 
  1 0 4.69 ± 0.09 0.0161 ± 0.0013 2.00 ± 0.09 ≤ 1 x10-4 
Figure 64. H/D exchange kinetic profiles for MPGES1 as a function of GSH/1 binding, 
residues 2 – 39. Shown are the average kinetic profiles for deuterium incorporation as a 
function of time for MPGES1 in complex with either GSH (black) or inhibitor 1 (red), with 
the number of exchangeable amide protons for each peptide in parentheses. The data were fit 
to a sum of first-order rate terms, as described in the Materials and Methods chapter. 
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Peptide Afast (D) A1 (D) k1 (min-1) A2 (D) k2 (min-1) A3 (D) k3 (min-1) 
A 37-54 (16)   
 
    
  GSH 3.9 5.90 ± 0.15 0.0601 ± 0.0054 6.18 ± 0.26 ≤ 1 x10-4   
  1 4.3 5.75 ± 0.11 0.0649 ± 0.0045 5.96 ± 0.21 ≤ 1 x10-4   
        
B 49-58 (8)        
  GSH 0 1.37 ± 0.08 0.141 ± 0.025 6.44 ± 0.07 ≤ 1 x 10-4   
  1 0 1.89 ± 0.46 0.0210 ± 0.0065 5.95 ± 0.47 ≤ 2.54 x 10-3   
        
C 60-68 (7)   
 
    
  GSH 2.6 4.37 ± 0.08 0.0131 ± 0.0011     
  1 2.6 4.36 ± 0.07 0.0119 ± 0.0009     
        
D 63-78 (15)        
  GSH 0 5.11 ± 0.09 0.103 ± 0.006 10.00 ± 0.12 ≤ 1 x10-4   
  1 0 8.73 ± 0.33 0.185 ± 0.021 7.05 ± 0.31 ≤ 1 x10-4   
        
E 78-83 (4)        
  GSH 0.8 0.94 ± 0.02 0.00428 ± 0.00038 2.30 ± 0.13 ≤ 1 x10-4   
  1 0 0.72 ± 0.19 0.802 ± 0.053 2.42 ± 0.12 0.0141 ± 0.0018 0.86 ± 0.12 ≤ 1 x10-4 
        
F 90-92 (2)        
  GSH 0 2 ≤ 1 x10-4     
  1 0 2 ≤ 1 x10-4     
Figure 65. H/D exchange kinetic profiles for MPGES1 as a function of GSH/1 binding, 
residues 37 – 92. Shown are the average kinetic profiles for deuterium incorporation as a 
function of time for MPGES1 in complex with either GSH (black) or inhibitor 1 (red), 
with the number of exchangeable amide protons for each peptide in parentheses. 
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Peptide Afast (D) A1 (D) k1 (min-1) A2 (D) k2 (min-1) 
A 92-100 (6)   
 
  
  GSH 0 6 ≤ 1 x10-4   
  1 0 6 ≤ 1 x10-4   
      
B 104-107 (3)      
  GSH 0 0.37 ± 0.05 0.0365 ± 0.0021 2.56 ± 0.05 ≤ 4.90 x10-4 
  1 0 0.60 ± 0.07 0.0535 ± 0.0051 2.35 ± 0.07 ≤ 1.72 x10-3 
      
C 108-123 (15)   
 
  
  GSH 0 1.07 ± 0.07 0.261 ± 0.029 14.06 ± 0.05 ≤ 1 x10-4 
  1 0 1.04 ± 0.03 0.168 ± 0.016 13.98 ± 0.13 ≤ 1 x10-4 
      
D 124-129 (5)      
  GSH 0 0.99 ± 0.04 0.0227 ± 0.0022 4.00 ± 0.16 ≤ 1 x10-4 
  1 0 3.83 ± 0.11 0.0220 ± 0.0025 0.90 ± 0.11 ≤ 1 x10-4 
      
E 130-132 (2)      
  GSH 0 0.90 ± 0.02 0.0454 ± 0.0046 0.75 ± 0.05 ≤ 1 x10-4 
  1 0.5 1.48 ± 0.03 0.0248 ± 0.0024   
      
F 133-140 (6)      
  GSH 0 1.12 ± 0.03 0.00446 ± 0.00055 4.88 ± 0.03 ≤ 1 x10-4 
  1 0.9 5.09 ± 0.09 0.0130 ± 0.0010   
Figure 66. H/D exchange kinetic profiles for MPGES1 as a function of GSH/1 binding, 
residues 92 – 140. Shown are the average kinetic profiles for deuterium incorporation as 
a function of time for MPGES1 in complex with either GSH (black) or inhibitor 1 (red), 
with the number of exchangeable amide protons for each peptide in parentheses. 
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Peptide Afast (D) A1 (D) k1 (min-1) A2 (D) k2 (min-1) 
A 141-152 (11)   
 
  
  GSH 0.8 1.11 ± 0.11 0.254 ± 0.029 9.06 ± 0.06 ≤ 1 x10-4 
  1 0.7 1.27 ± 0.12 0.364 ± 0.037 9.03 ± 0.06 ≤ 1 x10-4 
Figure 67. H/D exchange kinetic profiles for MPGES1 as a function of GSH/1 binding, 
residues 141 – 152. Shown are the average kinetic profiles for deuterium incorporation as 
a function of time for MPGES1 in complex with either GSH (black) or inhibitor 1 (red), 
with the number of exchangeable amide protons for each peptide in parentheses. 
 
 
 
 
 
 
Figure 68. Synthesis of MF63, step 1: 1-(3-phenanthryl)ethanone oxime. To a solution of 
1-(3-phenanthryl)ethanone in 25 mL of ethanol was added 4 g of hydroxylamine 
hydrochloride. The reaction mixture was heated to reflux followed by the addition of 7 
mL of pyridine. After 3 h, the reaction was cooled down to room temperature and the 
solvent was removed in vacuo. Ice was added to the residue and the mixture was stirred 
for 1 h. The resulting off-white solid was filtered and washed with water. 5.02 g of the 
product (94 %) was obtained by recrystallization from ether. 
1H NMR (CDCl3, 400 MHz) δ (ppm) 8.93 (s, 1H), 8.74 (d, J = 8.2 Hz, 1H), 7.92 (d, J = 
7.2 Hz, 1H), 7.90 (dd, J = 8.4, 14.0 Hz, 2H), 7.76 (dd, J = 8.8, 14.8 Hz, 2H), 7.71-7.60 
(m, 2H), 2.49 (s, 3H); LCMS, single peak, 1.51 min, m/e, 236.28 (M+1). 
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Figure 69. Synthesis of MF63, step 2: 3-phenanthrylamine. To 60 g of polyphosphoric 
acid was added 5.02 g of 1-(3-phenanthryl)ethanone oxime  at room temperature. The 
reaction mixture was stirred at 100 oC for 2 h, cooled down to room temperature followed 
by the addition of ice. Stirred 30 minutes, filtered and washed with water. This white 
solid was then placed in 50 mL of methanol and 4 mL of concentrated HCl. The reaction 
was refluxed overnight, cooled down to room temperature and concentrated down. A 
mixture of ethyl acetate/water was added to the residue and the resulting solution was 
made basic with 10 N KOH. The aqueous layer was extracted with ethyl acetate and 
combined organic layers were washed with water, brine, dried over MgSO4 and solvent 
was removed under reduced pressure to afford 3.74g (90%) of 3-phenanthrylamine as a 
beige solid. LCMS, single peak, 1.09 min, m/e, 194.24 (M+1). 
 
 
 
Cl
 
 
Figure 70. Synthesis of MF63, step 3: 3-chlorophenanthrene. 3.39 g of CuCl2 and 4.84 
mL of t-butyl nitrite were dissolved in 10 mL of acetonitrile. The 3-phenanthrylamine 
(3.74 g) was added over 10 minutes as a solution in 6 mL of acetonitrile. The reaction 
was stirred for 45 minutes at 65  oC, cooled down to room temperature followed by the 
addition of 100 mL of 1 N HCl. The aqueous layer was extracted with dichloromethane 
and combined organic layers were washed with water, brine, dried over MgSO4 and 
solvent was remove under reduced pressure. The residue was purified by flash 
chromatography on silica gel (hexane/ethyl acetate = 7/3) to produce 2.53 g (63%) of 3-
chlorophenanthrene as a white solid. 1H NMR (CDCl3, 400 MHz) δ (ppm) 8.65 (d, J = 
1.6 Hz, 1H), 8.60 (d, J = 8.0 Hz, 1H), 7.90 (dd, J = 1.6, 8.0 Hz, 1H), 7.82 (d, J = 8.4 Hz, 
1H), 7.75-7.61 (m, 4H), 7.55 (dd, J = 2.0, 8.8 Hz, 1H); LCMS, single peak, 1.75 min, 
m/e, 213.67 (M+1). 
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Figure 71. Synthesis of MF63, step 4: 3-chlorophenanthrene-9,10-dione. To a solution of 
2.53 g of 3-chlorophenanthrene in 70 mL of acetic acid was added 4.75 g of CrO3. The 
reaction was stirred for 2 h at 100  oC, cooled down to room temperature and poured into 
300 mL of water. The suspension was stirred for 1h, filtered and washed with water. The 
residue was dried under high vacuum to afford 2.5 g (86%) of 3-chlorophenanthrene-
9,10-dione. 1H NMR (CDCl3, 400 MHz) δ (ppm) 8.21 (d, J = 8.0 Hz, 1H), 8.14 (d, J = 
8.4 Hz, 1H), 8.00-7.95 (m, 2H), 7.75 (t, J = 8.0 Hz, 1H), 7.53 (t, J = 8.0 Hz, 1H), 7.44 
(dd, J = 1.6, 8.0 Hz, 1H); LCMS, single peak, 1.47 min, m/e, 243.66 (M+1). 
 
 
 
 
 
Figure 72. Synthesis of MF63, step 5: 6-chloro-2-(2,6-dibromophenyl)-3a,11b-dihydro-
1H-phenanthro[9,10-d]imidazole. To a solution of 0.613 g of 3-chlorophenanthrene-9,10-
dione in 25 mL of acetic acid was added 0.8 g of ammonium bicarbonate followed by  
1.0 g of 2,6-dibromobenzaldehyde.  The reaction was stirred overnight at 130 oC, cooled 
down to room temperature, and poured into the 40 mL of water. The residue was filtered, 
washed with water, and purified by flash column chromatography (hexane/ethyl acetate = 
6/4) to afford 0.75 g (61%) of white solid product. LCMS, single peak, 1.55 min, m/e, 
486.90 (M+1). 
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Figure 73. Synthesis of MF63, final step. To a solution of 0.75 g of 6-chloro-2-(2,6-
dibromophenyl)-3a,11b-dihydro-1H-phenanthro[9,10-d]imidazole was added 0.348 g of 
CuCN. The reaction was stirred overnight at 80 oC, cooled down to room temperature, 
poured into a mixture of 40 mL of water, 40 mL of ethyl acetated and 5.5 mL of 
concentrated ammonium hydroxide, and stirred for 1 h at room temperature. The aqueous 
layer was extracted with ethyl acetate and the combined organic layers were washed with 
10% ammonium hydroxide, water, brine, dried over MgSO4 and solvent was removed 
under reduced pressure. The residue was purified by flash column chromatography 
(hexane/ethyl acetate = 5/5) to afford 0.346 g (59%) of 2-(6-chloro-3a,11b-dihydro-1H-
phenanthro[9,10-d]imidazol-2-yl) isophthalo-nitrile. 1H NMR (DMSO, 400 MHz) δ 
(ppm) 14.32 (s, 1H), 9.04-8.88 (m, 2H), 8.60-8.36 (m, 4H), 7.98 (t, J = 8.0 Hz, 1H), 7.90-
7.76 (m, 2H), 7.75-7.67 (m, 1H); LCMS, single peak, 1.54 min, m/e, 381.06 (M+1). 
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Peptide/ 
Inhibitor Afast (D) A1 (D) k1 (min
-1) A2 (D) k2 (min-1) 
A 2-13 (10)   
 
  
  none 8.6 1.44 ± 0.10 0.536 ± 0.087   
  2 8.7 1.26 ± 0.11 0.230 ± 0.055   
  3 8.7 1.35 ± 0.11 0.321 ± 0.063   
  4 8.6 1.39 ± 0.07 0.158 ± 0.025   
      
B 14-17 (3)      
  none 0 0.74 ± 0.03 0.0971 ± 0.0142 2.29 ± 0.03 ≤ 1 x 10-4 
  2 0 0.59 ± 0.07 0.0723 ± 0.0134 2.39 ± 0.07 ≤ 6.05 x 10-4 
  3 0 0.47 ± 0.03 0.0358 ± 0.0077 2.48 ± 0.05 ≤ 1 x 10-4 
  4 0 0.51 ± 0.02 0.0965 ± 0.0113 2.35 ± 0.02 ≤ 5.18 x 10-4 
      
C 18-23 (5)   
 
  
  none 0 5 ≤ 1 x 10-4   
  2 0 0.46 ± 0.04 0.303 ± 0.070 4.54 ± 0.02 ≤ 1 x 10-4 
  3 0 5 ≤ 1 x 10-4   
  4 0.31 0.58 ± 0.01 0.0139 ± 0.0014 4.11 ± 0.05 ≤ 1 x 10-4 
      
D 23-27 (4)      
  none 0 4 ≤ 1 x 10-4   
  2 0 4 ≤ 1 x 10-4   
  3 0 4 ≤ 1 x 10-4   
  4 0 4 ≤ 1 x 10-4   
 
Figure 74. H/D exchange kinetic profiles for MPGES1•GSH as a function of inhibitor 
binding, residues 2-27. Shown are the average kinetic profiles for deuterium 
incorporation as a function of time for MPGES1 complexed with GSH in the absence of 
an inhibitor (black), or in the presence of inhibitor 2 (blue), 3 (red), or 4 (green). The data 
were fit to a sum of first-order rate terms, as described in the Materials and Methods 
chapter. 
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Peptide/ 
Inhibitor Afast (D) A1 (D) k1 (min
-1) A2 (D) k2 (min-1) A3 (D) k3 (min-1) 
A 28-31 (3)        
  none 0 0.33 ± 0.03 0.141 ± 0.015 2.55 ± 0.02 ≤ 5.12 x 10-4   
  2 0 0.40 ± 0.04 0.0687 ± 0.0170 2.57 ± 0.04 ≤ 1.05 x 10-3   
  3 0 0.49 ± 0.01 0.00637 ± 0.00078 2.65 ± 0.09 ≤ 1 x 10-4   
  4 0 0.48 ± 0.04 0.0686 ± 0.0130 2.48 ± 0.03 ≤ 1.19 x 10-3   
        
B 32-39 (7)        
  none 0 1.05 ± 0.03 0.102 ± 0.009 5.90 ± 0.04 ≤ 1 x 10-4   
  2 0 1.85 ± 0.05 0.0345 ± 0.0038 5.22 ± 0.15 ≤ 1 x 10-4   
  3 0 0.44 ± 0.13 0.186 ± 0.011 0.95 ± 0.14 0.0115 ± 0.0029 5.61 ± 0.14 ≤ 1 x 10-4 
  4 0 1.78 ± 0.05 0.0382 ± 0.0041 5.15 ± 0.13 ≤ 1 x 10-4   
        
C 37-54 (16)   
 
    
  none 3.9 5.90 ± 0.15 0.0601 ± 0.0054 6.18 ± 0.26 ≤ 1 x 10-4   
  2 9.1 3.54 ± 0.12 00194 ± 0.0028 3.09 ± 0.69 ≤ 1 x 10-4   
  3 7.9 6.16 ± 0.11 0.0270 ± 0.0020 1.93 ± 0.18 ≤ 1 x 10-4   
  4 3.5 7.34 ± 0.14 0.0792 ± 0.0049 5.19 ± 0.15 ≤ 1 x 10-4   
        
D 49-58 (8)   
 
    
  none 0 1.37 ± 0.08 0.141 ± 0.025 6.44 ± 0.07 ≤ 1 x 10-4   
  2 0 1.80 ± 0.04 0.0354 ± 0.0030 6.16 ± 0.10 ≤ 1 x 10-4   
  3 0 2.17 ± 0.06 0.0886 ± 0.0075 5.90 ± 0.08 ≤ 1 x 10-4   
  4 0 1.68 ± 0.06 0.217 ± 0.022 6.31 ± 0.04 ≤ 5.20 x 10-4   
 
Figure 75. H/D exchange kinetic profiles for MPGES1•GSH as a function of inhibitor 
binding, residues 28-58. Shown are the average kinetic profiles for deuterium 
incorporation as a function of time for MPGES1 complexed with GSH in the absence of 
an inhibitor (black), or in the presence of inhibitor 2 (blue), 3 (red), or 4 (green). 
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Peptide/ 
Inhibitor Afast (D) A1 (D) k1 (min
-1) A2 (D) k2 (min-1) 
A 60-68 (7)      
  none 2.6 4.37 ± 0.08 0.0131 ± 0.0011   
  2 2.3 4.68 ± 0.10 0.0141 ± 0.0013   
  3 1.6 5.43 ± 0.09 0.0172 ± 0.0013   
  4 2.3 4.66 ± 0.15 0.0153 ± 0.0021   
      
B 63-78 (15)      
  none 0 5.11 ± 0.09 0.103 ± 0.006 10.00 ± 0.12 ≤ 1 x 10-4 
  2 0 5.43 ± 0.23 0.215 ± 0.026 10.03 ± 0.21 ≤ 1 x 10-4 
  3 0 5.53 ± 0.21 0.180 ± 0.018 10.00 ± 0.19 ≤ 1 x 10-4 
  4 0 5.00 ± 0.13 0.0844 ± 0.0073 10.02 ± 0.20 ≤ 1 x 10-4 
      
C 78-83 (4)      
  none 0.8 0.94 ± 0.02 0.00428 ± 0.00038 2.30 ± 0.13 ≤ 1 x 10-4 
  2 0 2.28 ± 0.04 0.0206 ± 0.0014 1.69 ± 0.18 ≤ 1 x 10-4 
  3 0 0.62 ± 0.18 0.609 ± 0.028 3.62 ± 0.02 ≤ 4.80 x 10-4 
  4 0 0.59 ± 0.08 0.749 ± 0.022 3.35 ± 0.03 ≤ 8.29 x 10-4 
      
D 90-92 (2)      
  none 0 2 ≤ 1 x 10-4   
  2 0 2 ≤ 1 x 10-4   
  3 0 2 ≤ 1 x 10-4   
  4 0 2 ≤ 1 x 10-4   
 
Figure 76. H/D exchange kinetic profiles for MPGES1•GSH as a function of inhibitor 
binding, residues 60-92. Shown are the average kinetic profiles for deuterium 
incorporation as a function of time for MPGES1 complexed with GSH in the absence of 
an inhibitor (black), or in the presence of inhibitor 2 (blue), 3 (red), or 4 (green). 
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Peptide/ 
Inhibitor Afast (D) A1 (D) k1 (min
-1) A2 (D) k2 (min-1) 
A 92-100 (6)   
 
  
  none 0 6 ≤ 1 x 10-4   
  2 0 6 ≤ 1 x 10-4   
  3 0 6 ≤ 1 x 10-4   
  4 0 6 ≤ 1 x 10-4   
      
B 104-107 (3)      
  none 0 0.37 ± 0.05 0.0365 ± 0.0021 2.56 ± 0.05 ≤ 4.90 x 10-4 
  2 0 3 ≤ 1 x 10-4   
  3 0 3 ≤ 1 x 10-4   
  4 0 3 ≤ 1 x 10-4   
      
C 108-123 (15)      
  none 0 1.07 ± 0.07 0.261 ± 0.029 14.06 ± 0.05 ≤ 1 x 10-4 
  2 0 0.79 ± 0.03 0.0460 ± 0.0055 14.24 ± 0.05 ≤ 1 x 10-4 
  3 0.9 14.15 ± 0.02 ≤ 1 x 10-4   
  4 0 0.26 ± 0.02 0.139 ± 0.033 14.69 ± 0.02 ≤ 1 x 10-4 
      
D 124-129 (5)      
  none 0 0.99 ± 0.04 0.0227 ± 0.0022 4.00 ± 0.16 ≤ 1 x 10-4 
  2 0 1.54 ± 0.03 0.0182 ± 0.0017 3.02 ± 0.18 ≤ 1 x 10-4 
  3 0 5 ≤ 1 x 10-4   
  4 0 1.84 ± 0.04 0.0361 ± 0.0030 2.92 ± 0.10 ≤ 1 x 10-4 
 
Figure 77. H/D exchange kinetic profiles for MPGES1•GSH as a function of inhibitor 
binding, residues 92-129. Shown are the average kinetic profiles for deuterium 
incorporation as a function of time for MPGES1 complexed with GSH in the absence of 
an inhibitor (black), or in the presence of inhibitor 2 (blue), 3 (red), or 4 (green). 
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Peptide/ 
Inhibitor Afast (D) A1 (D) k1 (min
-1) A2 (D) k2 (min-1) 
A 130-132 (2)      
  none 0 0.90 ± 0.02 0.0454 ± 0.0046 0.75 ± 0.05 ≤ 1 x 10-4 
  2 0 0.78 ± 0.04 0.125 ± 0.019 1.21 ± 0.04 ≤ 1 x 10-4 
  3 0 0.48 ± 0.02 0.0172 ± 0.0031 1.37 ± 0.10 ≤ 1 x 10-4 
  4 0 0.85 ± 0.01 0.0202 ± 0.0013 0.95 ± 0.05 ≤ 1 x 10-4 
      
B 133-140 (6)      
  none 0 1.12 ± 0.03 0.00446 ± 0.00055 4.88 ± 0.03 ≤ 1 x 10-4 
  2 0 3.50 ± 0.06 0.00787 ± 0.00061 2.12 ± 0.06 ≤ 1 x 10-4 
  3 0.8 2.85 ± 0.06 0.00440 ± 0.00046 2.40 ± 0.06 ≤ 1 x 10-4 
  4 0 1.25 ± 0.11 0.0567 ± 0.0128 4.28 ± 0.11 ≤ 1.09 x 10-3 
      
C 141-152 (11)      
  none 0.8 1.11 ± 0.11 0.254 ± 0.029 9.06 ± 0.06 ≤ 1 x 10-4 
  2 0 11 ≤ 1 x 10-4   
  3 0 11 ≤ 1 x 10-4   
  4 1.1 9.92 ± 0.03 ≤ 1 x 10-4   
 
Figure 78. H/D exchange kinetic profiles for MPGES1•GSH as a function of inhibitor 
binding, residues 130-152. Shown are the average kinetic profiles for deuterium 
incorporation as a function of time for MPGES1 complexed with GSH in the absence of 
an inhibitor (black), or in the presence of inhibitor 2 (blue), 3 (red), or 4 (green). 
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Figure 79. Fragmentation spectrum of Cys-15d-PGJ2. The reduced form of the 
cysteine/15d-PGJ2 adduct was subject to MS/MS fragmentation following reduction by 
NaBH3CN. Fragments in the low-mass range indicate that cysteine forms a Michael 
adduct at position C-9 of 15d-PGJ2. 
 
 
 
 
Figure 80. 1H-NMR Spectra of 9-GS-15d-PGJ2 at 900 MHz. The sample was solubilized 
and analyzed in (A) CD3OD and (B) D2O. Spectrum A was acquired at 25 °C, while 
spectrum B was acquired at 45 °C. 
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Figure 81. Two-dimensional NMR spectroscopy of 9-GS-15d-PGJ2 at 600 MHz. The 
spectra were collected with CD3OD as the solvent. (A) COSY, (B) NOESY, and (C) 
HSQC analyses are shown with CH in red and CH2 in blue. All spectra were acquired at 
25 °C. 
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Figure 82. Two-dimensional NMR spectroscopy of  9-GS-15d-PGJ2 at 900 MHz. spectra 
were collected with  D2O as the solvent. (A) DFQ-COSY, (B) NOESY, and (C) HSQC 
analyses are shown with CH in red and CH2 in blue. All spectra were acquired at 25 °C. 
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Table 4. NMR Data of the glutathione conjugate of 15d-PGJ2 in CD3OD and D2O. 
CD3OD      D2O 
H n δ (ppm)  J(Hz)   H n δ (ppm)  J(Hz) 
Prostaglandin moiety     Prostaglandin moiety 
2 2 2.51 t  6.5   2 2 2.48 t  7.3 
3 2 2.15 m  6.7   3 2 1.79 m  7.2 
4 2 2.06 m  7.0   4 2 2.22 m   
5 1 5.51 m   3.9,5.8   5 1 5.56 m  7.3,9.8  
6 1 5.51 m  3.9,5.8   6 1 5.62 m  7.2,10.1 
7a 1 2.27 d  2.1   7a 1 2.41 t  7.5 
7b 1 2.36 d  2.4   7b 1 2.51 t  6.8 
8 1 3.06 d  5.1   8 1 3.11 d  7.3 
9 1 4.57 dd  3.8,4.7   9 1 4.75 t  6.6 
10a 1 2.82 dd  4.5,8.7   10a 1 3.02 dd  5.4,8.0 
10b 1 3.05 dd  5.1,8.7   10b 1 3.23 dd  6.0,7.7 
13 1 6.96 d  8.3   13 1  7.15 d  11.0 
14 1 6.30 m  9.0   14 1 6.37 t  6.3 
15 1 6.30 m  9.0   15 1 6.37 q                 11.3,14.5 
16 2 2.25 m  3.2   16 2 2.37 m  5.5,7.8 
17 2 1.60 m  7.1,7.4   17 2 1.57 m  6.7,7.2 
18 2 1.33 m  3.4,3.6   18 2 1.44 m 
19 2 1.33 m  3.4,3.6   19 2 1.44 m 
20 3 0.91  t  6.8   20 3 1.02  t   6.8 
 
Glutathionyl moiety     Glutathionyl moiety 
glu-α 1 3.63t   6.4   glu-α 1 3.58 d  8.4 
glu- βa 1 1.64 dd  7.2,7.5   glu- βa 1 1.78 dd  7.3,8.0 
glu- βb 1 2.05 m  6.5   glu- βb 1 2.25 m   
glu-γ 2 2.17 m  7.8   glu-γ 2 2.15 m 
cys-α 1 3.45 d  6.8   cys-α 1 3.15 m  
cys-β 1 2.31 dd  2.1,4.0   cys-β 1 3.11 d  7.38 
cys-β 1 2.93 dd  11.8,7.1   cys-β 1 3.17 d  10.2 
gly-α 2 3.88 s     gly-α 2 3.52 s 
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Figure 83. Fragmentation spectrum of MPGES1 C59-15d-PGJ2. After pepsin digestion, 
the adduct of peptide 49-59 was subject to fragmentation following reduction by 
NaBH3CN, first selecting peptide (49-59)-11-OH-15d-PGJ2 for MS/MS then C59-11-
OH-15d-PGJ2 for MS3. Fragments in the low-mass range indicate that residue C59 of 
MPGES1 forms a Michael adduct at position C-9 of 15d-PGJ2. 
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Peptide/Ligand Afast (D) A1 (D) k1 (min-1) A2 (D) k2 (min-1) 
A 2-13 (10) native      
 GSH 8.6 1.44 ± 0.10 0.536 ± 0.087   
 GSO3¯  8.7 1.31 ± 0.11 0.747 ± 0.132   
 GSH + 15d-PGJ2 8.6 1.44 ± 0.10 0.155 ± 0.032   
 GSO3¯  + 15d-PGJ2 8.4 1.59 ± 0.07 0.221 ± 0.027   
 
     
B 2-13 (10) C59A      
 GSH 8.0 1.98 ± 0.14 0.661 ± 0.100     
 GSO3¯  9.1 0.92 ± 0.16 0.511 ± 0.204     
 GSH + 15d-PGJ2 8.0 1.99 ± 0.08 0.285 ± 0.030     
 GSO3¯  + 15d-PGJ2 8.8 1.24 ± 0.03 0.178 ± 0.014     
      
C 14-17 (3) native      
 GSH 0 0.74 ± 0.03 0.0971 ± 0.0142 2.29 ± 0.03 ≤ 1 x10-4 
 GSO3¯  0 0.95 ± 0.02 0.0127 ± 0.0011 2.06 ± 0.10 ≤ 1 x10-4 
 GSH + 15d-PGJ2 0 0.67 ± 0.03 0.0740 ± 0.0108 2.30 ± 0.05 ≤ 1 x10-4 
 GSO3¯  + 15d-PGJ2 0.1 1.02 ± 0.01 0.0282 ± 0.0015 1.91 ± 0.05 ≤ 1 x10-4 
      
D 14-17 (3) C59A      
 GSH 0.1 0.88 ± 0.03 0.0145 ± 0.0021 2.06 ± 0.20 ≤ 1 x10-4 
 GSO3¯  0.4 0.56 ± 0.03 0.0111 ± 0.0031 2.08 ± 0.05 ≤ 1 x10-4 
 GSH + 15d-PGJ2 0 0.96 ± 0.02 0.0255 ± 0.0019 2.01 ± 0.07 ≤ 1 x10-4 
 GSO3¯  + 15d-PGJ2 0.5 0.54 ± 0.02 0.0203 ± 0.0031 1.95 ± 0.11 ≤ 1 x10-4 
 
Figure 84. H/D exchange kinetic profiles for MPGES1 as a function of 15d-PGJ2 
binding, residues 2-17. The total number of exchangeable sites is given in parentheses. 
Traces on the left represent those for the native enzyme, while traces on the right 
represent those for the C59A mutant. The data for enzyme bound to GSH only (black), 
GSH plus 15d-PGJ2 (red), GSO3¯  only (blue), and GSO3¯  plus 15d-PGJ2 (green), were fit 
to a sum of first-order exponential rate terms, as described in the Materials and Methods 
chapter. 
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Peptide/Ligand Afast (D) A1 (D) k1 (min-1) A2 (D) k2 (min-1) 
A 18-23 (5) native      
 GSH 0 5 ≤ 1 x10-4   
 GSO3¯  0.3 3.00 ± 0.07 0.0115 ± 0.0012 1.70 ± 0.07 ≤ 1 x10-4 
 GSH + 15d-PGJ2 0 0.32 ± 0.05 0.474 ± 0.184 4.75 ± 0.02 ≤ 1.87 x10-4 
 GSO3¯  + 15d-PGJ2 0 2.90 ± 0.07 0.0140 ± 0.0015 2.08 ± 0.04 ≤ 1 x10-4 
 
     
B 18-23 (5) C59A      
 GSH 0 5 ≤ 1 x10-4     
 GSO3¯  0.2 2.81 ± 0.07 0.0285 ± 0.0028 1.97 ± 0.22 ≤ 1 x10-4 
 GSH + 15d-PGJ2 0.1 1.02 ± 0.01 0.0110 ± 0.0004 3.88 ± 0.12 ≤ 1 x10-4 
 GSO3¯  + 15d-PGJ2 0 4.10 ± 0.11 0.0491 ± 0.0050 1.03 ± 0.25 ≤ 1 x10-4 
      
C 23-27 (4) native      
 GSH 0 4 ≤ 1 x10-4   
 GSO3¯  0 4 ≤ 1 x10-4   
 GSH + 15d-PGJ2 0 4 ≤ 1 x10-4   
 GSO3¯  + 15d-PGJ2 0 4 ≤ 1 x10-4   
      
D 23-27 (4) C59A      
 GSH 0 4 ≤ 1 x10-4   
 GSO3¯  0 4 ≤ 1 x10-4   
 GSH + 15d-PGJ2 0 4 ≤ 1 x10-4   
 GSO3¯  + 15d-PGJ2 0 4 ≤ 1 x10-4   
 
Figure 85. H/D exchange kinetic profiles for MPGES1 as a function of 15d-PGJ2 
binding, residues 18-27. The total number of exchangeable sites is given in parentheses. 
Traces on the left represent those for the native enzyme, while traces on the right 
represent those for the C59A mutant. The data for enzyme bound to GSH only (black), 
GSH plus 15d-PGJ2 (red), GSO3¯  only (blue), and GSO3¯  plus 15d-PGJ2 (green) are 
shown. 
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Peptide/Ligand Afast (D) A1 (D) k1 (min-1) A2 (D) k2 (min-1) A3 (D) k3 (min-1) 
A 28-31 (3) native        
 GSH 0.1 0.33 ± 0.03 0.141 ± 0.015 2.55 ± 0.02 ≤ 5.12 x10-4   
 GSO3¯  0 1.90 ± 0.03 0.0127 ± 0.0009 1.16 ± 0.26 ≤ 1 x10-4   
 GSH + 15d-PGJ2 0.1 2.91 ± 0.02 ≤ 1.19 x10-3     
 GSO3¯  + 15d-PGJ2 0 0.76 ± 0.08 0.122 ± 0.006 1.03 ± 0.02 0.00807 ± 0.00025 1.21 ± 0.08 ≤ 1 x10-4 
 
       
B 28-31 (3) C59A        
 GSH 0.1 0.56 ± 0.05 0.0415 ± 0.0097 2.37 ± 0.05 ≤ 3.29 x10-4     
 GSO3¯  0 1.19 ± 0.08 0.164 ± 0.026 1.19 ± 0.08 0.00783 ± 0.00103 0.62 ± 0.08 ≤ 1 x10-4 
 GSH + 15d-PGJ2 0 0.43 ± 0.06 0.0478 ± 0.0161 2.56 ± 0.06 ≤ 4.83 x10-4     
 GSO3¯  + 15d-PGJ2 0 1.37 ± 0.19 0.243 ± 0.071 1.21 ± 0.20 0.0178 ± 0.005 0.42 ± 0.02 ≤ 1 x10-4 
        
C 32-39 (7) native        
 GSH 0.1 1.05 ± 0.03 0.102 ± 0.009 5.90 ± 0.04 ≤ 1 x10-4   
 GSO3¯  0 4.99 ± 0.09 0.0161 ± 0.0013 2.00 ± 0.09 ≤ 1 x10-4   
 GSH + 15d-PGJ2 0 0.99 ± 0.03 0.0224 ± 0.0029 5.98 ± 0.11 ≤ 1 x10-4   
 GSO3¯  + 15d-PGJ2 0 4.95 ± 0.07 0.132 ± 0.017 1.98 ± 0.04 ≤ 1 x10-4   
        
D 32-39 (7) C59A        
 GSH 0.1 0.86 ± 0.02 0.0312 ± 0.0031 6.02 ± 0.07 ≤ 1 x10-4   
 GSO3¯  0.4 4.61 ± 0.07 0.0284 ± 0.0018 2.01 ± 0.24 ≤ 1 x10-4   
 GSH + 15d-PGJ2 0.1 1.04 ± 0.02 0.0224 ± 0.0015 5.87 ± 0.08 ≤ 1 x10-4   
 GSO3¯  + 15d-PGJ2 0 5.90 ± 0.08 0.0421 ± 0.0022 1.34 ± 0.21 ≤ 1 x10-4   
 
Figure 86. H/D exchange kinetic profiles for MPGES1 as a function of 15d-PGJ2 
binding, residues 28-39. The total number of exchangeable sites is given in parentheses. 
Traces on the left represent those for the native enzyme, while traces on the right 
represent those for the C59A mutant. The data for enzyme bound to GSH only (black), 
GSH plus 15d-PGJ2 (red), GSO3¯  only (blue), and GSO3¯  plus 15d-PGJ2 (green) are 
shown. 
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Peptide/Ligand Afast (D) A1 (D) k1 (min-1) A2 (D) k2 (min-1) A3 (D) k3 (min-1) 
A 37-54 (16) native        
 GSH 3.9 5.90 ± 0.15 0.0601 ± 0.0054 6.18 ± 0.26 ≤ 1 x10-4   
 GSO3¯  4.3 5.75 ± 0.11 0.0649 ± 0.0045 5.96 ± 0.21 ≤ 1 x10-4   
 GSH + 15d-PGJ2 1.8 4.99 ± 0.12 0.0205 ± 0.0021 9.17 ± 0.57 ≤ 1 x10-4   
 GSO3¯  + 15d-PGJ2 2.2 1.95 ± 0.03 0.206 ± 0.027 2.81 ± 0.03 0.00848 ± 0.00020 9.00 ± 0.03 ≤ 1 x10-4 
 
       
B 37-54 (16) C59A        
 GSH 3.5 6.38 ± 0.14 0.0591 ± 0.0045 6.08 ± 0.26 ≤ 1 x10-4   
 GSO3¯  3.8 6.88 ± 0.21 0.0410 ± 0.0049 5.33 ± 0.51 ≤ 1 x10-4   
 GSH + 15d-PGJ2 3.5 7.40 ± 0.17 0.0235 ± 0.0022 5.13 ± 0.06 ≤ 1 x10-4   
 GSO3¯  + 15d-PGJ2 3.6 7.78 ± 0.20 0.0364 ± 0.0036 4.67 ± 0.25 ≤ 1 x10-4   
        
C 49-59 (9) native        
 GSH 1.4 1.02 ± 0.16 0.491 ± 0.027 2.05 ± 0.18 0.0380 ± 0.0039 4.56 ± 0.19 ≤ 1 x10-4 
 GSO3¯  2.0 3.53 ± 0.26 0.117 ± 0.015 3.49 ± 0.23 ≤ 1.14 x10-3   
 GSH + 15d-PGJ2 0.5 2.05 ± 0.05 0.0108 ± 0.0011 6.43 ± 0.16 ≤ 1 x10-4   
 GSO3¯  + 15d-PGJ2 1.1 3.54 ± 0.25 0.0252 ± 0.0024 4.33 ± 0.26 ≤ 4.44 x10-4   
        
D 49-59 (9) C59A        
 GSH 1.8 2.64 ± 0.09 0.0473 ± 0.0049 4.58 ± 0.16 ≤ 1 x10-4   
 GSO3¯  2.0 2.86 ± 0.31 0.0606 ± 0.0063 4.13 ± 0.30 ≤ 1.16 x10-3   
 GSH + 15d-PGJ2 2.1 2.75 ± 0.08 0.0259 ± 0.0032 4.15 ± 0.19 ≤ 1 x10-4   
 GSO3¯  + 15d-PGJ2 2.2 3.12 ± 0.21 0.125 ± 0.024 3.70 ± 0.18 ≤ 9.67 x10-4   
 
Figure 87. H/D exchange kinetic profiles for MPGES1 as a function of 15d-PGJ2 
binding, residues 37-59. The total number of exchangeable sites is given in parentheses. 
Traces on the left represent those for the native enzyme, while traces on the right 
represent those for the C59A mutant. The data for enzyme bound to GSH only (black), 
GSH plus 15d-PGJ2 (red), GSO3¯  only (blue), and GSO3¯  plus 15d-PGJ2 (green) are 
shown. 
 
 
 
 
163 
 
 
 
Peptide/Ligand Afast (D) A1 (D) k1 (min-1) A2 (D) k2 (min-1) 
A 60-68 (7) native      
 GSH 2.6 4.37 ± 0.08 0.0131 ± 0.0011   
 GSO3¯  2.6 4.36 ± 0.07 0.0119 ± 0.0009   
 GSH + 15d-PGJ2 1.3 0.54 ± 0.18 0.160 ± 0.015 5.12 ± 0.16 ≤ 1.99 x10-3 
 GSO3¯  + 15d-PGJ2 1.1 5.03 ± 0.11 0.0116 ± 0.0011 0.84 ± 0.11 ≤ 1 x10-4 
 
     
B 60-68 (7) C59A      
 GSH 2.5 4.48 ± 0.06 0.0168 ± 0.0010   
 GSO3¯  2.5 4.50 ± 0.11  0.0202 ± 0.0021   
 GSH + 15d-PGJ2 2.5 4.48 ± 0.06 0.0129 ± 0.0008   
 GSO3¯  + 15d-PGJ2 2.4 4.60 ± 0.07 0.0193 ± 0.0012   
      
C 63-78 (15) native      
 GSH 0 5.11 ± 0.09 0.103 ± 0.006 10.00 ± 0.12 ≤ 1 x10-4 
 GSO3¯  0 8.73 ± 0.33 0.185 ± 0.021 7.05 ± 0.31 ≤ 1 x10-4 
 GSH + 15d-PGJ2 0 5.36 ± 0.20 0.189 ± 0.021 10.03 ± 0.20 ≤ 1 x10-4 
 GSO3¯  + 15d-PGJ2 0 7.04 ± 0.18 0.0553 ± 0.0053 8.46 ± 0.35 ≤ 1 x10-4 
      
D 63-78 (15) C59A      
 GSH 0 5.19 ± 0.07 0.128 ± 0.006 9.97 ± 0.09 ≤ 1 x10-4 
 GSO3¯  0 8.61 ± 0.20 0.0982 ± 0.0076 6.76 ± 0.28 ≤ 1 x10-4 
 GSH + 15d-PGJ2 0 4.44 ± 0.15 0.103 ± 0.012 10.66 ± 0.18 ≤ 1 x10-4 
 GSO3¯  + 15d-PGJ2 0 7.80 ± 0.15 0.0573 ± 0.0039 7.31 ± 0.23 ≤ 1 x10-4 
 
Figure 88. H/D exchange kinetic profiles for MPGES1 as a function of 15d-PGJ2 
binding, residues 60-78. The total number of exchangeable sites is given in parentheses. 
Traces on the left represent those for the native enzyme, while traces on the right 
represent those for the C59A mutant. The data for enzyme bound to GSH only (black), 
GSH plus 15d-PGJ2 (red), GSO3¯  only (blue), and GSO3¯  plus 15d-PGJ2 (green) are 
shown. 
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Peptide/Ligand Afast (D) A1 (D) k1 (min-1) A2 (D) k2 (min-1) A3 (D) k3 (min-1) 
A 78-83 (4) native        
 GSH 0.8 0.94 ± 0.02 0.00428 ± 0.00038 2.30 ± 0.13 ≤ 1 x10-4   
 GSO3¯  0 0.72 ± 0.19 0.802 ± 0.053 2.42 ± 0.12 0.0141 ± 0.0018 0.86 ± 0.12 ≤ 1 x10-4 
 GSH + 15d-PGJ2 0 0.61 ± 0.04 0.193 ± 0.036 3.40 ± 0.03 ≤ 5.47 x10-4   
 GSO3¯  + 15d-PGJ2 0 1.88 ± 0.06 0.0296 ± 0.0025 2.20 ± 0.07 ≤ 7.05 x10-4   
 
       
B 78-83 (4) C59A        
 GSH 0.8 1.24 ± 0.02 0.00227 ± 0.00016 1.99 ± 0.02 ≤ 1 x10-4     
 GSO3¯  0.1 0.78 ± 0.17 0.555 ± 0.031 2.35 ± 0.14 0.0187 ± 0.0025 0.76 ± 0.29 ≤ 1 x10-4 
 GSH + 15d-PGJ2 0 0.58 ± 0.05 0.235 ± 0.058 3.43 ± 0.03 ≤ 5.16 x10-4     
 GSO3¯  + 15d-PGJ2 0 0.83 ± 0.07 0.551 ± 0.053 1.28 ± 0.05 0.0113 ± 0.0012 1.89 ± 0.06 ≤ 1 x10-4 
        
C 90-92 (2) native        
 GSH 0 2 ≤ 1 x10-4     
 GSO3¯  0 2 ≤ 1 x10-4     
 GSH + 15d-PGJ2 0 2 ≤ 1 x10-4     
 GSO3¯  + 15d-PGJ2 0 2 ≤ 1 x10-4     
        
D 90-92 (2) C59A        
 GSH 0 2 ≤ 1 x10-4     
 GSO3¯  0 2 ≤ 1 x10-4     
 GSH + 15d-PGJ2 0 2 ≤ 1 x10-4     
 GSO3¯  + 15d-PGJ2 0 2 ≤ 1 x10-4     
 
Figure 89. H/D exchange kinetic profiles for MPGES1 as a function of 15d-PGJ2 
binding, residues 78-92. The total number of exchangeable sites is given in parentheses. 
Traces on the left represent those for the native enzyme, while traces on the right 
represent those for the C59A mutant. The data for enzyme bound to GSH only (black), 
GSH plus 15d-PGJ2 (red), GSO3¯  only (blue), and GSO3¯  plus 15d-PGJ2 (green) are 
shown. 
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Peptide/Ligand Afast (D) A1 (D) k1 (min-1) A2 (D) k2 (min-1) 
A 92-100 (6) native      
 GSH 0 6 ≤ 1 x10-4   
 GSO3¯  0 6 ≤ 1 x10-4   
 GSH + 15d-PGJ2 0 6 ≤ 1 x10-4   
 GSO3¯  + 15d-PGJ2 0 6 ≤ 1 x10-4   
 
     
B 92-100 (6) C59A      
 GSH 0 6 ≤ 1 x10-4   
 GSO3¯  0 6 ≤ 1 x10-4   
 GSH + 15d-PGJ2 0 6 ≤ 1 x10-4   
 GSO3¯  + 15d-PGJ2 0 6 ≤ 1 x10-4   
      
C 104-107 (3) native      
 GSH 0.1 0.37 ± 0.05 0.0365 ± 0.0021 2.56 ± 0.05 ≤ 4.90 x10-4 
 GSO3¯  0.1 0.60 ± 0.07 0.0535 ± 0.0051 2.35 ± 0.07 ≤ 1.72 x10-3 
 GSH + 15d-PGJ2 0 3 ≤ 1 x10-4   
 GSO3¯  + 15d-PGJ2 0 3 ≤ 1 x10-4   
      
D 104-107 (3) C59A      
 GSH 0.1 0.40 ± 0.03 0.0498 ± 0.0088 2.54 ± 0.03 ≤ 4.49 x10-4 
 GSO3¯  0 0.44 ± 0.03 0.299 ± 0.061 2.56 ± 0.02 ≤ 1.98 x10-3 
 GSH + 15d-PGJ2 0 3 ≤ 1 x10-4     
 GSO3¯  + 15d-PGJ2 0 3 ≤ 1 x10-4     
 
Figure 90. H/D exchange kinetic profiles for MPGES1 as a function of 15d-PGJ2 
binding, residues 92-107. The total number of exchangeable sites is given in parentheses. 
Traces on the left represent those for the native enzyme, while traces on the right 
represent those for the C59A mutant. The data for enzyme bound to GSH only (black), 
GSH plus 15d-PGJ2 (red), GSO3¯  only (blue), and GSO3¯  plus 15d-PGJ2 (green) are 
shown. 
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Peptide/Ligand Afast (D) A1 (D) k1 (min-1) A2 (D) k2 (min-1) A3 (D) k3 (min-1) 
A 108-123 (15) native        
 GSH 0 1.07 ± 0.07 0.261 ± 0.029 14.06 ± 0.05 ≤ 1 x10-4   
 GSO3¯ 0 1.04 ± 0.03 0.168 ± 0.016 13.98 ± 0.13 ≤ 1 x10-4   
 GSH + 15d-PGJ2 0 15 ≤ 1 x10-4     
 GSO3¯  + 15d-PGJ2 0 1.52 ± 0.03 0.0798 ± 0.0057 13.46 ± 0.05 ≤ 1 x10-4   
 
       
B 108-123 (15) C59A        
 GSH 0 1.00 ± 0.03 0.211 ± 0.027 13.98 ± 0.02 ≤ 1 x10-4   
 GSO3¯ 0 1.14 ± 0.04 0.118 ± 0.013 13.96 ± 0.04 ≤ 1 x10-4   
 GSH + 15d-PGJ2 0 0.99 ± 0.03 0.0524 ± 0.0053 13.97 ± 0.05 ≤ 1 x10-4   
 GSO3¯  + 15d-PGJ2 0 0.95 ± 0.03 0.0592 ± 0.0074 14.09 ± 0.05 ≤ 1 x10-4   
        
C 124-129 (5) native        
 GSH 0 0.99 ± 0.04 0.0227 ± 0.0022 4.00 ± 0.16 ≤ 1 x10-4   
 GSO3¯ 0.3 3.83 ± 0.11 0.0220 ± 0.0025 0.90 ± 0.11 ≤ 1 x10-4   
 GSH + 15d-PGJ2 0 5 ≤ 1 x10-4     
 GSO3¯  + 15d-PGJ2 0 1.69 ± 0.03 0.147 ± 0.016 1.96 ± 0.03 0.00986 ± 0.00027 1.35 ± 0.03 ≤ 1 x10-4 
        
D 124-129 (5) C59A        
 GSH 0 1.08 ± 0.03 0.0323 ± 0.0031 3.92 ± 0.07 ≤ 1 x10-4   
 GSO3¯ 0 4.02 ± 0.14 0.0391 ± 0.0052 1.17 ± 0.33 ≤ 1 x10-4   
 GSH + 15d-PGJ2 0 1.94 ± 0.05 0.0650 ± 0.0058 3.17 ± 0.06 ≤ 1 x10-4   
 GSO3¯  + 15d-PGJ2 0 3.32 ± 0.10 0.0412 ± 0.0046 1.68 ± 0.18 ≤ 1 x10-4   
 
Figure 91. H/D exchange kinetic profiles for MPGES1 as a function of 15d-PGJ2 
binding, residues 108-129. The total number of exchangeable sites is given in 
parentheses. Traces on the left represent those for the native enzyme, while traces on the 
right represent those for the C59A mutant. The data for enzyme bound to GSH only 
(black), GSH plus 15d-PGJ2 (red), GSO3¯  only (blue), and GSO3¯  plus 15d-PGJ2 (green) 
are shown. 
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Peptide/Ligand Afast (D) A1 (D) k1 (min-1) A2 (D) k2 (min-1) 
A 130-132 (2) native      
 GSH 0.4 0.90 ± 0.02 0.0454 ± 0.0046 0.75 ± 0.05 ≤ 1 x10-4 
 GSO3¯  0.5 1.48 ± 0.03 0.0248 ± 0.0024   
 GSH + 15d-PGJ2 0 0.48 ± 0.04 0.225 ± 0.059 1.58 ± 0.03 ≤ 8.24 x10-4 
 GSO3¯  + 15d-PGJ2 0.4 1.01 ± 0.13 0.0485 ± 0.0015 0.56 ± 0.13 ≤ 3.10 x10-3 
 
     
B 130-132 (2) C59A      
 GSH 0.3 0.77 ± 0.08 0.301 ± 0.084 0.89 ± 0.05 ≤ 1 x10-4 
 GSO3¯  0.3 1.74 ± 0.05 0.0235 ± 0.0026     
 GSH + 15d-PGJ2 0 0.48 ± 0.04 0.118 ± 0.026 1.53 ± 0.03 ≤ 4.82 x10-4 
 GSO3¯  + 15d-PGJ2 0.3 1.70 ± 0.02 0.0155 ± 0.0008     
      
C 133-140 (6) native      
 GSH 0 1.12 ± 0.03 0.00446 ± 0.00055 4.88 ± 0.03 ≤ 1 x10-4 
 GSO3¯  0.9 5.09 ± 0.09 0.0130 ± 0.0010   
 GSH + 15d-PGJ2 0 0.87 ± 0.10 0.226 ± 0.028 5.16 ± 0.07 ≤ 7.19 x10-4 
 GSO3¯  + 15d-PGJ2 1.0 5.00 ± 0.11 0.0544 ± 0.0042   
      
D 133-140 (6) C59A      
 GSH 0 1.17 ± 0.03 0.00811 ± 0.00082 4.80 ± 0.04 ≤ 1 x10-4 
 GSO3¯  0.5 5.50 ± 0.10 0.0185 ± 0.0014     
 GSH + 15d-PGJ2 0 1.91 ± 0.11 0.0933 ± 0.0145 4.13 ± 0.10 ≤ 9.43 x10-4 
 GSO3¯  + 15d-PGJ2 0.3 5.75 ± 0.18 0.159 ± 0.015     
 
Figure 92. H/D exchange kinetic profiles for MPGES1 as a function of 15d-PGJ2 
binding, residues 130-140. The total number of exchangeable sites is given in 
parentheses. Traces on the left represent those for the native enzyme, while traces on the 
right represent those for the C59A mutant. The data for enzyme bound to GSH only 
(black), GSH plus 15d-PGJ2 (red), GSO3¯  only (blue), and GSO3¯  plus 15d-PGJ2 (green) 
are shown. 
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Peptide/Ligand Afast (D) A1 (D) k1 (min-1) A2 (D) k2 (min-1) 
A 141-152 (11) native      
 GSH 0.8 1.11 ± 0.11 0.254 ± 0.029 9.06 ± 0.06 ≤ 1 x10-4 
 GSO3¯  0.7 1.27 ± 0.12 0.364 ± 0.037 9.03 ± 0.06 ≤ 1 x10-4 
 GSH + 15d-PGJ2 0 11 ≤ 1 x10-4   
 GSO3¯  + 15d-PGJ2 0 11 ≤ 1 x10-4   
 
     
B 141-152 (11) C59A      
 GSH 0.8 1.23 ± 0.10 0.290 ± 0.060 8.98 ± 0.07 ≤ 1 x10-4 
 GSO3¯  1.0 1.15 ± 0.03 0.186 ± 0.015 8.87 ± 0.03 ≤ 1 x10-4 
 GSH + 15d-PGJ2 0 11 ≤ 1 x10-4     
 GSO3¯  + 15d-PGJ2 0 11 ≤ 1 x10-4     
 
Figure 93. H/D exchange kinetic profiles for MPGES1 as a function of 15d-PGJ2 
binding, residues 141-152. The total number of exchangeable sites is given in 
parentheses. Traces on the left represent those for the native enzyme, while traces on the 
right represent those for the C59A mutant. The data for enzyme bound to GSH only 
(black), GSH plus 15d-PGJ2 (red), GSO3¯  only (blue), and GSO3¯  plus 15d-PGJ2 (green) 
are shown. 
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